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ABSTRACT 
The development of a strategy to improve oxygen delivery to cells seeded on scaffolds is 
essential for the success of tissue engineering applications. The focus of this work was to 
explore the application of cyclodextrin inclusion complexes (CD:ICs) with 
perfluorocarbons as oxygen carriers. CD:ICs were prepared from alpha-cyclodextrin and 
perfluoroperhydrophenanthrene via co-precipitation, paste mixing, and dry mixing 
complexation techniques. Characterization indicated that paste mixing at a 2:1 host:guest 
ratio was the most effective method for complexation between the parent molecules. The 
CD:ICs were then successfully incorporated in 3D fibrous mats via electrospinning with 
poly(carbonate urethane) and polycaprolactone as biostable and biodegradable polymer 
matrices, respectively. Electrospinning conditions were optimized to achieve appropriate 
fiber morphology for tissue engineering applications and material characterization 
indicated some of the CD:ICs were present on the fiber surface. The dissolved oxygen 
concentration increased significantly in the presence of either CD:ICs or CD:IC-
functionalized fibrous mats at various conditions in model solutions. Overall, this study 
demonstrates that CD:ICs prepared with perfluorocarbons are potential oxygen carriers, 
and when embedded in scaffolds they may present a viable approach to enhancing oxygen 
delivery to cells seeded on tissue engineering scaffolds. 
 
Keywords: tissue engineering, oxygen delivery, scaffold, electrospinning, 
perfluorocarbons, cyclodextrin, inclusion complex 
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1 INTRODUCTION 
1.1 Scope 
Tissue engineering continues to emerge as a strategy for the repair and regeneration of 
diseased or damaged tissues and organs as an alternative to current therapies.1 Scaffold-
guided tissue engineering involves seeding cells onto a porous three-dimensional (3D) 
scaffold that supports in vitro tissue formation and maturation. The resulting engineered 
tissue is envisioned to be implanted in a patient where it further grows, going through self-
repair remodeling. The ultimate objective of tissue engineering is thus to develop 
responsive living tissues with properties similar to those of the native tissues they are 
intended to replace, and can be applied to many, if not all, tissues in the body. However, 
one of the major factors hindering the success of scaffold-guided tissue engineering is the 
inability to deliver sufficient oxygen to the growing constructs in vitro. Previous attempts 
to overcome this limitation have been riddled with drawbacks; so the task remains a 
fundamental consideration for fabricating engineered tissues.2-4 
 
Oxygen delivery, in particular, is a limiting step for developing tissues of a clinically-
relevant size because of the low solubility of oxygen in culture media, which is further 
exacerbated by the high oxygen requirements for cells, which consume five to six moles 
of oxygen per mole of monosaccharide.5 Clearly, the delivery of oxygen to cells requires 
the development of an oxygen delivery system that is more efficient than molecular 
diffusion alone. When designing an alternative oxygen delivery strategy, arguably the most 
important factor is the length of and extent of delivery with the goal of continuous and 
sustained delivery such that sufficient quantities are available until the cells seeded on the 
scaffold are adequately matured into clinically-relevant thick tissues. If the developed 
strategy involves altering the scaffold in some way, it must be done such that the scaffold 
properties, particularly porosity and morphology, are not adversely affected. Finally, it is 
imperative that the materials used are cytocompatible and do not introduce any toxic or 
otherwise harmful by-products. 
 
2 
 
 
 
In this work, cyclodextrin inclusion complexes were prepared with a perfluorocarbon, and 
explored for their ability to enhance oxygen delivery when embedded in tissue engineering 
scaffolds. 
 
1.2 Thesis Outline 
In view of the scope described above, the work presented in this thesis underscores the 
importance of addressing oxygen delivery limitations in fabricating engineered tissues of 
clinical relevance. Firstly, Chapter 2 provides an in-depth literature review covering 
pertinent information related to the topics being discussed, specifically tissue engineering, 
oxygen mass transfer in tissues, the chemistry of perfluorocarbon compounds, and 
cyclodextrin inclusion complexes. This thesis is separated into three main objectives, with 
all materials and methods, including experimental parameters, presented at the beginning 
of each chapter. Chapter 3 describes the initial objective of preparation and characterization 
of cyclodextrin inclusion complexes with perfluorocarbons. Chapter 4 describes the 
fabrication and characterization of tissue engineering scaffolds incorporating the prepared 
cyclodextrin inclusion complexes. Chapter 5 describes the in vitro analysis of oxygen 
delivery for both the cyclodextrin/perfluorocarbon inclusion complexes and the 
functionalized three dimensional scaffolds. Finally, Chapter 6 provides a general 
conclusion of the major findings in this study, its strengths and limitations, and future 
directions. 
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2 LITERATURE REVIEW* 
2.1 Tissue Engineering 
Tissue engineering is the assembly of cells and their support structures for the repair and 
regeneration of diseased or damaged tissues and organs as an alternative to current 
therapies.1 One strategy of tissue engineering (Figure 2-1), involves seeding cells onto a 
porous three-dimensional (3D) scaffold that supports in vitro tissue formation and 
maturation. The resulting engineered tissue is implanted in a patient where it further grows, 
through self-repair remodeling. The ultimate objective of tissue engineering is thus to 
develop responsive living tissues with properties similar to those of the native tissues they 
are intended to replace, and can be applied to many, if not all, tissues in the body. Not 
surprisingly, tissue engineering continues to be a promising alternative to current 
treatments for diseased and damaged organs, and it has already found applications in a 
variety of other areas such as drug research and discovery.2-4 The strategies of tissue 
engineering are conceptually simple and appealing yet they have proven to be challenging 
engineering tasks. Despite rapid advances made in this field,5, 6 success is still limited due 
to significant knowledge gaps in the ability to control, coordinate, and direct tissue 
formation, which are the ultimate goals for tissue engineering. 
 
 Scaffolds 
With the few exceptions,7-9 exogenous porous 3D scaffolds which mimic the extracellular 
matrix (ECM) are required for the growth of cells to form an engineered construct.10, 11 
Depending on the intended application, scaffolds may be designed to be biodegradable so 
that only the neo-tissue will remain after a given period of culture time or following 
implantation, or they may be biostable such that a composite tissue that provides long-term 
support could be fabricated.12-15 In the case of biodegradable scaffolds, cells will remodel 
the scaffold with their own ECM proteins creating the intended tissue without 
                                                 
 
* Parts of this chapter have been published: Tierney GB Deluzio, Dawit G Seifu, Kibret Mequanint, 3D 
scaffolds in tissue engineering and regenerative medicine: beyond the structural templates? Pharmaceutical 
Bioprocessing 2013, 1(3), 267-281. 
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compromising the tissue structural integrity. This, however, requires strict coordination of 
the scaffold biodegradation rate with the biosynthetic rate and is one of the major obstacles 
in the field today. In addition, a scaffold must have several required characteristics: 
biocompatibility, appropriate mechanical strength and compliance, optimal porosity for 
cell seeding, in vitro nutrient and oxygen transport, and the ability to bind to cells and 
release growth factors when needed.  Although some of these criteria could be met with 
existing scaffolds, they do not always provide biological cues for embedded cells and do 
not interact with the cells. In the body, cells reside within the ECM, which provides tissues 
with the appropriate architecture as well as signaling cues that influence key cell function 
such as adhesion, migration, proliferation, differentiation, and secretion of ECM 
components.16 Fabrication of tissues in vitro thus requires that cells be given a more 
Figure 2-1: Schematic diagram showing the essential stages of scaffold-guided tissue 
engineering 
6 
 
 
 
specific level of instruction so that tissue regeneration in the host is successful. With the 
discovery of cell adhesion peptide domains in fibronectin, collagen, and laminin, the design 
of synthetic extracellular matrices with biological activity has become a valuable strategy 
to impart biomimetic properties.17-19 
 
The selection of scaffold type and material depends on the specific tissue engineering 
application, as well as the applicable design criteria. Natural materials such as collagen,20 
chitosan,21 and hyaluronic acid22 have the advantage of being generally nontoxic in 
addition to providing biological cues to promote cell attachment and proliferation. 
However, these natural materials are difficult to fabricate due to their limited processing 
parameters and often result in constructs with poor mechanical properties. Synthetic 
materials, on the other hand, are readily available and generally easy to modify, with 
minimal batch to batch variations.  However, they do not innately possess appropriate sites 
to enhance cellular interactions and therefore lack bioactivity. The method of scaffold 
fabrication also significantly impacts the physical and chemical properties of the resulting 
tissue engineered construct. Other aspects, including reproducibility and cost-
effectiveness, should also be considered when selecting materials and fabrication 
techniques. Common methods for scaffold fabrication include solvent casting/particulate 
leaching and electrospinning, with more advanced techniques, such as rapid 3D plotting, 
solid free form, and 3D projection stereolithography, being developed.23-26 Since the work 
in this thesis utilized electrospinning to fabricate scaffolds, a succinct review of the 
electrospinning process is described in the following section (2.1.1.1). 
 
2.1.1.1 Electrospinning 
One of the most commonly utilized methods for scaffold fabrication is electrospinning. 
Electrospinning was initially developed in 1902,27, 28 and it has been applied to fabricate 
tissue engineering scaffolds since the mid-1990s. Electrospinning is a versatile technique 
that enables the production of multi-functional fibers in the nano- to micrometer range from 
a wide variety of materials including but not limited to polymers, polymer blends, sol-gels, 
composites, and ceramics.29-31 In general, electrospinning is a relatively simple, versatile, 
and cost-effective method. The typical electrospinning setup consists of a syringe pump, a 
7 
 
 
 
 
high voltage source, and a collector (Figure 2-2). The selected polymer is dissolved in a 
solvent and the resulting polymer solution is loaded into a syringe. A strong electrostatic 
force is applied to the needle tip via a high voltage supply, inducing a charge in the solution. 
As the polymer solution is forced through the syringe via the syringe pump, the charge 
induced within the polymer begins to overcome the surface tension holding the polymer 
solution suspended at the needle tip. The solution at the tip begins to elongate and form a 
conical shape known as a Taylor cone.28, 32, 33 When the critical value at which the surface 
tension is overcome is reached, the solution is ejected from the tip of the Taylor cone as a 
charged jet.32, 34, 35 The solvent evaporates during the flight of the jet in air across the 
distance between the needle tip and collector, resulting in the continuous accumulation of 
solid polymer fibers in a non-woven arrangement on the grounded collector. The collector 
can be one of several configurations, including a stationary plate or a rotating mandrel.27, 
28 The electrospinning jet is composed of four regions: the base, jet, splay, and collection.36 
In the first region, the base, the jet emerges to form the Taylor cone. The polymer jet is 
then accelerated and stretched by the electric forces, decreasing its diameter and increasing 
the charge density. The jet then appears to splay into many small fibers of approximately 
equal diameter, yet the jet is actually a single, rapidly whipping jet that undergoes bending 
and stretching.32, 35 The fibrous mats that result from electrospinning possess important 
characteristics for tissue engineering scaffolds. These characteristics include a large 
surface-to-volume ratio, pore sizes and fibers in the nano-range, and an interconnected 
structure,36 and make the fibrous configurations that result from electrospinning useful in 
mimicking of the ECM. Electrospinning is generally a simple and cost-effective technique. 
Furthermore, it is relatively simple to incorporate various additives during the 
electrospinning process in order to improve on the functionality of the fibers.29, 31 The main 
disadvantage of electrospinning is that the small pore spacing leads to difficulties with cell 
infiltration during cell delivery and fostering; however, electrospun nanofibers best mimic 
several ECM proteins.37, 38 
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The characteristics of the resultant fibrous mats can be controlled by a number of 
parameters: solution properties, controlled variables, and ambient parameters.32, 36 The 
solution properties include viscosity, conductivity, surface tension, polymer molecular 
weight, dipole moment, and dielectric constant of the polymer solution. It is difficult to 
determine the effect of individual solution properties as they are usually connected and are 
therefore difficult to isolate. Nevertheless, the viscosity of the solution, as controlled by 
altering the polymer concentration, has a significant effect on the fiber size and 
morphology; they are directly proportional, with fiber diameter generally increasing as 
solution viscosity is increased. At very low viscosities, there are not enough chain 
entanglements and overlapping to create a stable jet, so the process is characteristic of 
electrospraying, yielding beads or fibers possessing defects such as beading.39 Increasing 
the molecular weight of the polymer also decreases the number of beads and droplets 
formed on the fibers.36 Increasing the conductivity of the solution generally decreases 
beading, resulting in more uniform and smaller fibers. The controlled variables include 
flow rate, electric field strength, distance between tip and collector, needle tip design, and 
collector composition and geometry. Decreasing the flow rate generally results in fibers 
with smaller diameters, as flow rate and fiber diameter are directly proportional. If the flow 
rate is too high, the wet fibers will not have enough time to dry before reaching the 
collector, resulting in beading and fiber fusion. Similarly, there is a minimum distance 
Figure 2-2: Schematic of electrospinning set-up 
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between the needle tip and collector required in order to give the fibers enough time to dry, 
with beading observed at distances that are too close or far. In general, increasing the 
voltage also causes an increase in beading. Overall, fiber diameter is inversely proportional 
to both distance and electric potential.36 Furthermore, a solvent with suitable volatility 
should be selected to facilitate sufficient evaporation over the allocated needle tip to 
collector distance.35 
 
Incorporating cyclodextrins (CDs) or their inclusion complexes (ICs) into an electrospun 
mat can impart unique characteristics to the fibers, creating interesting functionality, and 
potentially improving the application of cyclodextrin and/or electrospun fibers.31 A number 
of studies have explored the functionalization of electrospun nanofibers with CDs 
incorporated for a variety of applications, for example poly(methyl methacrylate) 
containing CD-menthol-ICs,29 polystyrene fibers containing CD-menthol-ICs,40 polyvinyl 
alcohol nanofibers incorporating CD-vanillin-ICs,41 polystyrene incorporating CDs as 
molecular filters,42 and polyacrylonitrile with silver/β-CD nanoparticles.30 Moreover, 
polymer-free nanofibers have been prepared by electrospinning cyclodextrin, its 
derivatives, and their inclusion complexes alone.39 For instance, polymer-free nanofibers 
have been obtained from hydroxypropyl-β-cyclodextrin and its inclusion complexes with 
triclosan, and the resulting fibrous mats possess some mechanical integrity and can be 
handled and folded as a free-standing web.43 The success of this procedure is dependent 
upon considerable aggregates and adequate interactions between the CD molecules, 
effectively acting as chain entanglements in the solution in order to create a stable jet.39 
Cyclodextrin has been shown to positively affect the electrospinning of polymer solutions. 
The addition of CD increases the conductivity of the polymer solution, allowing for 
successful electrospinning of bead-free fibers from low polymer concentrations.29, 40 This 
is because the polymer solution is subjected to higher stretching under the high electric 
field.31 The addition of CD can also influence the viscosity of the polymer solution, 
potentially furthering the effect of CD on fiber morphology. However, in the case of 
electrospinning polyvinyl alcohol with a CD-vanillin-ICs, the conductivity of the resulting 
polymer solution was lower, resulting in less stretching of the electrified jet, and in turn 
thicker fibers, contradictory to the general observed trend.41 
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2.2 Oxygen Mass Transfer in Tissues 
 The Challenges of Oxygen Transfer in Engineered Tissues 
The success of engineered tissues has been limited by the inability to deliver sufficient 
oxygen to the growing constructs. Oxygen delivery, in particular, is a limiting step for 
clinically-relevant size tissues because of its low solubility in culture media.44 This is 
further exacerbated by the fact that cells consume five to six moles of oxygen per mole of 
monosaccharide according to the following mole balance. 
 
 C6H12O6+6O2→6CO2+6H2O   (2-1) 
 
Clearly, the delivery of this much oxygen to cells requires the development of an oxygen 
delivery system that is more efficient than molecular diffusion alone.45 
 
The lack of sufficient oxygen supply to cells is exemplified by results showing cellular 
spheroids containing a hypoxic and necrotic center surrounded by a rim of viable cells.46,47 
This is because the cells located in the center of the tissue engineered constructs experience 
different environmental conditions than those located at the peripheral boundaries.48 It has 
been shown that oxygen concentrations decline rapidly from the exterior to the interior 
within the structure and that the oxygen gradients are more pronounced during the early 
stages of tissue development.48 In addition to cellular necrosis, insufficient oxygen levels 
result in a shift to anaerobic metabolism and energy conservation.49 For the tissue 
engineering approach to become a clinical success, it is vital that the challenge of delivering 
sufficient oxygen to cells seeded on scaffolds is overcome.  
 
 In vivo Oxygen Transfer 
In the body, oxygen is supplied in sufficient amounts via two specialized systems: 
convection and hemoglobin. Firstly, the circulatory system enhances the delivery of 
oxygen to vascularized tissues via convection of blood through the capillary network which 
has the effect of decreasing the distance required for diffusion. Furthermore, hemoglobin, 
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a natural oxygen carrier protein, overcomes the very low solubility of oxygen in plasma by 
carrying 65 times more oxygen than blood plasma alone.50 
 
 Alternative Oxygen Delivery Strategies 
The delivery of nutrients and the removal of metabolic waste materials remains to be a 
fundamental consideration for fabricating engineered tissues.51, 52, 53 A number of 
approaches have been developed to improve the delivery of oxygen to cells seeded on 
tissue engineering constructs, as summarized in Figure 2-3, adapted from Malda et al.48 
This section evaluates a few such studies with the intent of bringing attention to the 
limitations of current strategies and rationale for this research. 
 
One approach to reducing hypoxia in vitro is the use of perfusion bioreactors where oxygen 
dissolved in the culture medium diffuses to the scaffold interior. For this purpose, 
bioreactors have been developed with the intent to mechanically stimulate the growing 
tissue constructs with physiologically relevant forces and to improve mass transfer within 
the tissue. Although the former is largely successful, the latter has shown to be a formidable 
engineering task. Therefore, the delivery of nutrients and the removal of metabolic waste 
materials remained to be a fundamental consideration for fabricating engineered 
tissues.52,54,55 
 
In the case of flow-induced mass transfer, the high flow rate required to maintain an 
adequate oxygen concentration for cell viability often surpasses the shear stress tolerance 
of the cells.56 Alternatively, one feasible approach involves the use of perfluorocarbon 
(PFC) emulsions as an oxygen carrier emulating the role of hemoglobin in the physiologic 
system.52 PFCs have a high dissolving power for oxygen and are hydrophobic, lipophobic, 
and stable which makes them generally biologically compatible. However, unlike oxygen 
chemically bound to hemoglobin, solubilized oxygen can be rapidly and extensively 
extracted from PFC molecules.57 As oxygen is depleted from the culture medium, it is 
replenished via diffusion of dissolved oxygen from the PFC particles.52 The oxygen 
unloading of the PFC emulsion is facilitated by its increased surface area. One 
disadvantage of these emulsions is their lack of stability, resulting in stringent storage 
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requirements and an overall lack of user-friendliness.57 Moreover, their high density causes 
them to settle in the culture well or medium reservoir.50 From this, it can be inferred that 
binding the oxygen carrier molecules to the scaffold would be advantageous. 
 
One study aimed to closely mimic the biological environment by incorporating a parallel 
array of channels within the porous 3D scaffold, representing the capillary network, and 
supplementing the medium with a PFC emulsion, representing the hemoglobin.50 Porous 
biorubber scaffolds, made of poly(glycerol-sebacate), were fabricated using a salt leaching 
technique with sodium chloride as a porogen and an array of cubically packed parallel 
channels was created using a computerized carbon dioxide laser system. Although it was 
demonstrated that the channel walls were highly porous, as required for efficient nutrient 
and oxygen transport, technical restrictions limited the size and spacing of the channels, 
Figure 2-3: Approaches to reduce hypoxia in vitro, promote 
angiogenesis, or both after implantation of engineered tissues. Adapted 
from Malda, J.; Klein, T.J.; Upton, Z., The roles of hypoxia in the in 
vitro engineering of tissues. Tissue Engineering 2007, 13, (9), 2153-2162 
with permission from Mary Ann Liebert, Inc. 
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resulting in channels that were much larger than the native capillaries. Increased 
availability of oxygen resulted in significantly lower levels of lactate dehydrogenase, an 
enzyme indicative of tissue breakdown signifying decreased cell death; increased DNA 
content and cell density, indicating higher construct cellularity; and lower lactate to glucose 
ratio, suggestive of more aerobic metabolism than the control. Electron microscopy of the 
constructs following cell culturing showed that the channels remained open with cells 
present between them; however, a compact and continuous tissue was not formed. 
Moreover, settling of the PFC droplets was still evident within the experimental setup, 
owing to the high density of the PFC emulsion, and the cells exhibited a rounded 
morphology owing to the direct exposure to shear stress above their tolerance, due to the 
perfusion culture conditions. As such, a number of the limitations associated with the 
perfusion bioreactor and PFC emulsion strategies remained apparent with this technique.50 
 
Another method for improving the delivery of oxygen to cells is incorporating oxygen 
generating chemicals into the 3D scaffolds. Calcium peroxide (CPO), which decomposes 
in water to produce oxygen according to the following set of equations, was embedded into 
poly(lactic-co-glycolic acid) (PLGA) scaffolds. 
  
 2CaO2+4H2O→2Ca(OH)2+2H2O2    (2-2) 
 2H2O2→O2+2H2O      (2-3) 
 
The porous 3D PLGA constructs were prepared via particulate leaching with paraffin as a 
porogen and contained CPO at concentrations of 0, 1, 5, and 10 wt. %. Scanning electron 
microscopy data suggested that the pore size and porosity of the scaffold were unaffected 
by the incorporation of CPO and the scaffold maintained a highly porous and open pore 
structure. To test the effect on oxygen delivery, NIH3T3 fibroblasts were seeded onto 
PLGA and PLGA-CPO scaffolds with the addition of catalase to capture the hydrogen 
peroxide by-products that may be toxic to cells. Under normoxic conditions (21 % oxygen, 
5 % carbon dioxide), significant cell viability with the incorporation of 5 % CPO was 
shown. When scaffolds containing 5 % CPO were seeded with cells and cultured in a 
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hypoxic environment (1 % oxygen, 5 % carbon dioxide), the metabolic activity on the 
PLGA-CPO scaffold increased significantly compared with control scaffolds. The hypoxic 
condition was chosen to test the oxygen generation from the CPO.58 
 
A similar study of incorporating CPO into 3D polycaprolactone (PCL) nanofibers was 
carried out to test the antibacterial properties of the calcium hydroxide produced during 
oxygen generation.59 The reported results were not consistent with the previous study58 
since the scaffolds were reported to be cytotoxic to human osteoblast cells. The 
cytotoxicity, however, appeared to be temporary as cells regained a healthy status and 
spread over the nanofiber mesh. This negative effect may be attributed to the initial burst 
release of calcium hydroxide, suggesting that the effect may be transient, causing no long-
term harm to tissue development. 
 
As an alternative to calcium peroxide, sodium percarbonate (SPO) can be used as an 
oxygen generating biomaterial. SPO decomposes in water according to the following 
equations.60 
 
 [Na2CO3]2 ∙ 3H2O2→4Na
++2CO3
2-+3H2O2  (2-4) 
 2H2O2→O2+2H2O     (2-5) 
 
In a feasibility study, SPO was incorporated in a PLGA film using a solvent casting 
fabrication technique. Oxygen was released steadily from the polymeric oxygen generating 
(POG) film during the first 24 hours, after which it decreased until it reached complete 
conversion at roughly 70 hours. Using a skin flap model in nude mice to study the effects 
of the POG film, it was shown that necrosis was initially delayed for two days compared 
to control models with PLGA-only films, yet after seven days the POG and control groups 
were comparable. On a tissue level, exposure to the POG film resulted in significantly less 
degradation, visible by a reduced amount of skin discolouration. This was further supported 
by lower levels of lactate observed in POG groups, indicating that the cells were receiving 
adequate oxygen to prevent anaerobic metabolism, as well as improved tissue strength as 
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determined by biomechanical testing, indicating decreased degradation of ECM proteins. 
It is logical that the beneficial effects are limited to the first two days as the majority of the 
oxygen generation occurs during the first 24 hours. Evaluating oxygen delivery in an in 
vivo model is crucial because the role that oxygen plays in tissue regeneration is complex 
and varies between in vitro and clinical data.  
 
The method of incorporating oxygen generating compounds, such as CPO and SPO, into 
3D porous scaffolds shows potential for enhancing oxygen delivery to seeded cells. 
However, calcium hydroxide and hydrogen peroxide are a strong base and oxidizing agent, 
respectively which could be detrimental to cells seeded on the scaffolds. Inclusion of 
catalase or ascorbic acid to protect against oxidative stress and remove potentially harmful 
by-products could help to alleviate these effects. Based on the inconsistency in the reported 
cytotoxicity of the by-products of the decomposition of CPO and SPO, further studies are 
required to determine the amount of cell protector required to fully prevent toxic effects. 
In addition, incorporating oxygen generating compounds delivers oxygen for a limited 
time, until the oxygen generating compound is completely consumed. Further studies must 
be done to determine if this is enough time to extend cell viability until tissue maturation 
is established and if the amount of oxygen delivered could support larger constructs with 
higher densities of cells.61 
 
Clearly, one major drawback of directly incorporating the oxygen generating compound 
into the tissue engineering construct is the rapid burst release resulting in enhanced oxygen 
delivery over a short period as well as toxic amounts of hydrogen peroxide. In order to 
overcome this limitation, the solid peroxide can be encapsulated within a hydrophobic, 
biostable polymer that will restrict interaction with water, thereby modulating oxygen 
generation. In one study, polydimethylsiloxane (PDMS) disks containing 25 % (w/w) CPO 
powder were fabricated with the intent of enhancing cell viability within 3D tissue 
engineered constructs.62 In an open system at 0.05 mM oxygen, the PDMS-CPO disks were 
able to generate oxygen for approximately 40 days. The oxygen delivery potential of the 
PDMS-CPO disks was tested by centrally incorporating the PDMS-CPO disks within 3D 
agarose constructs containing varying cell densities of a β cell line, MIN6 cells, and 
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culturing them under normoxic or hypoxic oxygen conditions (0.20 or 0.05 mM oxygen, 
respectively) for three days. The cell viability was improved under hypoxic conditions with 
the inclusion of the PDMS-CPO disk to the extent that the results were not statistically 
significant to the corresponding normoxic group. It is likely that this improvement is not 
as drastic under normoxic conditions because oxygen is no longer the limiting factor, rather 
glucose availability or contact inhibition are preventing further increases in cell 
proliferation. It was determined that the PDMS-CPO disks were most beneficial, in terms 
of metabolic activity, at high cell loading densities, likely owing to the higher total rate of 
oxygen consumption. As expected, a rim of live cells surrounding a core of dead cells was 
evident on control constructs from live/dead confocal imaging.  On the contrary, the live 
and dead cells were intermingled throughout the CPO-containing construct and the necrotic 
core was absent. Interestingly, when measurements were made three days after removing 
the PDMS-CPO disk, results were statistically equivalent to the control group, reinforcing 
the hypothesis that the observed improvement to cell viability was due solely to the 
released oxygen. 
 
A recent study in our laboratory tested the oxygen delivery capability of fluorinated porous 
zeolite Y particles embedded into a 3D poly(carbonate urethane) (PCU) scaffold.61 The 
zeolite Y particles were prepared and then fluorinated with 
1H,1H,2H,2H-perfluorodecyltriethoxysilane resulting in fluorinated-zeolite (FZ) particles 
with particle diameters between 850-1000 nm. Three dimensional PCU scaffolds 
containing 2 wt. % embedded FZ particles were fabricated by the solvent casting and 
particulate leaching method with NH4Cl porogens. Inclusion of greater than 2 wt. % FZ 
particles was not possible due to insufficient mechanical integrity. Data confirmed that the 
FZ particles were not leached out during the fabrication process.  In addition, results 
showed open and well-defined pores with high interconnectivity, uniform distribution of 
FZ particles throughout the scaffold, and that the FZ particles were contained mostly at the 
surface of the scaffold which is crucial for oxygen extraction by cells. This was important 
for efficient cell infiltration and nutrient transport. To test the effect of the FZ particles on 
oxygen delivery, human coronary artery smooth muscle cells (HCASMC) were seeded 
onto the FZ modified and control scaffolds and were cultured for 4, 7, and 14 days.  Cell 
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number increased significantly after 4 and 7 days of culture on the PCU-FZ scaffolds 
compared with control scaffolds likely attributed to increased oxygen delivery. Although 
the HCASMC attached and spread on both control scaffolds, the infiltration depth was 
double on the FZ modified scaffolds suggesting enhanced availability of oxygen at greater 
depths in the scaffold. 
 
Alternatively, oxygen delivery vectors can be prepared from cyclodextrin, cyclic 
oligosaccharides made up of six to eight glucose units with a unique shape that allows them 
to readily form inclusion complexes. Perfluorocarbon nanocapsules (PFC-NC) with a mean 
diameter of 350 nm have been synthesized from perfluorodecalin and 
2,3-di-O-decafluorooctanoylcyclomaltooctaose (β-CD-𝐶8
𝐹) as vehicles for oxygen 
solubilization and delivery.63 The liberation of oxygen from the nanocapsules was 
evaluated over a period of 24 hours following oxygenation of the PFC-NC suspension with 
pure oxygen at 1 mL/min for 5 minutes. Compared to pure water oxygenized under the 
same conditions, the PFC-NC showed both a delayed and prolonged release of oxygen. 
However, no cell or scaffold studies have been carried out to date utilizing this biomaterial. 
In comparison, PFC-NC must be oxygenated prior to use whereas FZ particles are able to 
solubilize the oxygen when necessary according to Henry’s law. Since oxygen supply is 
facilitated by the unloading of the oxygen molecule from the nanocapsule, the delivery is 
not indefinite. Theoretically, however, the PFC-NC could be reloaded with oxygen, though 
this is difficult to imagine as a realistic tissue engineering approach. PFC-NC require less 
oxygenation than PFC emulsions and have the additional benefit of improved stability, 
with the ability to be conserved for three months at 4 or 25 °C, thus overcoming one of the 
main drawbacks of PFC emulsions, their lack of stability and resultant stringent storage 
conditions.57 Since the particles are significantly smaller than the FZ particles, it can 
reasonably be assumed that these molecules could be embedded in a 3D scaffold without 
adversely affecting its properties. 
 
As mentioned above, the delivery of oxygen to cells seeded on scaffolds is vital for 
successfully developing tissues of clinical relevance. The preceding cited studies have 
provided platforms to incorporate oxygen delivery vectors into 3D scaffolds without 
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adversely affecting the porosity or morphology. An important factor is the length of the 
oxygen delivery time provided by these vectors. Oxygen must be delivered to the cells 
seeded on the scaffold in sufficient quantities until the engineered tissue matures. 
Development of an improved method for oxygen delivery to cells, thereby preventing cell 
necrosis would allow for enhanced tissue structures, ultimately leading to the fabrication 
of clinically relevant tissues. Although the supply of oxygen to thick tissue constructs in 
vitro (such as muscle and bone) can, in part, be addressed by strategies discussed above, 
combination of these with prevascularization before transplantation is conceptually an 
attractive approach. Such an approach relies on the seeding of endothelial cells to form 
primitive capillary-like tubes within the constructs that may improve the vascularization, 
blood perfusion, and survival of the tissue constructs after transplantation.64, 65 Both 
naturally occurring and synthetic scaffolds that were prevascularized appeared to have 
better host integration and vascularization in animal experiments compared with control 
scaffolds.65-67 It is, however, not clear if the in vivo vascular networks formed are nascent 
with invested pericytes and/or smooth muscle cells. Despite this, it is likely that these 
emerging data and shared strategies accelerate functional tissue fabrication and host 
integration. 
 
2.3 The Chemistry of Perfluorocarbon Compounds 
The search for alternative oxygen binding chemicals has been and remains to be an active 
area of research.68 From a clinical standpoint, this search has been fuelled by increasing 
negative public perceptions about blood safety coupled with the potential risk of 
transmitting diseases through transfusion.69, 70 There are two general categories of current 
approaches for developing alternative oxygen binding chemicals, those based on 
hemoglobin and those based on perfluorinated compounds. Products based on hemoglobin 
include modified hemoglobin derived from either human or animal sources, or genetically 
engineered recombinant microorganisms and plants.71-73 Perfluorinated compounds, on the 
other hand, have been synthesized as emulsions because PFC liquids are immiscible with 
aqueous systems, including blood and other body fluids.73 Oxygent™ (Alliance 
Pharmaceutical Corp., San Diego, CA), for example, is an improved second-generation 
perfluorocarbon emulsion based on perflubron (perfluorooctylbromide, C8F17Br) that is 
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highly stable and can carry over twenty times more oxygen than plasma.74 
Perfluorocarbons are organic molecules where the carbon network is surrounded entirely 
by fluorine atoms. Because fluorine has a much denser electron cloud, a significantly larger 
electron affinity, and a lower polarizability than hydrogen, in addition to being the most 
electronegative atom, the resulting perfluorinated molecules are quite different than their 
hydrogen analogues. The larger, electronically denser fluorine atoms cover and protect the 
carbon backbone much more effectively than hydrogen atoms. The extreme electron 
attracting character of fluorine enhances the C─C bond energy in the skeleton by shrinking 
the orbitals of the carbons. Moreover, the match between the carbon and fluorine orbitals 
is superior to that of carbon and hydrogen; in fact, it is the strongest single bond found in 
molecular compounds (approximately 530 kJ/mol).68, 75 The larger fluorine atom is space 
demanding, forcing the carbon skeleton to adopt a helical rather than zig-zag arrangement. 
As well, the bulkiness makes the perfluorinated chains more rigid and allows for fewer 
kinks. This steric shielding results in PFCs being inert as there are no low energy molecular 
orbitals accessible for reaction.76 Overall, the excellent steric and electronic protection the 
fluorine atoms confer on the carbon skeleton make PFCs both chemically and 
thermodynamically stable.76 
 
 Oxygen Solubility in PFCs 
PFCs do not chemically bind to gases, but they have the ability to dissolve large quantities 
of non-polar gases such as oxygen and carbon dioxide. This ability is due to the extremely 
low polarizability of fluorine which translates into low van der Waals forces within the 
PFC liquid because van der Waals interactions depend on fluctuations in polarity of the 
electronic cloud. As van der Waals interactions are the only intermolecular forces that keep 
non-polar molecules together, in PFCs they are weak, in sharp contrast with the strong 
intramolecular bonds. Gas dissolution, therefore, is a passive process whereby the gas 
molecules occupy “cavities” within the intermolecular spaces of the PFC liquid.76, 77 
 
Oxygen carrying by PFCs is dissimilar to that of hemoglobin where the oxygen is 
chemically bound via a strong, localized chemical coordination bond between the dioxygen 
molecule and the iron atom of the hemoglobin molecule.78 Therefore, oxygen unloading 
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from PFCs is enhanced significantly by the lack of chemical fixation and occurs roughly 
twice as fast as from hemoglobin,70 providing immediate availability to tissues. The 
difference in the interactions of oxygen with hemoglobin and PFCs is reflected in the 
difference in oxygen uptake profiles as a function of partial pressure (pO2) which is 
sigmoid for hemoglobin and linear for PFCs. The linearity of the oxygen uptake profile for 
PFCs is the result of Henry’s law in which solubility (c) is directly proportional to the gas 
partial pressure (p),73 shown in the following equation where kH is a Henry’s law constant. 
 
 𝑝 = 𝑘𝐻𝑐      (2-6) 
 
Linear PFCs, such as perflubron, dissolve oxygen more effectively than cyclic molecules, 
such as perfluorodecalin. In general, oxygen solubility in a PFC is inversely proportional 
to the molecular weight and directly proportional to the number of fluorine atoms, with a 
typical value of 45 mL/100 mL at standard conditions,75 roughly 20-25 times greater than 
in either water or blood plasma under the same conditions.  
 
 PFCs for Enhanced Oxygen Delivery 
In addition to being chemically unreactive, PFCs are also biologically inert. This is enabled 
by both their hydrophobicity and lipophobicity, such that they are not soluble in either the 
aqueous phase or lipids, and are therefore immiscible with body fluids and do not diffuse 
into interstitial fluids.78 Furthermore, they are not metabolized in the body as there are no 
enzymes capable of recycling them thus they do not present any metabolite-related toxicity, 
and are excreted primarily as a vapour through the lungs.77 Intravenous-administered PFC 
droplets are also cleared from the circulation by phagocytic cells of the monocyte-
macrophage system.73 Pure PFCs do not have any negative effects on cell cultures, simply 
benefits resulting from their ability to enhance oxygen delivery, but PFC emulsions can 
have toxic effect due to the emulsifiers used.76 The lack of toxicity and negative side effects 
of liquid PFCs on living cells has been confirmed by in vitro experiments and also in 
clinical investigations.79-82 Other characteristics that make PFCs suitable for biological 
applications is that they are sterilizable, for example by autoclaving, and carry no risks of 
infection.57 In order to be utilized for oxygen delivery, they must have rapid excretion, 
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preferably a few days and no longer than a few weeks,57 and the ability to be easily 
synthesized on a large scale in a highly pure form at a reasonable price.78 The greatest 
disadvantage of using PFC emulsions is their lack of stability, resultant stringent storage 
requirements, and overall lack of user-friendliness.57 
 
In order to utilize PFCs as oxygen vectors in vivo, they must be emulsified into a stable, 
injectable, and small emulsion. They can then be injected intravascularly, increasing the 
oxygen solubility in the plasma phase. Perflubron and perfluorodecalin are the two 
compounds most widely evaluated as the principal constituents of injectable PFC 
emulsions. Both compounds have molecular weights within the range 460-500 g/mol, 
which is recognized as giving acceptable tissue retention times, and can be manufactured 
to a high degree of purity.77 Clark and Gollan83 were the first to demonstrate that mice 
could live while breathing an O2-saturated liquid PFC without any harm to the animals. 
The first preparation of a physiologically adjusted PFC emulsion was reported by Sloviter 
and Kamimoto using bovine serum albumin as a surfactant.84 There is also growing interest 
in the use of PFCs for regulating oxygen supply to cultured cells with the potential to reduce 
or eliminate cellular damage caused by conventional, vigorous aeration methods.85 PFCs 
are especially advantageous for use in cell and tissue culture systems since they are heat 
stable, readily sterilized, and can be recovered from aqueous systems with the potential for 
recycling, thus making them economically viable, and have been used as oxygen vectors 
for both mammalian and insect cells grown in vitro.73, 85, 86 Specifically, in cardiac and 
tracheal tissue engineering, PFCs have been shown to improve oxygenation of tissue 
engineered constructs without adverse effects.50, 52, 87 The major limitation in this area of 
application, however, is droplet settling in culture wells or medium reservoirs due to their 
high density.57 
 
2.4 Cyclodextrin Inclusion Complexes 
 Cyclodextrins 
Cyclodextrins, also known as cycloamyloses, cyclomaltoses, or Shardinger dextrins, are 
cyclic oligosaccharides containing six (α-CD), seven (β-CD), or eight (γ-CD) linked 
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glucopyranose units. Due to steric factors, cyclodextrins built from less than six 
glucopyranose units do not exist; however, cyclodextrins with greater than eight 
glucopyranose units have been synthesized.88, 89 Due to their molecular structure and the 
lack of free rotation about the bonds connecting the glucopyranose units, CDs have a 
unique toroid or truncated cone shape (shown in Figure 2-4). The hydrophilic hydroxyl 
groups are located on the outer surface, with the primary and secondary hydroxyl groups 
located on the narrow and wide side, respectively.90 This structure renders the CDs water-
soluble and concurrently generates a hydrophobic inner cavity.89, 91 CDs are capable of 
accommodating a variety of molecules entirely or partially within their cavity, forming a 
non-covalent host-guest system known as an inclusion complex. 
 
CDs are produced by the enzymatic degradation of starch, a renewable material derived 
from potatoes, corn, rice, etc.39, 89 When the amylose fraction of starch is degraded by 
glucosyltransferases, one or several turns of the amylose helix are hydrolyzed off and their 
ends are joined together, thereby producing the cyclic oligosaccharides.91 CDs are 
produced in amounts of thousands of tons per year using environmentally friendly 
technologies, with prices at levels acceptable for most industrial purposes.88 CDs are 
widely accepted as having low toxicity both orally and intravenously. Orally administered 
CDs have been shown to be harmless because only insignificant amounts are absorbed;92, 
93 and unmodified CDs are completely resistant towards β-amylase, and α-amylase is 
capable of hydrolyzing CDs only at a slow rate.94 After intravenous injections, CDs are 
mainly excreted in their intact form by renal filtration as they are minimally susceptible to 
hydrolytic cleavage or degradation by human enzymes.89 In general, CDs are only able to 
permeate lipophilic biological membranes with considerable difficulty.95 Although tests 
showed that cyclodextrins cannot be considered toxic due to extremely high LD50 values, 
at very high concentrations CDs can extract cholesterol and other lipid membrane 
components from cells, leading to the disruption of cell membranes.89, 92, 96 
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Because they are natural and relatively non-toxic, have a low price and are commercially 
available, and possess the ability to form inclusion complexes with a wide range of guest 
molecules, CDs have been applied to many areas including but not limited to 
pharmaceutical,97, 98 food,40, 99 cosmetic,100, 101 and textile industries.102, 103 Their 
significance in pharmaceuticals alone is well evidenced by the increasing number of 
marketed or approved medicinal products containing CDs.104 Furthermore, the 
functionalization of fibers with CD and/or its inclusion complexes leads to fibrous mats 
Figure 2-4: Molecular structure and toroidal shape of cyclodextrin molecules 
α-CD β-CD 
γ-CD 
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with unique characteristics, potentially broadening the application areas of both 
cyclodextrins and nanofibers.29  
 
 Inclusion Complexes 
Arguably the most interesting property of CDs is their ability to form inclusion complexes, 
a unique form of chemical complex, with a variety of solid, liquid, and gaseous guest 
molecules.95 The formation of cyclodextrin inclusion complexes (CD:ICs) depends largely 
on the agreement between the dimensions of the cyclodextrin cavity and the guest 
molecule, with the guest molecule apparently striving to fill up the cyclodextrin cavity.92, 
105 If the guest is the wrong size, it will not fit properly into the cyclodextrin cavity.95 
Molecules of a very small size will not form stable complexes with cyclodextrins as they 
will slip out of the cavity. Moreover, molecules that are too large or bulky will also not 
form inclusion complexes with cyclodextrins. Nevertheless, if certain functional groups or 
side chains of the molecule can penetrate the CD cavity then partial complex formation is 
possible. Most frequently, complexes are formed at a 1:1 CD:guest ratio, although if a guest 
is too long to be completely enclosed by one CD cavity, multiple CDs can be threaded onto 
the guest creating 2:1, 3:1, etc. (CD:guest) ratios92, 94 Furthermore, in the case of some low 
molecular weight molecules, more than one guest may fit into the cavity.95 The mechanism 
of complex formation is depicted in Figure 2-5 for CD:ICs formed at 1:1 and 2:1 CD:guest 
ratios. Due to the steric requirement of complexation, the different cyclodextrins show 
different capabilities to form inclusion complexes with the same guest molecules. The 
naturally occurring cyclodextrins have the same cavity depth (~7.8 Å), but the number of 
glucose units determines the internal diameter of the cavity and its volume: α-CD, β-CD, 
and γ-CD are roughly 6 Å, 7 Å, and 9 Å in diameter, respectively.29, 41, 95, 106 Some 
properties and dimensions of CDs are shown in Table 2-1. The spatial requirements for 
inclusion complex formation can be compared to the “lock and key” mechanism of enzyme 
catalysis, where the substrate must be oriented properly with respect to the active centers 
of the enzyme.106 Moreover, complex (CS) formation between the cyclodextrin (C) and 
guest (substrate, S) components occurs according to the following equation, and can be 
quantitatively described by the dissociation constant KD.
92 
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 C+S
KD
↔ C∙S      (2-7) 
 KD=
[C]∙[S]
[C∙S]
      (2-8) 
 
In solution, the process by which an inclusion complex is formed occurs according to a 
number of distinct steps.94, 107 Initially, the guest approaches the CD molecule and the water 
structure breaks down, both inside the CD ring and around the guest, with the water 
molecules entering the bulk solution. Next, the interactions between the guest molecule 
and groups on the inner rim of the CD cavity are formed, including possibly hydrogen 
bonds. Finally, the water structure is reconstructed around the complex and any exposed 
parts of the guest. The thermodynamic interactions between the components of the system 
are favourable for complex formation, creating a positive energetic driving force that pulls 
the guest into the cyclodextrin cavity. Firstly, repulsive forces are decreased as the polar 
water molecules are displaced from the apolar cyclodextrin cavity to join the larger pool, 
and the number of hydrogen bonds formed increases. Secondly, there is a reduction in 
+ 
(a) 
(b) 
Figure 2-5: Inclusion complex formation between cyclodextrin host and a guest 
molecule (a) 1:1 CD:guest (b) 2:1 CD:guest 
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repulsive interactions between the hydrophobic guest molecule and the aqueous 
environment as it enters the cavity and increases the hydrophobic interactions.95 These 
driving forces do not exist in the dry, crystalline state, thus, isolating a product in solid 
state is difficult.88 
 
Table 2-1: Properties and dimensions of the naturally occurring cyclodextrins 
 Dimensions (Å)   
 
Gluco-
pyranose 
Units 
Molecular 
Weight 
(g/mol) 
a b c d e 
Cavity 
Volume 
(Å3) 
α 6 972.84 14.6 5.3 4.7 13.2 7.9 174 
β 7 1134.98 15.4 6.5 6.0 14.9 7.9 262 
γ 8 1297.12 17.5 8.3 7.5 16.1 7.9 427 
          
 
The inclusion complex is characterized by the absence of ordinary chemical bonds; the 
interactions between the guest molecule and surrounding cyclodextrin are non-covalent 
and generally weak. The interactions can be van der Waals, hydrophobic interactions, 
dispersion forces, hydrogen bonding, electrostatic interaction, and steric effects.92, 105, 106, 
108, 109 In general, van der Waals forces predominate and include both permanent induced-
dipole-dipole interactions and London dispersion forces.92, 94, 95 Once inside the cavity, the 
guest molecule may adjust its conformation in order to take maximum advantage of the 
weak van der Waals forces that exist.95 Hydrophobic effects are involved because the guest 
molecule replaces the enthalpy-rich, energetically unfavoured water molecules present in 
the slightly apolar cyclodextrin cavity. If the complex is formed in solution, the liberated 
water molecules are taken up by the bulk water where they can form more hydrogen bonds 
than when contained in the cavity, and therefore gain degrees of freedom and contribute to 
the stability of the complex owing to the resulting increase in entropy.92, 94 Moreover, this 
leads to a decrease of cyclodextrin ring strain, from the high energy conformation of the 
CD-water complex to the lower energy conformation of the CD-guest complex, and an 
apolar-apolar association, resulting in a more stable lower energy state overall.94, 95 
Depending on the guest molecule, the formation of hydrogen bonds with the CD hydroxyl 
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groups can be involved.89, 94 The ion-dipole type of electrostatic interaction, between 
undistorted charge distributions of the two molecules, can take place in CD complexation 
because CDs are polar molecules, with modestly large dipole moments.109 
 
Once a complex has been formed and dried, it is stable and exhibits a long shelf life when 
stored in dry conditions at or below ambient temperature.95 Complex dissociation is 
typically driven by a large increase in the number of water molecules in the surrounding 
environment, frequently by dissolving a dried complex in water.95 The resulting 
concentration gradient shifts the equilibrium in Equation 2-7 to the left. Therefore, in 
highly dilute and dynamic systems, such as the body, once the guest dissociates it has 
difficulty finding another cyclodextrin to re-complex with and is left free in solution. For 
this reason, the guest availability in the body is not hampered by slow release, but in fact, 
it has been shown that the rates of formation/dissociation are close to diffusion controlled 
limits.110 Moreover, complex dissociation can be triggered by an increase in temperature 
which weakens the complex.92, 93 Because the normal body tissue temperature is roughly 
37°C, the difference in temperature can contribute to guest dissociation in vivo.93 
Furthermore, if the guest is lipophilic and has access to tissue but not cyclodextrin, the 
tissue acts as a sink and causes dissociation of the complex based on simple mass action 
principles.93 
 
Inherent in the formation of a cyclodextrin inclusion complex is the covering of the guest 
molecule either partially or entirely by cyclodextrin. This provides stabilization and 
protection of the guest from evaporation, degradation, oxidation, etc., as well as alters 
many of the physiochemical properties of the molecule.41, 90 These physiochemical changes 
facilitate the use of characterization techniques to confirm that the guest is indeed contained 
within the cyclodextrin cavity. Cyclodextrin maintains some of its ability to form hydrogen 
bonds with other molecules enabling them to remain at least partially water soluble in the 
form of an inclusion complex.105 In fact, the ability to enhance the aqueous solubility of 
highly insoluble drugs is one of the most studied applications of cyclodextrin inclusion 
complexes along with controlled and/or delayed release of the drug.40, 41, 95 
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Complexes can be formed via a variety of techniques, and the selection is dependent on the 
characteristic properties of each specific guest molecule and the equipment available. One 
of the most commonly utilized techniques in the laboratory is co-precipitation, where the 
guest is added to an aqueous solution of cyclodextrin with stirring. The inclusion complex 
either precipitates out immediately or upon slow cooling and/or evaporation. The collected 
precipitate may be washed, though this step is frequently detrimental to the complex. 
Although the co-precipitation method works for a variety of guest molecules, it is difficult 
to scale up due to the large quantity of water required. The main advantage is that complex 
formation is visible by the disappearance of the guest.92, 93, 95, 105, 111 Slurry complexation 
involves less water than co-precipitation, suspending cyclodextrin at a 50-60% solids 
concentration. The aqueous phase becomes saturated with cyclodextrin in solution and, as 
guest molecules complex with the dissolved cyclodextrin, the complex will precipitate out 
of the aqueous phase. More cyclodextrin dissolves, continuing to saturate the aqueous 
phase, form the complex, and precipitate out of solution.93, 95, 111 Using even less water, 
paste complexation involves adding a small amount of water to the cyclodextrin to form a 
paste. The guest is added and they are mixed using a device such as a mortar in pestle, or 
on a large scale using a kneader. This method is most suitable for industrial synthesis. The 
resulting complex can be dried directly and milled to obtain a powder if a hard mass is 
formed.92, 93, 95, 105, 111 Dry complexation, on the other hand, does not involve the use of any 
water, the guest and cyclodextrin are simply mixed together. This method works best with 
oils or other liquid guests. There is a risk of the mixing not being sufficiently thorough, 
resulting in incomplete complexation.93, 95, 111 Less frequently used methods include damp 
mixing and heating,93, 95 extrusion,93, 95 and layering.92 
 
It is necessary to optimize the amount of water, degree and time of mixing, temperature 
and heating time for each specific guest and complexation technique. Heat can be used to 
increase the amount of CD dissolved, therefore increasing the probability of complexation, 
providing the guest can tolerate the increased temperature. Additionally, heat can also 
destabilize the complex, with most complexes beginning to decompose at 50-60 °C, though 
heat stability varies with differing guests and some can be highly thermally stable.95 For 
this reason, if a solid complex is desired, care must be taken so as not to destroy the 
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complex with heat during the drying process. For extremely delicate complexes, a 
desiccator or freeze dryer may be used to dry the complexes in order to minimize the loss 
of the volatile guest.95 Water is usually the preferred solvent for complexation techniques 
due to the solubility of cyclodextrin, and also because water is easily displaced from the 
cavity to make room for the guest molecule. However, not all guests are readily solubilized 
in water and as a result, complexation can be very slow or impossible. In these cases, an 
organic solvent can be used to dissolve the guest, but the solvent must not complex 
preferentially with the cyclodextrin or have increased affinity for the guest, and must be 
easily removed by evaporation.93 Furthermore, the use of too much solvent can cause the 
guest to be so dilute that it does not come in contact with the cyclodextrin in a sufficient 
amount to facilitate complexation. Moreover, some guest molecules, such as high 
molecular weight oils, can preferentially associate with themselves rather than interact with 
cyclodextrin. To counter this, the amount of solvent is increased, accompanied by sufficient 
mixing in order to disperse and separate the guest molecules from each other.95 Different 
complexation techniques, such as paste or dry mixing could be more efficient for these 
types of guest molecules. 
 
Based on the complexation techniques, CD:ICs can exist in both solution and solid state, 
with their structures differing significantly in each state. In solution, the formation of 
inclusion complexes is not a fixed state but rather a dynamic equilibrium between 
complexed and non-complexed guest molecules where the guest molecule continuously 
associates and dissociates from the host.90, 93, 95 The guest is contained within the cavity, 
and the entire complex is solvated by water molecules. On the other hand, in the crystal 
state the guest may not be included within the cyclodextrin cavity but rather be enclosed in 
a void space of a lattice or merely aggregate to the outside of the cyclodextrin, forming a 
microcrystalline or amorphous powder.88, 90, 92 This arrangement can lead to the formation 
of nonstoichiometric inclusion complexes.106 One of the benefits of preparing inclusion 
complexes in solution is that more cyclodextrin molecules become available for 
complexation whereas in the crystalline form only the surface molecules of the 
cyclodextrin crystal are available for complexation.95 
 
30 
 
 
 
 
2.5 Rationale and Objectives of Study 
Scaffold-guided tissue engineering continues to emerge as a strategy for the repair and 
regeneration of diseased or damaged tissues and organs as an alternative to current 
therapies.1 However, one of the major factors hindering the success of scaffold-guided 
tissue engineering is the inability to deliver sufficient oxygen to the growing constructs. 
Although numerous strategies have been developed to overcome this limitation, they have 
been riddled with drawbacks; thus delivering sufficient oxygen remains a fundamental 
consideration for fabricating engineered tissues.51-53 One approach to improve oxygen 
delivery to constructs is the use of perfusion bioreactors whereby oxygen dissolved in the 
culture medium diffuses to the scaffold material. However, the flow rate required to 
maintain an adequate oxygen concentration for cell viability often surpasses the shear stress 
tolerance of cells.56 Alternatively, perfluorocarbons have been extensively explored as 
oxygen carriers due to their high dissolving power for oxygen, though the focus has been 
on fabricating perfluorocarbon emulsions which lack stability and are overall user-
unfriendly.57 Moreover, the high density of the emulsions causes them to settle in the 
culture well or medium reservoir.50 
 
By shifting the focus from PFC emulsions to alternative oxygen delivery strategies, some 
of the drawbacks of first generation approaches can be remedied. A promising strategy 
involves embedding oxygen generating compounds, such as calcium peroxide58 or sodium 
percarbonate60 which decompose in water to produce oxygen, directly into the tissue 
engineering scaffold. This approach has the advantage of providing oxygen throughout the 
construct, notably in the center which is difficult to reach by diffusion alone, but it is limited 
as the oxygen generating compound is eventually depleted. Tissue engineering scaffolds 
incorporating fluorinated porous zeolite particles provide an alternative to this approach 
whereby the embedded compound does not generate oxygen but enhances oxygen delivery 
using the principles of oxygen solubility in PFCs.61 
 
Cyclodextrins, cyclic oligosaccharides, have a unique shape that enables them to include a 
wide range of guest molecules within their cavity forming an inclusion complex. In 
addition, they are natural and relatively non-toxic, making them suitable for biological 
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applications, and have a low price and are commercially available.112 Because inclusion of 
a guest molecule within the cyclodextrin cavity provides stabilization, it may serve to 
overcome some of the shortcomings of PFC emulsions. Moreover, cyclodextrin inclusion 
complexes have been incorporated into three-dimensional scaffolds via electrospinning;41, 
42, 113 this immobilization of the CD:IC within the scaffold would impart enhanced oxygen 
delivery throughout the construct, and delay or prevent settling of the PCFs in the culture 
well or medium reservoir. Ultimately, the benefits of this approach would serve to enhance 
oxygen delivery to the cells seeded on the construct, potentially facilitating the 
development of thick constructs suitable for clinical applications. 
 
It was hypothesized that cyclodextrin/perfluorocarbon inclusion complexes incorporated 
into three-dimensional tissue engineering scaffolds would enhance oxygen delivery to 
seeded cells. In view of the above rationale, the following objectives were formulated: 
 Prepare and characterize (FTIR, TGA, XRD) an inclusion complex from 
cyclodextrin and a perfluorocarbon 
 Fabricate a three-dimensional scaffold containing the cyclodextrin inclusion 
complex 
 Evaluate the ability of the cyclodextrin inclusion complex to act as an oxygen 
carrier both on its own and when embedded in a scaffold 
 
  
32 
 
 
 
 
2.6  References 
1. Langer, R.; Vacanti, J. P., Tissue engineering. Science 1993, 260, (5110), 920-6. 
2. L'Heureux, N.; Stoclet, J. C.; Auger, F. A.; Lagaud, G. J.; Germain, L.; Andriantsitohaina, 
R., A human tissue-engineered vascular media: a new model for pharmacological studies of 
contractile responses. FASEB J 2001, 15, (2), 515-24. 
3. Katare, R. G.; Ando, M.; Kakinuma, Y.; Sato, T., Engineered heart tissue: a novel tool to 
study the ischemic changes of the heart in vitro. PLoS One 2010, 5, (2), e9275. 
4. Hansen, A.; Eder, A.; Bönstrup, M.; Flato, M.; Mewe, M.; Schaaf, S.; Aksehirlioglu, B.; 
Schwoerer, A. P.; Schwörer, A.; Uebeler, J.; Eschenhagen, T., Development of a drug screening 
platform based on engineered heart tissue. Circ Res 2010, 107, (1), 35-44. 
5. Laflamme, M. A.; Murry, C. E., Heart regeneration. Nature 2011, 473, (7347), 326-35. 
6. Fisher, M. B.; Mauck, R. L., Tissue engineering and regenerative medicine: recent 
innovations and the transition to translation. Tissue Eng Part B Rev 2013, 19, (1), 1-13. 
7. Gauvin, R.; Ahsan, T.; Larouche, D.; Lévesque, P.; Dubé, J.; Auger, F. A.; Nerem, R. M.; 
Germain, L., A novel single-step self-assembly approach for the fabrication of tissue-engineered 
vascular constructs. Tissue Eng Part A 2010, 16, (5), 1737-47. 
8. L'Heureux, N.; Pâquet, S.; Labbé, R.; Germain, L.; Auger, F. A., A completely biological 
tissue-engineered human blood vessel. FASEB J 1998, 12, (1), 47-56. 
9. Norotte, C.; Marga, F. S.; Niklason, L. E.; Forgacs, G., Scaffold-free vascular tissue 
engineering using bioprinting. Biomaterials 2009, 30, (30), 5910-7. 
10. Niklason, L. E.; Gao, J.; Abbott, W. M.; Hirschi, K. K.; Houser, S.; Marini, R.; Langer, R., 
Functional arteries grown in vitro. Science 1999, 284, (5413), 489-93. 
11. Engelmayr, G. C.; Cheng, M.; Bettinger, C. J.; Borenstein, J. T.; Langer, R.; Freed, L. E., 
Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat Mater 2008, 7, (12), 
1003-10. 
12. Grenier, S.; Sandig, M.; Holdsworth, D. W.; Mequanint, K., Interactions of coronary artery 
smooth muscle cells with 3D porous polyurethane scaffolds. J Biomed Mater Res A 2009, 89, (2), 
293-303. 
13. Grenier, S.; Sandig, M.; Mequanint, K., Smooth muscle alpha-actin and calponin 
expression and extracellular matrix production of human coronary artery smooth muscle cells in 
3D scaffolds. Tissue Eng Part A 2009, 15, (10), 3001-11. 
14. Lee, K. W.; Stolz, D. B.; Wang, Y., Substantial expression of mature elastin in arterial 
constructs. Proc Natl Acad Sci U S A 2011, 108, (7), 2705-10. 
15. Williamson, M. R.; Black, R.; Kielty, C., PCL-PU composite vascular scaffold production 
for vascular tissue engineering: attachment, proliferation and bioactivity of human vascular 
endothelial cells. Biomaterials 2006, 27, (19), 3608-16. 
33 
 
 
 
 
16. Cukierman, E.; Pankov, R.; Stevens, D. R.; Yamada, K. M., Taking cell-matrix adhesions 
to the third dimension. Science 2001, 294, (5547), 1708-12. 
17. Dubey, G.; Mequanint, K., Conjugation of fibronectin onto three-dimensional porous 
scaffolds for vascular tissue engineering applications. Acta Biomater 2011, 7, (3), 1114-25. 
18. Martin, T. A.; Caliari, S. R.; Williford, P. D.; Harley, B. A.; Bailey, R. C., The generation 
of biomolecular patterns in highly porous collagen-GAG scaffolds using direct photolithography. 
Biomaterials 2011, 32, (16), 3949-57. 
19. Sanghvi, A. B.; Miller, K. P.; Belcher, A. M.; Schmidt, C. E., Biomaterials 
functionalization using a novel peptide that selectively binds to a conducting polymer. Nat Mater 
2005, 4, (6), 496-502. 
20. Weinberg, C. B.; Bell, E., A blood vessel model constructed from collagen and cultured 
vascular cells. Science 1986, 231, (4736), 397-400. 
21. Hoemann, C. D.; Sun, J.; Légaré, A.; McKee, M. D.; Buschmann, M. D., Tissue 
engineering of cartilage using an injectable and adhesive chitosan-based cell-delivery vehicle. 
Osteoarthritis Cartilage 2005, 13, (4), 318-29. 
22. Ramamurthi, A.; Vesely, I., Evaluation of the matrix-synthesis potential of crosslinked 
hyaluronan gels for tissue engineering of aortic heart valves. Biomaterials 2005, 26, (9), 999-1010. 
23. Madurantakam, P. A.; Cost, C. P.; Simpson, D. G.; Bowlin, G. L., Science of nanofibrous 
scaffold fabrication: strategies for next generation tissue-engineering scaffolds. Nanomedicine 
(Lond) 2009, 4, (2), 193-206. 
24. Hutmacher, D. W., Scaffold design and fabrication technologies for engineering tissues--
state of the art and future perspectives. J Biomater Sci Polym Ed 2001, 12, (1), 107-24. 
25. Peltola, S. M.; Melchels, F. P.; Grijpma, D. W.; Kellomäki, M., A review of rapid 
prototyping techniques for tissue engineering purposes. Ann Med 2008, 40, (4), 268-80. 
26. Carletti, E.; Motta, A.; Migliaresi, C., Scaffolds for tissue engineering and 3D cell culture. 
Methods Mol Biol 2011, 695, 17-39. 
27. Agarwal, S.; Wendorff, J. H.; Greiner, A., Progress in the field of electrospinning for tissue 
engineering applications. Adv Mater 2009, 21, (32-33), 3343-51. 
28. Sill, T. J.; von Recum, H. A., Electrospinning: applications in drug delivery and tissue 
engineering. Biomaterials 2008, 29, (13), 1989-2006. 
29. Uyar, T.; Nur, Y.; Hacaloglu, J.; Besenbacher, F., Electrospinning of functional 
poly(methyl methacrylate) nanofibers containing cyclodextrin-menthol inclusion complexes. 
Nanotechnology 2009, 20, (12), 125703. 
30. Wang, S.; Bai, J.; Li, C.; Zhang, J., Functionalization of electrospun beta-
cyclodextrin/polyacrylonitrile (PAN) with silver nanoparticles: Broad-spectrum antibacterial 
property. Applied Surface Science 2012, 261, 499-503. 
34 
 
 
 
 
31. Uyar, T.; Havelund, R.; Hacaloglu, J.; Zhou, X.; Besenbacher, F.; Kingshott, P., The 
formation and characterization of cyclodextrin functionalized polystyrene nanofibers produced by 
electrospinning. Nanotechnology 2009, 20, (12), 125605. 
32. Doshi, J.; Reneker, D. H., Electrospinning process and applications of electrospun fibers. 
Journal of Electrostatics 1995, 35, 151-160. 
33. Xie, J.; Li, X.; Xia, Y., Putting Electrospun Nanofibers to Work for Biomedical Research. 
Macromol Rapid Commun 2008, 29, (22), 1775-1792. 
34. Bai, J.; Yang, Q.; Li, M.; Zhang, C.; Yiaoxian, L., Synthesis of poly(N-
vinylpyrrolidone)/beta-cyclodextrin composite nanofibers using electrospinning techniques. 
Journal of Materials Processing Technology 2008, 208, 251-254. 
35. Anandharamakrishnan, C., Electrospraying and Electrospinning Techniques for 
Nanoencapsulation. In Techniques for Nanoencapsulation of Food Ingredients, SpringerBriefs: 
2014; Vol. Food, Health, and Nutrition, p 24. 
36. Pham, Q. P.; Sharma, U.; Mikos, A. G., Electrospinning of polymeric nanofibers for tissue 
engineering applications: a review. Tissue Eng 2006, 12, (5), 1197-211. 
37. Akhyari, P.; Kamiya, H.; Haverich, A.; Karck, M.; Lichtenberg, A., Myocardial tissue 
engineering: the extracellular matrix. Eur J Cardiothorac Surg 2008, 34, (2), 229-41. 
38. Shin, H.; Jo, S.; Mikos, A. G., Biomimetic materials for tissue engineering. Biomaterials 
2003, 24, (24), 4353-64. 
39. Celebioglu, A.; Uyar, T., Cyclodextrin nanofibers by electrospinning. Chem Commun 
(Camb) 2010, 46, (37), 6903-5. 
40. Uyar, T.; Hacaloglu, J.; Besenbacher, F., Electrospun polystyrene fibers containing high 
temperature stable volatile fragrance/flavor facilitated by cyclodextrin inclusion complexes. 
Reactive & Functional Polymers 2009, 69, 145-150. 
41. Kayaci, F.; Uyar, T., Encapsulation of vanillin/cyclodextrin inclusion complex in 
electrospun polyvinyl alcohol (PVA) nanowebs: Prolonged shelf-life and high temperature stability 
of vanillin. Food Chemistry 2012, 133, 641-649. 
42. Uyar, T.; Havelund, R.; Hacaloglu, J.; Besenbacher, F.; Kingshott, P., Functional 
electrospun polystyrene nanofibers incorporating α-, β-, and γ-cyclodextrins: comparison of 
molecular filter performance. ACS Nano 2010, 4, (9), 5121-30. 
43. Celebioglu, A.; Uyar, T., Electrospinning of polymer-free nanofibers from cyclodextrin 
inclusion complexes. Langmuir 2011, 27, (10), 6218-26. 
44. Rappaport, C., Review-progress in concept and practice of growing anchorage-dependent 
mammalian cells in three dimension. In Vitro Cell Dev Biol Anim 2003, 39, (5-6), 187-92. 
45. Seifu, D. G. Oxygen delivery strategies in tissue-engineered constructs. University of 
Western Ontario, Electronic Thesis and Dissertation Repository, 2012. 
35 
 
 
 
 
46. Sutherland, R. M.; Sordat, B.; Bamat, J.; Gabbert, H.; Bourrat, B.; Mueller-Klieser, W., 
Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res 
1986, 46, (10), 5320-9. 
47. Wendt, D.; Stroebel, S.; Jakob, M.; John, G. T.; Martin, I., Uniform tissues engineered by 
seeding and culturing cells in 3D scaffolds under perfusion at defined oxygen tensions. Biorheology 
2006, 43, (3-4), 481-8. 
48. Malda, J.; Klein, T. J.; Upton, Z., The roles of hypoxia in the in vitro engineering of tissues. 
Tissue Eng 2007, 13, (9), 2153-62. 
49. Semenza, G. L., Life with oxygen. Science 2007, 318, (5847), 62-4. 
50. Radisic, M.; Park, H.; Chen, F.; Salazar-Lazzaro, J. E.; Wang, Y.; Dennis, R.; Langer, R.; 
Freed, L. E.; Vunjak-Novakovic, G., Biomimetic approach to cardiac tissue engineering: oxygen 
carriers and channeled scaffolds. Tissue Eng 2006, 12, (8), 2077-91. 
51. Malda, J.; Rouwkema, J.; Martens, D. E.; Le Comte, E. P.; Kooy, F. K.; Tramper, J.; van 
Blitterswijk, C. A.; Riesle, J., Oxygen gradients in tissue-engineered PEGT/PBT cartilaginous 
constructs: measurement and modeling. Biotechnol Bioeng 2004, 86, (1), 9-18. 
52. Radisic, M.; Deen, W.; Langer, R.; Vunjak-Novakovic, G., Mathematical model of oxygen 
distribution in engineered cardiac tissue with parallel channel array perfused with culture medium 
containing oxygen carriers. Am J Physiol Heart Circ Physiol 2005, 288, (3), H1278-89. 
53. Radisic, M.; Malda, J.; Epping, E.; Geng, W.; Langer, R.; Vunjak-Novakovic, G., Oxygen 
gradients correlate with cell density and cell viability in engineered cardiac tissue. Biotechnol 
Bioeng 2006, 93, (2), 332-43. 
54. Malda, J.; Rouwkema, J.; Martens, D. E.; le Comte, E. P.; Kooy, F. K.; Tramper, J.; van 
Blitterswijk, C. A.; Riesle, J., Oxygen gradients in tissue-engineered PEGT/PBT cartilaginous 
constructs: Measurement and modeling. Biotechnol Bioeng 2004, 86, (1), 9-18. 
55. Radisic, M.; Malda, J.; Epping, E.; Geng, W. L.; Langer, R.; Vunjak-Novakovic, G., 
Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. 
Biotechnol Bioeng 2006, 93, (2), 332-343. 
56. Yu, X.; Botchwey, E. A.; Levine, E. M.; Pollack, S. R.; Laurencin, C. T., Bioreactor-based 
bone tissue engineering: the influence of dynamic flow on osteoblast phenotypic expression and 
matrix mineralization. Proc Natl Acad Sci U S A 2004, 101, (31), 11203-8. 
57. Riess, J. G., Highly fluorinated systems for oxygen transport, diagnosis and drug delivery. 
Colloids Surf., A 1994, 84, 33-48. 
58. Oh, S. H.; Ward, C. L.; Atala, A.; Yoo, J. J.; Harrison, B. S., Oxygen generating scaffolds 
for enhancing engineered tissue survival. Biomaterials 2009, 30, (5), 757-62. 
59. Wang, J.; Zhu, Y.; Bawa, H. K.; Ng, G.; Wu, Y.; Libera, M.; van der Mei, H. C.; Busscher, 
H. J.; Yu, X., Oxygen-generating nanofiber cell scaffolds with antimicrobial properties. ACS Appl 
Mater Interfaces 2011, 3, (1), 67-73. 
36 
 
 
 
 
60. Harrison, B. S.; Eberli, D.; Lee, S. J.; Atala, A.; Yoo, J. J., Oxygen producing biomaterials 
for tissue regeneration. Biomaterials 2007, 28, (31), 4628-34. 
61. Seifu, D. G.; Isimjan, T. T.; Mequanint, K., Tissue engineering scaffolds containing 
embedded fluorinated-zeolite oxygen vectors. Acta Biomater 2011, 7, (10), 3670-8. 
62. Pedraza, E.; Coronel, M. M.; Fraker, C. A.; Ricordi, C.; Stabler, C. L., Preventing hypoxia-
induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating 
biomaterials. Proc Natl Acad Sci U S A 2012, 109, (11), 4245-50. 
63. Skiba, M.; Skiba-Lahiani, M.; Arnaud, P., Design of nanocapsules based on novel 
fluorophilic cyclodextrin derivatives and their potential role in oxygen delivery. Journal of 
Inclusion Phenomena and Macrocyclic Chemistry 2002, 44, 151-154. 
64. Finkenzeller, G.; Torio-Padron, N.; Momeni, A.; Mehlhorn, A. T.; Stark, G. B., In vitro 
angiogenesis properties of endothelial progenitor cells: a promising tool for vascularization of ex 
vivo engineered tissues. Tissue Eng 2007, 13, (7), 1413-20. 
65. Levenberg, S.; Rouwkema, J.; Macdonald, M.; Garfein, E. S.; Kohane, D. S.; Darland, D. 
C.; Marini, R.; van Blitterswijk, C. A.; Mulligan, R. C.; D'Amore, P. A.; Langer, R., Engineering 
vascularized skeletal muscle tissue. Nat Biotechnol 2005, 23, (7), 879-84. 
66. Bach, A. D.; Arkudas, A.; Tjiawi, J.; Polykandriotis, E.; Kneser, U.; Horch, R. E.; Beier, 
J. P., A new approach to tissue engineering of vascularized skeletal muscle. J Cell Mol Med 2006, 
10, (3), 716-26. 
67. Asakawa, N.; Shimizu, T.; Tsuda, Y.; Sekiya, S.; Sasagawa, T.; Yamato, M.; Fukai, F.; 
Okano, T., Pre-vascularization of in vitro three-dimensional tissues created by cell sheet 
engineering. Biomaterials 2010, 31, (14), 3903-9. 
68. Riess, J. G., Oxygen carriers ("blood substitutes")--raison d'etre, chemistry, and some 
physiology. Chem Rev 2001, 101, (9), 2797-920. 
69. Finucane, M. L.; Slovic, P.; Mertz, C. K., Public perception of the risk of blood transfusion. 
Transfusion 2000, 40, (8), 1017-22. 
70. Lowe, K. C., Engineering blood: synthetic substitutes from fluorinated compounds. Tissue 
Eng 2003, 9, (3), 389-99. 
71. Jahr, J. S.; Akha, A. S.; Holtby, R. J., Crosslinked, polymerized, and PEG-conjugated 
hemoglobin-based oxygen carriers: Clinical safety and efficacy of recent and current products. Curr 
Drug Discov Technol 2011. 
72. Zuckerman, S. H.; Doyle, M. P.; Gorczynski, R.; Rosenthal, G. J., Preclinical biology of 
recombinant human hemoglobin, rHb1.1. Artif Cells Blood Substit Immobil Biotechnol 1998, 26, 
(3), 231-57. 
73. Lowe, K. C., Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev 
1999, 13, (3), 171-84. 
37 
 
 
 
 
74. Keipert, P. E., Perflubron emulsion (Oxygent(tm)): a temporary intravenous oxygen 
carrier. Anasthesiol Intensivmed Notfallmed Schmerzther 2001, 36 Suppl 2, S104-6. 
75. Lowe, K. C., Perfluorochemical respiratory gas carriers: applications in medicine and 
biotechnology. Sci Prog 1997, 80 ( Pt 2), 169-93. 
76. Riess, J. G., Understanding the fundamentals of perfluorocarbons and perfluorocarbon 
emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2005, 
33, (1), 47-63. 
77. Lowe, K. C., Fluorinated blood substitutes and oxygen carriers. J. Fluorine Chem. 2001, 
109, (1), 59-65. 
78. Riess, J. G., Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit Immobil 
Biotechnol 2006, 34, (6), 567-80. 
79. Castro, C. I.; Briceno, J. C., Perfluorocarbon-based oxygen carriers: review of products 
and trials. Artif Organs 2010, 34, (8), 622-34. 
80. Krafft, M. P., Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical 
research. Adv Drug Deliv Rev 2001, 47, (2-3), 209-28. 
81. Lowe, K. C., Perfluorochemical respiratory gas carriers: Benefits to cell culture systems. 
Journal of Fluorine Chemistry 2002, 118, 19-26. 
82. Pilarek, M.; Brand, E.; Hillig, F.; Krause, M.; Neubauer, P., Enhanced plasmid production 
in miniaturized high-cell-density cultures of Escherichia coli supported with perfluorinated oxygen 
carrier. Bioprocess Biosyst Eng 2013, 36, (8), 1079-86. 
83. Clark, L. C.; Gollan, F., Survival of mammals breathing organic liquids equilibrated with 
oxygen at atmospheric pressure. Science 1966, 152, (3730), 1755-6. 
84. Sloviter, H. A.; Kamimoto, T., Erythrocyte substitute for perfusion of brain. Nature 1967, 
216, (5114), 458-60. 
85. Lowe, K. C.; Davey, M. R.; Power, J. B., Perfluorochemicals: their applications and 
benefits to cell culture. Trends Biotechnol 1998, 16, (6), 272-7. 
86. King, A. T.; Mulligan, B. J.; Lowe, K. C., Perfluorochemicals and cell culture. Nature 
Biotechnology 1989, 7, 1037-1042. 
87. Tan, Q.; El-Badry, A. M.; Contaldo, C.; Steiner, R.; Hillinger, S.; Welti, M.; Hilbe, M.; 
Spahn, D. R.; Jaussi, R.; Higuera, G.; van Blitterswijk, C. A.; Luo, Q.; Weder, W., The effect of 
perfluorocarbon-based artificial oxygen carriers on tissue-engineered trachea. Tissue Eng Part A 
2009, 15, (9), 2471-80. 
88. Szejtli, J., Introduction and General Overview of Cyclodextrin Chemistry. Chem Rev 1998, 
98, (5), 1743-1754. 
38 
 
 
 
 
89. van de Manakker, F.; Vermonden, T.; van Nostrum, C. F.; Hennink, W. E., Cyclodextrin-
based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications. 
Biomacromolecules 2009, 10, (12), 3157-75. 
90. Singh, R.; Bharti, N.; Jyotsana, M.; Hiremath, S. N., Characterization of cyclodextrin 
inclusion complexes - A review. Journal of Pharmaceutical Science and Technology 2010, 2, (3), 
171-183. 
91. Saenger, W.; Jacob, J.; Gessler, K.; Steiner, T.; Hoffmann, D.; Sanbe, H.; Koizumi, K.; 
Smith, S. M.; Takaha, T., Structures of the Common Cyclodextrins and Their Larger Analogues-
Beyond the Doughnut. Chem Rev 1998, 98, (5), 1787-1802. 
92. Saenger, W., Cyclodextrin inclusion compounds in research and industry. Angewandte 
Chemie International Edition 1980, 19, 344-362. 
93. Shimpi, S.; Chauhan, B.; Shimpi, P., Cyclodextrins: application in different routes of drug 
administration. Acta Pharm 2005, 55, (2), 139-56. 
94. Bekers, O.; Uijtendaal, E. V.; Beijnen, J. H.; Bult, A.; Underberg, W. J. M., Cyclodextrins 
in the pharmaceutical field. Drug Development and Industrial Pharmacy 1991, 17, (11), 1503-
1549. 
95. Del Valle, E. M. M., Cyclodextrins and their uses: a review. Process Biochemistry 2004, 
39, 1033-1046. 
96. Bilensoy, E.; Hincal, A. A., Recent advances and future directions in amphiphilic 
cyclodextrin nanoparticles. Expert Opin Drug Deliv 2009, 6, (11), 1161-73. 
97. Rocks, N.; Bekaert, S.; Coia, I.; Paulissen, G.; Gueders, M.; Evrard, B.; Van Heugen, J. C.; 
Chiap, P.; Foidart, J. M.; Noel, A.; Cataldo, D., Curcumin-cyclodextrin complexes potentiate 
gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer 2012, 107, (7), 1083-
92. 
98. He, H.; Chen, S.; Zhou, J.; Dou, Y.; Song, L.; Che, L.; Zhou, X.; Chen, X.; Jia, Y.; Zhang, 
J.; Li, S.; Li, X., Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. 
Biomaterials 2013, 34, (21), 5344-58. 
99. Zhu, G.; Xiao, Z.; Zhou, R.; Zhu, Y., Study of production and pyrolysis characteristics of 
sweet orange flavor-β-cyclodextrin inclusion complex. Carbohydr Polym 2014, 105, 75-80. 
100. Kfoury, M.; Auezova, L.; Fourmentin, M.; Greiges-Gerges, H., Investigation of 
monoterpenes complexation with hydroxypropyl-beta-cyclodextrin. J. Incl. Phenom. Macrocycl. 
Chem. 2014. 
101. Pellegrini, M.; De Orsi, D.; Guarino, C.; Rotolo, M. C.; di Giovannandrea, R.; Pacifici, R.; 
Pichini, S., Ultra-performance liquid chromatography tandem mass spectrometry measurement of 
caffeine in caffeine-laced pants and in urine and skin of a pants user. Cosmetics 2014, 1, (2), 82-
93. 
102. Abdel-Halim, E. S.; Al-Deyab, S. S.; Alfaifi, A. Y., Cotton fabric finished with β-
cyclodextrin: Inclusion ability toward antimicrobial agent. Carbohydr Polym 2014, 102, 550-6. 
39 
 
 
 
 
103. Hebeish, A.; El-Shafei, A.; Sharaf, S.; Zaghloul, S., In situ formation of silver nanoparticles 
for multifunctional cotton containing cyclodextrin. Carbohydr Polym 2014, 103, 442-7. 
104. Giordano, F.; Novak, C.; Moyano, J. R., Thermal analysis of cyclodextrins and their 
inclusion compounds. Thermochimica Acta 2001, 380, 123-151. 
105. Khan, N. A.; Durakshan, M., Cyclodextrin: An Overview. International Journal of 
Bioassays 2013, 2, (6), 858-865. 
106. Frank, S. G., Inclusion compounds. J Pharm Sci 1975, 64, (10), 1585-604. 
107. Cramer, F.; Saenger, W.; Spatz, H.-C., Inclusion Compounds. The Formation of Inclusion 
Compounds of Alpha-Cyclodextrin in Aqueous Solutions. Thermodynamics and Kinetic. J. Am. 
Chem. Soc. 1967, 89, (1), 14-20. 
108. Rekharsky, M. V.; Inoue, Y., Complexation Thermodynamics of Cyclodextrins. Chem Rev 
1998, 98, (5), 1875-1918. 
109. Liu, L.; Guo, Q.-X., The driving forces in the inclusion complexation of cyclodextrins. 
Journal of Inclusion Phenomena and Macrocyclic Chemistry 2002, 42, 1-14. 
110. Loftsson, T.; Duchêne, D., Cyclodextrins and their pharmaceutical applications. Int J 
Pharm 2007, 329, (1-2), 1-11. 
111. Hedges, A. R., Industrial applications of cyclodextrins. Chem. Rev. 1998, 98, 2035-2044. 
112. Lo Nostro, P.; Santoni, I.; Bonini, M.; Baglioni, P., Inclusion compound from a 
semifluorinated alkane and beta-cyclodextrin. Langmuir 2003, 19, 2313-2317. 
113. Canbolat, M. F.; Celebioglu, A.; Uyar, T., Drug delivery system based on cyclodextrin-
naproxen inclusion complex incorporated in electrospun polycaprolactone nanofibers. Colloids 
Surf B Biointerfaces 2013, 115C, 15-21. 
 
 
  
40 
 
 
 
 
3 PREPARATION AND CHARACTERIZATION OF 
CYCLODEXTRIN INCLUSION COMPLEXES WITH 
PERFLUOROPERHYDROPHENANTHRENE 
Overview: This chapter discusses the preparation of a cyclodextrin inclusion complex from 
alpha-cyclodextrin and perfluoroperhydrophenanthrene. A number of different 
complexation techniques were employed and the products were characterized by Fourier 
transform infrared spectroscopy, thermogravimetric analysis, and X-ray diffraction. 
Following analysis, the most effective preparation technique was identified for application 
as an oxygen carrier for tissue engineering. 
 
Keywords: cyclodextrin, inclusion complex, perfluorocarbon 
 
3.1 Introduction 
Cyclodextrins are cyclic oligosaccharides with a unique toroidal shape which allows them 
to accommodate a variety of guest molecules within their cavity, forming non-covalent 
host-guest systems known as inclusion complexes. Cyclodextrins are natural and relatively 
non-toxic materials, making them suitable for biological applications, they have a low 
price, and are commercially available.1 Perfluorocarbons are organic molecules where the 
carbon network is surrounded entirely by fluorine atoms and they have the ability to 
dissolve large quantities of non-polar gases such as oxygen. Perfluorocarbons have been 
extensively explored as oxygen carriers to enhance the delivery of oxygen to cells in 
scaffold-guided tissue engineering applications. However, previous approaches involving 
PFCs have focused on fabricating PFC emulsions which lack stability and are not overall 
user-friendly.2 Moreover, the high density of the emulsions causes them to settle in the 
culture well or medium reservoir.3 This study explores the preparation and characterization 
of a cyclodextrin inclusion complex with a perfluorocarbon as a novel oxygen carrier for 
application in tissue engineering. Because inclusion of a guest molecule within the 
cyclodextrin cavity can provide stabilization, it may serve to overcome some of the 
shortcomings of PFC emulsions. Moreover, cyclodextrin inclusion complexes have been 
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incorporated into 3D scaffolds via electrospinning;4-6 this immobilization of the CD:IC 
within the scaffold would impart enhanced oxygen delivery throughout the construct, and 
delay or prevent settling of the PCFs in the culture well or medium reservoir. 
 
Table 3-1: Comparison of the dimensions of potential cyclodextrin host molecules to 
those of perfluorocarbon guest molecules. Sizes of guest molecules are approximated 
from a computer simulation.  
Cyclodextrin Cavity Diameter (Å) Cavity Height (Å) 
α-CD 4.7-5.3 7.9 
β-CD 6.0-6.5 7.9 
γ-CD 7.5-8.3 7.9 
Guest Molecule Diameter (Å) Height (Å) 
PFD 3 6-7 
PFP 5 11-12 
 
The formation of a cyclodextrin inclusion complex depends largely on the agreement 
between the dimensions of the cyclodextrin cavity and the guest molecule. Table 3-1 
shows the dimensions of the cyclodextrins and the guest molecules considered in this study. 
Perfluorodecalin (PFD) and perfluoroperhydrophenanthrene (PFP) were the PFC guest 
molecules considered in this study and their molecular structures are shown in Figure 3-1. 
PFD dissolves a high level of oxygen (100 mL of PFD dissolves roughly 40 mL of O2 at 
37 °C) and has a longer tissue retention time than the most widely used perflubron which 
suggests potential for clinical application.7 Furthermore, the feasibility of PFD as an 
oxygen carrier has been studied previously in our lab with promising results.8, 9 PFP, on 
the other hand, has been used as a perfluorinated, high molecular weight high boiling point 
oil additive to help prevent instability and retard phase separation in emulsions of PFD.10, 
11 From Table 3-1, it is clear that the best match of host and guest dimensions is between 
α-CD and PFP, with the 5 Å diameter PFC able to fit snugly inside the α-CD cavity. For 
this reason, PFP and α-CD were the components used to prepare the inclusion complex in 
this study. In fact, consistent with the internal cavity diameter, Druliner and Wasserman12 
reported that among a group of perfluoroalkanes studied, PFP was the only case in which 
any evidence of inclusion complex formation with α-CD was found. It should be noticed 
that considering that the depth of the CD cavity is roughly 8 Å, it is possible that two CD 
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rings can be threaded onto a single chain of the PFP.1 Therefore, both 1:1 and 2:1 α-
CD:PFP molar ratios were explored in the methodology. 
 
Complexes can be formed via numerous techniques, and the selection is dependent on the 
characteristic properties of the specific guest molecule and the equipment available.13 
Three complexation techniques were tested for optimal results in the preparation of the 
PFP/α-CD complexes: co-precipitation, paste mixing, and dry mixing, as reviewed in 
Section 2.4.2. When the cyclodextrin covers the guest molecule, either partially or entirely, 
it provides stabilization and protection, and alters many of the physiochemical properties 
of the guest.5, 14 These physiochemical changes are the basis for the characterization 
techniques used to confirm that the guest is indeed contained within the cyclodextrin 
cavity.  
 
3.2 Materials 
Perfluoroperhydrophenanthrene (C14F24) was obtained as a mixture of isomers (83 % 
purity) from Alfa Aesar (Ward Hill, MA). Perfluorodecalin (C10F18) was obtained as a 
mixture of cis and trans isomers (99.9 % purity) from Sigma Aldrich (Milwaukee, WI) 
Alpha-cyclodextrin (α-CD, 100 % purity) and beta-cyclodextrin (β-CD, 10.8 % moisture) 
were obtained commercially from Alfa Aesar. Solvents were purchased from Caledon Labs 
Figure 3-1: Molecular structure of perfluorodecalin (PFD, left) and 
perfluoroperhydrophenanthrene (PFP, right) 
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(Georgetown, ON). All other chemicals were purchased from Sigma Aldrich. Unless noted 
otherwise, all chemicals were used as received without any further modification. 
 
3.3 Methods 
 Preliminary Studies 
Initial complexation studies were carried out using PFD as the guest molecule with both α-
CD and β-CD as hosts. The co-precipitation technique was carried out at both a 1:1 and 2:1 
CD:PFD molar ratio. 
 
Alpha- or beta-cyclodextrin was added to de-ionized (d.i.) water to create a saturated 
aqueous solution. Weighed amounts of PFD were added to the α-CD solution at a ratio of 
1:1 or 2:1 CD to PFC. The solution was stirred continuously and vigorously (1000 rpm) at 
room temperature (RT) in a sealed vial. After 72 hours of mixing, the solvent (water) was 
evaporated over 2-3 days in an open system in order to obtain a solid product. The solid 
product was dried and stored in a desiccator with potassium hydroxide used as a desiccant.  
 
 Preparation of Cyclodextrin Inclusion Complexes with 
Perfluoroperhydrophenanthrene 
Throughout this chapter, α-CD is referred to as the “host” and PFP is referred to as the 
“guest”. Three complexation techniques were studied to obtain an inclusion complex 
between α-CD and PFP: co-precipitation, paste mixing, and dry mixing. All complexation 
techniques were carried out at both 1:1 and 2:1 molar ratios of α-CD to PFP (host to guest). 
Following complexation the product was not washed because the washing process is often 
detrimental to the complex. 
 
3.3.2.1 Co-precipitation 
The solid α-CD/PFP complexes were prepared using a co-precipitation method modified 
from a previously reported method also utilizing a PFC.15 Heating can be used to increase 
the amount of CD dissolved, thus increasing the probability of complexation. Therefore, in 
addition to RT, co-precipitation was carried out at the mild temperature of 40 °C, as most 
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complexes begin to decompose at 50-60 °C.16 The amount of solvent required was 
minimized, to prevent the guest molecule from becoming too dilute that it does not come 
in contact with the CD in sufficient amounts to facilitate complexation. Moreover, because 
the guest molecule is a high molecular weight fluorocarbon, it may preferentially associate 
with itself as opposed to interact with the CD, so a vigorous amount of stirring was utilized 
in order to disperse and separate the guest molecules from each other.16 
 
Alpha-cyclodextrin was added to d.i. water to create a saturated aqueous solution. Weighed 
amounts of PFP were added to the α-CD solution at a ratio of 1:1 or 2:1 α-CD to PFP. The 
solution was stirred continuously at 1000 rpm at either RT or 40 °C in a sealed vial. After 
72 hours of stirring, the solvent (water) was evaporated over 2-3 days in an open system at 
RT in order to obtain a solid product. The solid product was dried and stored in a desiccator 
with potassium hydroxide used as a desiccant. 
 
3.3.2.2 Paste Mixing 
Weighed amounts of α-CD and a minimal amount of d.i. water were combined to form a 
paste. Weighed amounts of PFP were added to the α-CD paste at a 1:1 or 2:1 α-CD to PFP 
molar ratio. The paste was thoroughly mixed using a ceramic mortar and pestle for ten 
minutes. The product was collected in a glass vial, dried and stored in a desiccator with 
potassium hydroxide used as a desiccant. 
 
3.3.2.3 Dry Mixing 
Weighed amounts of α-CD and PFP were combined at a 1:1 or 2:1 α-CD to PFP molar 
ratio. The dry mixture was thoroughly mixed with a ceramic mortar and pestle for ten 
minutes. The solid product was collected and stored in a desiccator with potassium 
hydroxide used as a desiccant. 
 
 Fourier Transform Infrared Spectroscopy 
The products obtained in the preliminary studies were characterized by Fourier transform 
infrared (FTIR) spectrometry using a Bruker Vector 22 (Bruker Optics, Billerica, MA) 
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equipped with a MIRacle Attenuated Total Reflectance (ATR) diamond crystal plate 
sample cell (PIKE Technologies, Madison, WI). In the follow-up studies, FTIR 
characterization of the α-CD/PFP complexes was carried out on a Bruker Tensor 27 
spectrometer equipped with an ATR attachment using a ZnSe crystal. 
 
In all cases, the samples were run as fine powders or a liquid (in the case of PFP) for 32 
scans with a resolution of 4 cm-1 over the scan range 600 to 4000 cm-1. All spectra were 
collected and processed with the OPUS software version 6.5. Absorption frequencies are 
reported in wavenumbers (cm-1). 
 
 Thermogravimetric Analysis 
Thermogravimetric analysis (TGA) was performed using an SDT Q600 Thermal Analyzer 
(TA Instruments, USA). Experiments were performed under nitrogen at a heating rate of 
10 °C/min up to 600 °C. The real time weight loss as a function of temperature was 
recorded during the experiment using the Universal Analysis 2000 data acquisition system. 
 
 X-ray Diffraction 
X-ray diffraction (XRD) spectra were collected with a Rigaku Ultima IV X-ray Diffraction 
Generator (Rigaku, Japan). The patterns were measured in the continuous mode, applying 
a CuΚα X-ray source at a range of 2θ = 2 – 60° with a scan rate of 2 °/min. The applied 
voltage and current were set to 40 kV and 40 mA, respectively. 
 
3.4 Results 
 Preliminary Studies 
Preliminary studies were carried out with PFD as the guest molecule for inclusion 
complexation with cyclodextrin. PFD was readily available and had been used previously 
in our lab as an oxygen carrier with promising results.8, 9 The products of the co-
precipitation complexation technique between both α- and β-CD and PFD were analyzed 
with FTIR spectroscopy. The FTIR spectra are shown in Figure 3-2 and Figure 3-3 for α-
CD and β-CD, respectively. The FTIR spectra of the products are compared to those of the 
46 
 
 
 
 
native CDs and as-received PFD. Peaks characteristic of the PFD guest are not evident in 
the FTIR spectra of the products. In fact, the spectra of the products are virtually identical 
to those of the respective parent CDs. Therefore, there is a lack of evidence of complexation 
with PFD in the FTIR spectra for either α-CD or β-CD. It is likely that an inclusion complex 
did not form between these specific host and guest molecules because of an unsuitable 
match between the dimensions of PFD and the CD cavity. The diameter of PFD is much 
smaller than the width of both the α- and β-CD cavity. Molecules of a very small size do 
not form stable complexes with cyclodextrins as they slip out of the cavity. As 
demonstrated in Table 3-1, the best match of host and guest dimensions is between α-CD 
and PFP. As such, the focus of further studies was complexation between α-CD and PFP. 
Furthermore, the number of complexation techniques explored was expanded in order to 
test for optimal results of complexation between α-CD and PFP. 
 
Furthermore, the complexes were initially dried in a vacuum oven at RT. However, it 
became apparent that this procedure likely compromised the product because most 
complexes start to decompose at 50-60°C.16 Thus, the procedure was altered and the 
complexes were dried in a desiccator as suggested in the literature for extremely delicate 
complexes in order to minimize the loss of the guest.16 
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Figure 3-2: FTIR spectra of (i) unmodified α-CD, products of RT co-precipitation at 
a (ii) 2:1 and (iii) 1:1 molar ratio, and (iv) as-received PFD 
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Figure 3-3: FTIR spectra of (i) unmodified β-CD, products of RT co-precipitation at 
a (ii) 2:1 and (iii) 1:1 molar ratio, and (iv) as-received PFD 
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 Fourier Transform Infrared Spectroscopy 
FTIR spectroscopy was carried out on the products obtained from each of the complexation 
techniques: co-precipitation, paste mixing, and dry mixing. FTIR spectroscopic techniques 
are not generally suitable for conclusively confirming the formation of an inclusion 
complex because there are only slight shifts and changes upon complexation.17 There are 
interferences in the spectra from the cyclodextrin, and some of the changes are very subtle, 
requiring careful interpretation of the spectrum.13 Moreover, if the fraction of the guest 
molecule included within the cyclodextrin cavity is less than 25 %, the bands which could 
be assigned to the guest molecule can be masked by the bands of the cyclodextrin and the 
water of crystallization.14, 17, 18 Nevertheless, changes in the fingerprint region (below 1300 
cm-1) can confirm that the products are different from each parent molecule as they possess 
new spectroscopic signals. Thus, FTIR was used in this study as an initial characterization 
technique because it is both inexpensive and readily available. The slight changes in the 
spectra of the products were used to identify the complexation techniques that were most 
effective. 
 
The various complexation techniques utilized in this study were carried out at both 1:1 and 
2:1 host to guest (α-CD:PFP) molar ratios; the FTIR spectra for these products are shown 
in Figure 3-4 and Figure 3-5, respectively. The FTIR spectra of the products are compared 
to those of the native α-CD, as-received PFP, and 1:1 or 2:1 physical mixtures of the two 
parent molecules. The spectrum for the unmodified α-CD shows peaks at 1024 and 1076 
cm-1 corresponding to coupled C-C/C-O stretching vibrations, and at 1153 cm-1 
corresponding to the anti-symmetric stretching vibration of the C-O-C glucosidic bridge, 
in agreement with the literature.19, 20 Furthermore, a broad band at roughly 3300 cm-1 is 
attributed to the symmetric and anti-symmetric OH stretching, and a peak at roughly 2900 
cm-1 is attributed to C-H vibrations.21, 22 When complex formation occurs, there is 
frequently a slight shift in the hydroxyl band which is usually ascribed to hydrogen bonding 
or other intermolecular interactions between the CD and guest molecule.23, 24 
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Figure 3-4: FTIR spectra of (i) unmodified α-CD, (ii) physical mixture of α-CD and 
PFP at a 1:1 molar ratio, inclusion complexes formed at a 1:1 (CD:PFP) molar ratio 
via (iii) dry mixing, (iv) paste mixing, (v) co-precipitation at 40°C, (vi) co-precipitation 
at RT(vii) and as-received PFP 
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Figure 3-5: FTIR spectra of (i) unmodified α-CD, (ii) physical mixture of α-CD and 
PFP at a 2:1 molar ratio, inclusion complexes formed at a 2:1 (CD:PFP) molar ratio 
via (iii) dry mixing, (iv) paste mixing, (v) co-precipitation at 40°C, (vi) co-precipitation 
at RT(vii) and as-received PFP 
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Table 3-2: Characteristic peaks (cm-1) of PFP and the corresponding peaks observed 
in the products of various complexation techniques at both 1:1 and 2:1 molar ratios 
of α-CD and PFP. A double dash indicates that a peak was not observed at that 
wavenumber. 
Peak PFP 
1:1 
Physical 
Mixture 
1:1 Co-
precipitation RT 
1:1 Co-
precipitation 40 
1:1 Paste 
Mixing 
1:1 Dry 
Mixing 
A 1323 1323 1329 1323 1325 1325 
B 1207 1209 -- 1209 1211 1211 
C 1188 1188 -- 1188 1192 1190 
D 1101 1099 1094 1101 1094 1094 
E 1018 1018 -- 1018 1020 1018 
F 970 970 -- 970 972 972 
G 910 910 905 910 910 910 
       
Peak PFP 
2:1 
Physical 
Mixture 
2:1 Co-
precipitation RT 
2:1 Co-
precipitation 40 
2:1 Paste 
Mixing 
2:1 Dry 
Mixing 
A 1323 1323 1329 1331 1325 1325 
B 1207 1209 -- -- 1211 1211 
C 1188 1190 -- -- 1192 1192 
D 1101 1099 -- 1094 1094 1093 
E 1018 1018 1022 1024 1020 1020 
F 970 970 -- -- 972 972 
G 910 910 904 905 912 910 
       
 
Peaks characteristic of the PFC guest are evident in the spectra of the products (Figure 3-4 
and Figure 3-5). Unequivocal assignment of the FTIR bands of PFP is beyond the scope 
of the present work. Nonetheless, a number of these characteristic peaks were selected such 
that they did not overlap with strong absorption bands for the α-CD and are denoted by the 
letters A-G. The wavenumbers at which these peaks occur shifts slightly upon 
complexation; the shifts observed in this study for the selected peaks are tabulated in Table 
3-2. A more thorough and quantitative characterization of the complexes was carried out 
by further analyzing the absorbance at these characteristic peaks. First, the absorbance 
value at each characteristic peak was divided by the absorbance values at the equivalent 
peak in the corresponding physical mixture, serving as an external standard. Secondly, the 
resulting values were divided by their average, acting as an internal standard. Finally, the 
53 
 
 
 
 
standard deviation of these normalized values was calculated and they are presented in 
Table 3-3. The standard deviation quantitatively demonstrates the difference between the 
peaks observed in the product and those observed in the physical mixture. Simply put, a 
larger standard deviation signifies a larger chemical shift (complexation), relative to the 
physical mixture. 
 
Table 3-3: Absorbance values at peaks characteristic of PFP, normalized to physical 
mixture (external standard) and concentration (internal standard) for products 
prepared via various complexation techniques at both a 1:1 and 2:1 ratio of α-CD and 
PFP 
Peak 
1:1 Co-
precipitation RT 
1:1 Co-
precipitation 40 
1:1 Paste 
Mixing 
1:1 Dry 
Mixing 
A 0.96 0.95 1.29 1.23 
B -- 1.02 0.80 1.03 
C -- 1.03 0.70 0.92 
D 1.55 1.09 1.32 1.08 
E -- 1.01 1.38 1.17 
F -- 0.93 0.85 0.84 
G 0.50 0.98 0.67 0.74 
St. Dev. 0.53 0.05 0.31 0.18 
     
Peak 
2:1 Co-
precipitation RT 
2:1 Co-
precipitation 40 
2:1 Paste 
Mixing 
2:1 Dry 
Mixing 
A 1.09 0.91 1.15 1.11 
B -- -- 0.57 0.79 
C -- -- 0.54 0.72 
D -- 1.41 1.51 1.34 
E 1.22 1.20 1.54 1.15 
F -- -- 0.91 0.98 
G 0.69 0.49 0.78 0.92 
St. Dev. 0.27 0.40 0.41 0.22 
     
 
Inclusion complex formation is characterized by weak, non-covalent interactions between 
the host and guest molecules. In addition to van der Waals forces, hydrophobic interactions 
are predicted to be involved in the inclusion of the PFP molecule within the α-CD cavity. 
During the co-precipitation technique, there are strong repulsions between the water 
molecules and the hydrophobic PFC. PFP can avoid contact with the water molecules by 
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entering the CD cavity and forming an inclusion complex. In addition, this results in the 
expulsion of enthalpy-rich, energetically unfavoured water molecules present in the 
slightly apolar cyclodextrin cavity. The expelled water molecules are taken up by the bulk 
solution where they can form more hydrogen bonds than when contained in the 
cyclodextrin cavity, and therefore gain degrees of freedom and contribute to the stability 
of the complex owing to the increase in entropy.17, 18 In a 1:1 conformation the guest would 
partially stick out of the α-CD cavity. Since the main driving force of this complexation is 
the minimization of the contact between the PFC and the aqueous environment, it can 
reasonably be expected that each PFP molecule would prefer to be totally covered by CDs. 
Consequently a 2:1 α-CD:PFP complex is more likely. However, it is evident from the 
FTIR spectra of the products obtained via the co-precipitation complexation technique at 
both 1:1 and 2:1 at RT, as well as at 2:1 and 40 °C, that salient peaks characteristic of PFP 
at 1207 and 1188 cm-1 (B and C, respectively in Figure 3-4 and Figure 3-5) were not 
observed. In fact, these spectra are almost identical to that of the un-modified α-CD and it 
can be concluded that these techniques are not effective in preparing an inclusion complex 
from these specific host and guest molecules. In contrast, the product prepared via 1:1 co-
precipitation at 40 °C does show the peaks characteristic of the PFP guest. However, when 
compared to the corresponding physical mixture the standard deviation of the normalized 
absorbance values is exceptionally low (Table 3-3). This demonstrates that the product 
from this technique is actually only a physical mixture of the two parent components and 
inclusion of the PFP within the α-CD cavity did not occur. 
 
Overall, the FTIR spectra of the products prepared via both the dry and paste mixing 
techniques indicate successful inclusion complex formation as the characteristic peaks of 
PFP, A-G in Figure 3-4 and Figure 3-5, are visible. In fact, it is evident that these 
characteristic peaks have shifted slightly (Table 3-2). For example, the characteristic bands 
of PFP at 1207 and 1188 cm-1 shifted to 1211 and 1192 cm-1, respectively for both the 2:1 
paste and dry mixing techniques. These peaks are also different than those observed in the 
2:1 physical mixture, at 1209 and 1190 cm-1, respectively. This suggests that host-guest 
interactions were formed in the product and is in agreement with the literature where 
similar shifts were reported.1, 15, 25 Further evidence of the effectiveness of the mixing 
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techniques is that the characteristic peaks were suppressed when compared to both PFP 
and the physical mixture. The attenuation of the absorption bands of guest molecules is 
typically observed for CD:IC systems because the inclusion of the guest molecules in the 
CD cavity hinders their molecular vibrations, and therefore the intensity of their absorption 
bands is diminished.26 Furthermore, the standard deviations of the absorbance values 
obtained for these products indicate significant differences from their corresponding 
physical mixtures (Table 3-3). It is likely that the mixing techniques were more successful 
than co-precipitation in preparing an inclusion complex with this specific guest due to its 
liquid form. The PFP may not have associated with the CD in solution in an amount 
sufficient to facilitate complexation for two reasons: it is possible that the PFP was too 
dilute in the aqueous solvent, and because PFP is a high molecular weight compound, it 
may preferentially associate with itself even with vigorous stirring. However, one of the 
limitations of the mixing techniques is the inability to guarantee homogeneous mixing; 
thus, the product may be a mixture of host, guest, and complex. In fact, the complexes 
prepared via the mixing technique at a 1:1 molar ratio show a larger hydroxyl vibrational 
band (roughly 3300 cm-1), potentially due to an amount of uncomplexed CD remaining in 
the product. Although this could be remedied by washing the product, there is a risk of 
destroying the complex or decreasing the product yield. 
 
The complexes prepared at a 2:1 molar ratio of the α-CD host to the PFP guest appeared to 
be the most successful overall. This corresponds with the α-CD cavity height being smaller 
than that of the PFP so that in order for the PFP to be fully covered, two α-CD molecules 
must be threaded onto one PFP molecule. Further characterization techniques were only 
carried out on the samples prepared at a 2:1 molar ratio. 
 
 Thermogravimetric Analysis 
TGA was carried out on the products of the co-precipitation, paste mixing, and dry mixing 
complexation techniques carried out at a 2:1 molar ratio (α-CD:PFP) for further 
confirmation of the formation of an inclusion complex. Thermal characterization 
techniques involve analyzing the broadening, shifting, and disappearance of existing peaks, 
as well as the appearance of new peaks, when compared to the parent molecules and/or the 
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physical mixture of the parent molecules. The thermograms for the parent molecules, α-
CD and PFP, their 2:1 physical mixture, and complexes prepared from co-precipitation (at 
RT), paste mixing, and dry mixing are shown in Figure 3-6. The TGA data is presented as 
weight percent, and both derivative weight and derivative heat flow (with respect to 
temperature) versus temperature. 
 
The thermogram for α-CD shows two mass losses centered at 60 and 90 °C, corresponding 
to a loss of absorbed water and water of crystallization, and a third at 320 °C corresponding 
to its decomposition.27 PFP, with a reported boiling point of 214-216 °C,28 shows a mass 
loss centered at 165 °C, corresponding to its complete vaporization. The difference with 
the literature data may be due different isomeric composition or the relatively low purity 
of the PFP molecule used in this study. The thermogram for the 2:1 physical mixture of α-
CD and PFP appears to be almost identical to that obtained for pure α-CD. This is 
potentially due to incomplete mixing of the parent molecules with the result that the 
fraction used for TGA analysis did not contain any PFP. It was not possible to remedy this 
by more thoroughly mixing the components as this would, in effect, be carrying out the dry 
mixing complexation technique. 
 
The thermograms for the products prepared by different complexation techniques all show 
two mass losses which occur at approximately 100 and 320 °C. The latter peak clearly 
corresponds to the degradation of α-CD. The loss of PFP overlaps with the loss of water at 
100 °C, and it was therefore difficult to elucidate differences in the thermograms by looking 
solely at weight loss and derivative weight. Comparing the derivative heat flow for the 
product prepared via co-precipitation (at RT) to that for α-CD, some differences are 
observed; however, the same basic shape of the thermogram of CD is maintained. For 
example, there are still two peaks around 100 °C, and although they have shifted slightly, 
the shifts are not sufficient to confirm complex formation. These results are in agreement 
with the FTIR results discussed previously (Section 3.4.2). 
 
The derivative heat flow (with respect to temperature) for the product prepared via dry 
mixing shows a very similar pattern to that of α-CD around 100 °C, indicating a large mass 
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loss at this temperature corresponds to the release of water. There are noticeable 
differences, however, starting at 300 °C when the α-CD begins to decompose. This 
provides evidence that some PFP was in fact included within the CD cavity, such that it 
was thermally stabilized and did not evaporate until the CD began to decompose, in 
agreement with results reported in the literature.29 The product prepared via paste mixing, 
on the other hand, shows a different derivative heat flow at both 100 and 320 °C. This 
indicates that this technique was more effective, with more PFP included within the cavity. 
Around 100 °C, there is only one endothermic peak, indicating that there was some degree 
of displacement of water molecules from the host CD cavity, which corresponds to the 
inclusion of PFP within that cavity.26 
 
If PFP molecules escape from the α-CD cavities at temperatures below 300 °C when α-CD 
begins to decompose, the weight loss should correspond to the mass fraction of PFP in the 
complexes. In the case that the CD:IC contains no water of crystallization, the calculated 
mass fraction of PFP approaches 25 %. However, it is clear from the thermograms, 
specifically those showing derivative heat flow, that there is some water remaining in the 
complexes, and therefore the calculated mass fraction of PFP is overestimated. The amount 
of water bound to the complex could likely be further decreased by using a more effective 
drying technique, such as heat-drying, however, this could be detrimental to the complex. 
The calculated mass loss below 123 °C for the complex prepared via paste mixing is less 
than the calculated expected mass loss. Taking into consideration that the observed mass 
loss also includes water loss, this is further evidence that some PFP was included within 
the α-CD cavity and was not thermally altered until the temperature at which the α-CD 
began to decompose. It is possible that some of the product of paste complexation is an 
inclusion complex and some is simply a physical mixture of the parent molecules. 
Increasing the mixing time for paste complexation could serve to reduce the amount of 
uncomplexed α-CD in the product. 
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Figure 3-6: TGA thermograms of unmodified α-CD and PFP, their 2:1 physical 
mixture, and complexes prepared via co-precipitation (at RT), paste mixing, and 
dry mixing at a 2:1 molar ratio 
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Unfortunately, the main thermal event for PFP in the complexes was not increased as is the 
case most reported in the literature for evidence supporting the formation of a stable 
inclusion complex.15, 25, 30 Interaction of the guest with the cyclodextrin provides a higher 
energy barrier to overcome for volatilization resulting in an increase in boiling temperature 
of about 10 °C.13 On the other hand, the inclusion complexes prepared with volatile guests 
often do not have substantially higher thermal decomposition temperatures.26 In this case, 
it was actually observed that the PFP in the products evaporated at a lower temperature 
than the unmodified PFP. Although inclusion within the cyclodextrin cavity can provide 
stability for the guest molecule, in this case the interactions with the CD cavity are weaker 
than those formed in the bulk solution between the liquid PFP molecules. It is also possible 
that the guest is not completely included within the cyclodextrin cavity, but rather is closed 
in a void space of a lattice or aggregated to the outside of the cyclodextrin, forming a 
microcrystalline or amorphous powder.14, 17, 31 This type of complex would have a much 
lower stability than if the guest was included entirely within the cyclodextrin cavity. 
Nevertheless, it was observed that some of the PFP was not removed until the CD began 
to decompose which has also been reported in the literature as evidence supporting the 
formation of an inclusion complex.5, 29 
 
Overall, thermal characterization using TGA did not prove to be an effective technique for 
confirming complex formation between the host and guest molecules used in this study. 
This was mainly due to the similarity of the guest vaporization temperature to that for 
water. Nonetheless, it was possible to further ascertain the effectiveness of the different 
complexation techniques, specifically providing the opportunity to further distinguish the 
differences between the paste and dry mixing complexation techniques, which showed 
similar efficacy when analyzed using FTIR. Overall, the TGA data suggests that the paste 
mixing technique was the most effective whereas co-precipitation (at RT) was the least 
effective, which is in agreement with the data obtained from FTIR characterization. The 
paste mixing technique is likely more effective due to the small amount of water utilized 
in this preparation technique which acts as a driving force for the PFP molecule to enter 
the hydrophobic CD cavity in order to reduce contact with the aqueous environment. 
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 X-ray Diffraction 
After initial characterization with FTIR, it was determined that inclusion complex 
formation occurred preferentially at a 2:1 α-CD:PFP molar ratio. XRD was carried out on 
complexes prepared at this ratio using co-precipitation (at RT), paste mixing, and dry 
mixing techniques. When an inclusion complex is formed with a solid substance as a guest, 
a comparison has to be made between the diffractogram of the product and that of the 
physical mixture of the two parent molecules. However, in the case of a liquid guest, as 
with PFP, no comparison is necessary because liquids do not have diffraction patterns of 
their own. Therefore, if the diffraction pattern of the product clearly differs from that of the 
unmodified cyclodextrin, the difference indicates complex formation. Complex formation 
leads to the sharpening and/or shifting of existing peaks, as well as the appearance of a few 
new peaks.14, 18 
 
CDs are crystalline and have crystal structures referred to as cage or channel type.32 The 
as-received CDs have a cage type packing structure characteristic of a random packing 
arrangement. In cage type packing, the CDs are arranged in a herringbone pattern (Figure 
3-7c) where both openings of each CD unit are closed by adjacent CD molecules. CDs take 
this form when small molecules, such as water, are included in its cavity. In general, CD 
molecules form the channel type arrangement when they are in an inclusion complex 
conformation. In this arrangement the CDs are aligned and stacked on top of each other in 
a head-to-head (Figure 3-7b) or head-to-tail fashion (Figure 3-7a), forming cylindrical 
channels.5 Depending on the nature and dimension of the guest, a variety of conformations 
can be adopted, from perfectly aligned to more or less displaced, possibly forming, in the 
most favourable case, endless channels.33 The two salient peaks in X-ray diffractograms 
most commonly reported as corresponding to the channel type packing structure for α-CD 
are centered at 2θ ≈ 13° and 20°.19 These peaks have also been reported as 2θ ≈ 19.6° and 
22.3°.19 
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XRD spectra for the host, α-CD, and products of the 2:1 co-precipitation (at RT), paste 
mixing, and dry mixing complexation techniques are shown in Figure 3-8. Salient peaks 
at 9.72°, 12.13°, 14.32°, and 21.67° previously reported as characteristic of cage-type 
packing in α-CD were observed and are denoted in Figure 3-8 by an asterisk.  
 
(a) (b) 
(c) 
Figure 3-7: Possible cyclodextrin conformations (a) head-
to-tail channel structure (b) head-to-tail channel structure 
(c) cage structure 
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The diffractogram for the product obtained via co-precipitation (at RT) shows a spectrum 
very different from that of the host α-CD. It can be seen that not only is there disappearance 
of characteristic peaks from the parent spectra, there is both sharpening and shifting of 
existing peaks. Furthermore, the peaks at 19.64° and 22.34° (A and B, respectively in 
Figure 3-8) can be attributed to the α-CD adopting a channel structure due to the formation 
of an inclusion complex.21, 34 It is possible that some of these changes can be attributed to 
recrystallization of the α-CD from the aqueous solvent used in the co-precipitation 
technique. 
 
Figure 3-8: XRD comparison of CD:ICs prepared from α-CD and PFP via different 
complexation techniques at a 2:1 host:guest ratio and that of the unmodified α-CD 
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The diffractogram for the product obtained via paste mixing shows a very similar spectrum 
to that of α-CD but with increased intensity. This can be attributed to a large amount of 
uncomplexed CD remaining in the product, possibly owing to the contribution of 1:1 
complexes in the product, resulting in an overall stoichiometric ratio less than 2:1.22 The 
XRD results for the product obtained via dry mixing, on the other hand, show a severely 
diminished structure when compared to the host diffractogram. Specifically, the peaks 
previously identified as being characteristic of a cage type structure in the host have either 
disappeared, in the case of the peak at 9.72°, or noticeably dwarfed, especially with the 
peak at 21.67°.   
 
Overall, because the diffraction patterns do not correspond exactly to those of the 
unmodified parent molecule, a true inclusion complex may exist. Products obtained by the 
three different complexation techniques all show unique features when compared to the 
diffractogram for α-CD. 
 
3.5 Conclusion 
Taken together, the results of the FTIR, TGA, and XRD characterization techniques 
confirm that inclusion complexation did in fact occur between the selected host and guest 
molecules, α-CD and PFP respectively. Following characterization with FTIR, it was 
possible to narrow down the complexation techniques and conditions to those most 
effective at yielding true complex formation. It was evident that a 2:1 molar ratio of the α-
CD host to PFP guest was preferred. This corresponds with the α-CD cavity height being 
smaller than that of the PFP so that in order for the CD to be fully covered, two α-CD 
molecules must be threaded onto one PFP molecule. From the FTIR spectra, it was also 
apparent that the mixing techniques were more effective than co-precipitation. Peaks 
characteristic of the PFP guest molecule were visible in the spectra for the mixing 
techniques, and in fact the peaks were both shifted and suppressed when compared to the 
FTIR spectra of the as-received PFP. These spectral features are evidence of host-guest 
interactions and the cavity hindering the vibrations of the PFP, ultimately indicating 
successful complex formation. Finally, a comparison of the standard deviations of 
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normalized absorbance values at the characteristic peaks indicated that the products 
prepared via the mixing technique were sufficiently different than the corresponding 
physical mixtures. 
 
TGA was subsequently carried out on the products of 2:1 co-precipitation (at RT), paste 
mixing, and dry mixing. This characterization technique was difficult with the specific 
guest molecule used in this study due to the similarity of its main thermal event to that of 
water. Nevertheless, the differences in the derivative heat flow thermograms for the 
products were sufficiently large compared to the thermogram of the unmodified α-CD to 
demonstrate successful complexation. Overall, TGA analysis indicated that the paste 
mixing technique was the most effective in preparing an inclusion complex in this study. 
 
Finally, XRD was carried out on the products of the 2:1 co-precipitation (at RT), paste 
mixing, and dry mixing. Differences in the diffractograms of the three products when 
compared to that of the unmodified α-CD show differences including the disappearance, 
sharpening, and shifting of existing peaks, as well as the occurrence of new peaks which 
all suggest successful complexation. Further analysis indicated that the dry mixing 
technique may be the most effective in preparing inclusion complexes between α-CD and 
PFP. In summary, characterization of the products prepared via the different complexation 
techniques utilized indicate that the mixing techniques were overall more effective than 
co-precipitation. Although TGA provided evidence that paste mixing was the best 
technique, characterization with XRD indicated that dry mixing may be more effective. 
Nevertheless, the paste mixing technique was selected for preparing an inclusion complex 
with α-CD and PFP due to its proven ability to produce the desired complex and the fact 
that it allowed for simple handling and preparation of the complex. 
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4 FABRICATION OF TISSUE ENGINEERED SCAFFOLDS 
INCORPORATING CYCLODEXTRIN INCLUSION 
COMPLEXES WITH 
PERFLUOROPERHYDROPHENANTHRENE 
Overview: This chapter discusses the incorporation of an inclusion complex from alpha-
cyclodextrin and perfluoroperhydrophenanthrene in 3D tissue engineering constructs. 
Scaffold fabrication was carried out via electrospinning and the inclusion complexes were 
incorporated in both biodegradable (PCL) and stable (PCU) materials. Optimized 
concentrations were identified and the effect of adding cyclodextrin explored. The resulting 
fibrous mats were imaged with scanning electron microscopy and the surface content was 
analyzed with X-ray photoelectron spectroscopy. 
 
Keywords: 3D scaffold, electrospinning, tissue engineering, cyclodextrin, inclusion 
complex, perfluorocarbons 
 
4.1 Introduction 
Tissue engineering involves the assembly of cells and their support structures for the repair 
and regeneration of diseased or damaged tissues and organs as an alternative to current 
therapies.1 One strategy of tissue engineering involves seeding cells onto a porous 3D 
scaffold that supports in vitro tissue formation and maturation. One of the major factors 
hindering the success of scaffold-guided tissue engineering is the inability to deliver 
sufficient oxygen to the growing constructs. A number of strategies to improve oxygen 
delivery have focused on the development of PFC emulsions. Although PFC emulsions 
show excellent oxygen carrying capacity, they lack stability causing overall user-
unfriendliness and they have a high density causing them to settle in the culture well or 
medium reservoir.2, 3 Another approach for improving oxygen delivery involves 
embedding oxygen generating compounds, such as calcium peroxide4 or sodium 
percarbonate5 which decompose in water to produce oxygen, directly into the tissue 
engineering scaffold. This approach has the advantage of providing oxygen throughout the 
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construct, notably in the center where it is difficult to reach by diffusion alone, but it is 
restricted because the oxygen generating compound is eventually depleted. Tissue 
engineering scaffolds incorporating fluorinated porous zeolite particles provide an 
alternative to this approach whereby the embedded compound does not generate oxygen 
but enhances its delivery using the principles of oxygen solubility in perfluorocarbons.6 
Cyclodextrin inclusion complexes with perfluorocarbons have been prepared previously 
for application as novel oxygen carriers. Because inclusion of a guest molecule within the 
cyclodextrin cavity can provide stabilization, it may serve to overcome some of the 
shortcomings of PFC emulsions. The goal of this study was to incorporate α-CD/PFP 
inclusion complexes into 3D fibrous scaffolds. Embedding the CD/PFC complexes in the 
scaffold would impart enhanced oxygen delivery throughout the construct, and delay or 
prevent settling of the PCFs in the culture well or medium reservoir. 
 
One of the most commonly utilized methods for scaffold fabrication is electrospinning. 
Electrospinning is a versatile technique that enables the production of multi-functional 
fibers in the nano- to micrometer range from a wide variety of materials and it is generally 
a relatively simple, versatile, and cost-effective method. Because electrospinning allows 
for the fabrication of scaffolds that closely mimic the scale and fibrous nature of the native 
ECM, electrospinning was selected as the scaffold fabrication technique for this study. It 
has been demonstrated that cyclodextrin inclusion complexes can be incorporated into 
three-dimensional scaffolds via electrospinning.7-9 In fact, cyclodextrin has been shown to 
positively affect the electrospinning of polymer solutions. The addition of CD increases 
the conductivity of the polymer solution, allowing for successful electrospinning of bead-
free fibers from lower polymer concentrations.10, 11 This is because the polymer solution is 
subjected to higher stretching under the high electric field.12 Moreover, it was reported that 
preparation of a homogenous film from polymer/cyclodextrin solutions via other 
fabrication techniques, such as spin coating or solvent casting methods, failed because the 
CD molecules phase separated and formed crystal aggregates either immediately or upon 
solvent evaporation.9, 12 
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Depending on the intended application, scaffolds may be designed to be biodegradable so 
that only the neo-tissue will remain after a given period of culture time or following 
implantation, or they may be biostable such that a composite tissue that provides long-term 
support could be fabricated.13-16 In the case of biodegradable scaffolds, cells will remodel 
the scaffold with their own ECM proteins creating the intended tissue without 
compromising tissue structural integrity. This, however, requires strict coordination of the 
scaffold biodegradation rate with the biosynthetic rate and is one of the major obstacles in 
the field today. In addition, a scaffold must have several required characteristics: 
biocompatibility, appropriate mechanical strength and compliance, optimal porosity for 
cell seeding, in vitro nutrient and oxygen transport, and the ability to bind to cells and 
release growth factors when needed.  PCU and PCL were selected as polymer materials 
because they have previously been utilized as polymers for scaffold fabrication in our lab 
and have been shown to have acceptable cell compatibility.17, 18 These polymer materials 
present the opportunity for a proof of concept study showing that the CD/PFC inclusion 
complex can be incorporated in both biostable (PCU) and biodegradable (PCL) tissue 
engineering scaffolds. 
 
4.2 Materials 
Perfluoroperhydrophenanthrene (PFP, mixture of isomers, 83 % purity) and alpha-
cyclodextrin (α-CD, 100 % purity) were obtained commercially from Alfa Aesar (Ward 
Hill, MA). Medical grade poly(carbonate urethane) (PCU) (Bionate® 55D) was obtained 
from DSM Biomedical (Berkeley, CA). Polycaprolactone (PCL), Mn 70,000-90,000, was 
purchased from Sigma Aldrich (Milwaukee, WI). Solvents were purchased from Caledon 
Labs (Georgetown, ON). All other chemicals were purchased from Sigma Aldrich. Unless 
noted otherwise, all chemicals were used as received without any further purification. 
 
4.3 Methods 
 Preparation of Inclusion Complex 
Weighed amounts of α-CD and a minimal amount of d.i. water were combined to form a 
paste. Weighed amounts of PFP were added to the α-CD paste at a 2:1 α-CD to PFP molar 
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ratio. The paste was thoroughly mixed using a ceramic mortar and pestle for ten minutes. 
The product was collected in a glass vial, dried and stored in a desiccator with potassium 
hydroxide as a desiccant. The products were analyzed with FTIR as discussed previously 
(Section 3.3.3) to ensure successful complexation consistent with previous results (Section 
3.4.2) 
 
 Fabrication of 3D Scaffolds 
4.3.2.1 Electrospinning of Poly(carbonate urethane) 
The polymer solution was prepared by varying concentrations of PCU in 
N,N-dimethylformamide (DMF), and also varying the amount of CD:IC added. The 
concentration of PCU ranged from 5-10 % (v/v) with respect to the solvent, and the 
concentration of CD:IC ranged from 5-60 % (w/w) with respect to PCU. First, the PCU 
was added to the corresponding amount of DMF and stirred until it was fully dissolved. 
Then the corresponding amount of CD:IC was added and stirred until it was fully dispersed 
in the polymer solution. 
 
The electrospinning conditions used were based on those previously optimized in our lab.17 
The viscous polymer solution was transferred to a 0.5 mL glass syringe equipped with a 
22 gauge stainless steel needle. The syringe was fixed horizontally on a syringe pump 
(KD101, KD Scientific, USA) which maintained the flow rate at 0.1 mL/h and was 
connected to a high voltage supply (ES30P, Gamma High Voltage, USA) which applied a 
voltage of 15 kV. The fibers were collected on a grounded stationary metal collector 
covered in aluminum foil, 8 cm from the needle tip. Following electrospinning, the 
scaffolds were removed from the electrospinning assembly and the solvent was allowed to 
evaporate in the fume hood. 
 
4.3.2.2 Electrospinning of Polycaprolactone 
The electrospinning of PCL was based on conditions obtained from literature, where a 
cyclodextrin/naproxen inclusion complex was incorporated into electrospun PCL fibers.7 
The polymer solution was prepared in a co-solvent mixture at a ratio of 3:1 or 1:1 DMF to 
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dichloromethane (DCM). The concentration of PCL ranged from 5-10 % (v/v) with respect 
to the total amount of solvent, and the concentration of CD:IC ranged from 15-50 % (w/w) 
with respect to PCL. First, the PCL was added to the corresponding amount of DMF and 
DCM solvents and stirred until it was fully dissolved. Then the corresponding amount of 
CD:IC was added, with stirring and vortexing used in order to fully disperse the CD:IC in 
the polymer solution. 
 
The viscous polymer solution was then transferred to a 0.5 mL glass syringe equipped with 
an 18, 20, or 22 gauge stainless steel needle. The syringe was fixed horizontally on a 
syringe pump (KD101, KD Scientific, USA) which maintained the flow rate at 0.1 mL/h 
and connected to a high voltage supply (ES30P, Gamma High Voltage, USA) which 
applied a voltage of 15 kV. The fibers were collected on a grounded stationary metal 
collector covered in aluminum foil, 8 or 10 cm from the needle tip. Following 
electrospinning, the scaffolds were removed from the electrospinning assembly and the 
solvent was allowed to evaporate in the fume hood. 
 
 Scanning Electron Microscopy 
Fiber morphology of the electrospun fibrous mats was visualized using scanning electron 
microscopy (SEM, 3400S, Hitachi, Ltd., Tokyo, Japan). The samples were mounted on 
aluminum stubs with carbon tape and sputtered with osmium prior to analysis (courtesy of 
the Nanofab facility, Filgen OPC80T, Japan). The stub was then placed in the SEM and 
scanned at a working distance of 5 mm at a constant accelerating voltage of 5 kV. Images 
were captured at various magnifications. The fiber diameters were measured using ImageJ 
software (NIH, USA), analyzing a total of 100 fibers from three different fields of view at 
10,000x magnification. Average fiber diameters were compared using the Student’s t-test 
with significance assigned to p < 0.05. 
 
 X-Ray Photoelectron Spectroscopy 
X-ray photoelectron spectroscopy (XPS) was carried out on the CD:IC and 3D scaffolds 
using a Kratos Axis Ultra Spectrometer (Kratos Analytical Ltd. Manchester, UK) using a 
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monochromatic Al Κα X-ray source (15 mA, 14 kV). The instrument work function was 
calibrated to give a binding energy (BE) of 83.96 eV for the Au 4f7/2 line for metallic gold 
and the spectrometer dispersion was adjusted to give a BE of 932.62 eV for the Cu 2p3/2 
line of metallic copper. The Kratos charge neutralizer system was used on all samples, 
which were analyzed to a depth of 5-7 nm, with detection limits ranging from 0.1 to 0.5 
atomic percent depending on the element. Survey scans were carried out on an analysis 
area of 300-700 µm at a pass energy of 160 eV. Spectra have been charge corrected to the 
main line of the carbon 1s spectrum (adventitious carbon) set to 284.8 eV. Spectra were 
analyzed using CasaXPS software version 2.3.14. 
 
4.4 Results and Discussion 
 Three-dimensional Electrospun Fibrous Mats 
Incorporating the inclusion complex prepared from α-CD and PFP into a 3D tissue 
engineering scaffold affords the possibility of enhancing cell viability within the construct 
due to the enhanced oxygen availability. In this study, electrospinning was used as a 
scaffold fabrication technique because it allows for the fabrication of fibrous structures that 
closely mimic the scale and fibrous nature of the native ECM, it is a relatively simple, cost-
effective, and versatile technique, and it has been reported that CD:ICs can be successfully 
incorporated into scaffolds with this technique. 
 
The method for preparing the electrospinning solution required optimization. Initially, the 
solution components, PCU, CD:IC, and DMF, were added concurrently and stirred until 
the polymer was fully dissolved and a homogeneous solution was produced. However, it 
was observed that the PFP separated as liquid drops at the bottom of the mixture and was 
displaced from the α-CD cavity, likely because the inclusion complex was destroyed during 
solvation in DMF. The resolution to this problem was to first fully dissolve the polymer in 
the solvent, and then add the CD:IC until it was thoroughly dispersed in the polymer 
solution. As a result, no displaced PFP was observed. It is possible that this was due to the 
non-ideality of the polymer solution, and that because the PCU is solvated in the DMF, the 
DMF molecules are not able to displace the PFP from the CD cavity.  
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Functionalized fibers were fabricated by electrospinning a PCU solution incorporating an 
inclusion complex prepared from α-CD and PFP. The PCU concentration was varied, 
testing the amounts 5, 7.5, 8, and 10 % (v/v) with respect to the DMF solvent. The amount 
of CD:IC incorporated was also varied, from 5-60 % (w/w) with respect to PCU. The 
concentration of CD:IC depended upon the specific PCU concentration being used, such 
that when the CD:IC concentration was increased, the polymer concentration was 
decreased. The sample nomenclature is based on the volume percentage of PCU and the 
weight percentage of CD:IC used in the sample preparation. For example, 10PCU-
20CD:IC refers to an electrospun fibrous mat prepared from 10 % (v/v) PCU with respect 
to the DMF solvent and 20 % (w/w) CD:IC with respect to PCU. Table 4-1 summarizes 
the different PCU/CD:IC concentrations tested and the resulting fiber morphology. 
 
Table 4-1: Concentrations of PCU/CD:IC electrospinning solutions and 
characteristics of the resulting fibers 
% (v/v) PCU % (w/w) CD:IC Fiber Morphology 
5 35 Heavily beaded nanofibers 
7.5 50 Bead-free nanofibers 
8 30 Bead-free nanofibers 
8 35 Fused nanofibers 
8 45 Not uniform, heavily beaded, nanofibers 
8 50 Bead-free nanofibers 
8 60 Not uniform, fused, beaded nanofibers 
10 5 Thick, fused microfibers 
10 20 Bead-free nanofibers 
10 25 Bead-free nanofibers 
10 30 Slightly beaded nanofibers 
 
Interestingly, with the incorporation of cyclodextrin it was possible to produce uniform, 
bead-free fibers from concentrations lower than 10 % (v/v) PCU. Our lab previously 
reported that electrospinning concentrations lower than 10 % (v/v) PCU was not achievable 
because the fibers were still wet when they reached the collector and fused with beading.17 
This ability to electrospin bead-free fibers from low polymer concentrations clearly 
demonstrates the positive effect of cyclodextrin on electrospinning. The addition of CD 
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increases the conductivity of the polymer solution, causing it to be subjected to greater 
stretching under the high electric field.10, 12, 11 Bead-free, uniform fibers were obtained at 
both 7.5 and 8 % PCU with the incorporation of various amount of cyclodextrin (Table 
4-1). However, when the PCU concentration was reduced to 5 %, vastly beaded fibers were 
obtained (see Figure 4-1A) because there was not enough chain entanglement and 
overlapping to create a stable jet.19 
 
  
Figure 4-1: Representative SEM images of electrospun mats at 10,000x magnification 
(A) 5 % (v/v) PCU, 35 % (w/w) CD:IC (B) 8 % (v/v) PCU, 60 % (w/w) CD:IC (C) 8 
% (v/v) PCU, 50 % (w/w) CD:IC (D) 8 % (v/v) PCU, 50 % (w/w) α-CD 
A B 
C D 
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Even though uniform, bead-free fibers were obtained at the initial tested concentrations of 
10PCU-20CD:IC and 10PCU-25CD:IC, the ultimate objective of this work was to enhance 
oxygen delivery to the cells eventually seeded onto these scaffolds; thus the goal was to 
maximize the amount of CD:IC incorporated in the electrospun fibers. In order for the 
solution to be electrospinnable and to produce uniform bead-free fibers, it was necessary 
to decrease the polymer concentration as the amount of CD:IC incorporated was increased. 
Figure 4-1B shows the non-uniformity of the fibers obtained from 8PCU-60CD:IC, where 
the fiber diameter ranges considerably and various beads and other defects are present. 
After the SEM images for all of the tested concentrations tested were analyzed, the optimal 
concentration for the PCU/CD:IC solution was determined to be 8PCU-50CD:IC, shown 
in Figure 4-1C. In addition to the fibers being bead-free, it can be seen that the fibers are 
randomly oriented which is desirable for tissue engineering as it mimics the actual 
physiological structure of the ECM and allows for cell infiltration, nutrient and waste 
transport, and subsequent vascularization. Electrospinning was also carried out at the 
optimized concentration with unmodified α-CD (8PCU-50CD), and the resulting fibers are 
shown in Figure 4-1D. No notable differences were observed between the fibers 
incorporating CD:IC compared to those with unmodified α-CD. 
 
Because PCU is a biostable polymer, further electrospinning studies were carried out using 
the biodegradable polymer PCL. In addition to its biodegradability, PCL was selected 
because it is biocompatible, it is commonly used in the field of biomedical engineering, 
and it is commercially available.18 The sample nomenclature is based on the volume 
percentage of PCL and the weight percentage of CD:IC used in the sample preparation. For 
example, 10PCL-20CD:IC refers to an electrospun fibrous mat prepared from 10 % (v/v) 
PCL with respect to solvent and 20 % (w/w) CD:IC with respect to polymer. Table 4-2 
summarizes the different concentrations tested and the resulting fiber morphology. 
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Table 4-2: Concentrations of PCL/CD:IC electrospinning solutions, the 
corresponding electrospinning conditions employed, and characteristics of the 
resulting fibers 
% 
(v/v) 
PCL 
% 
(w/w) 
CD:IC 
Solvent 
DMF:DCM 
Ratio 
Distance 
(cm) 
Needle 
Gauge 
Fiber Morphology 
5 50 3:1 10 22 Heavily beaded nanofibers 
8 15 3:1 10 22 
Uniform nanofibers with film 
formation 
8 20 3:1 10 22 
Not uniform, nanofibers, film 
formation 
8 50 3:1 10 22 
Not uniform, nanofibers, film 
formation, CD precipitation 
10 10 3:1 10 22 
Not uniform, nanofibers, film 
formation 
10 15 3:1 10 22 
Not uniform, mostly microfibers, 
film formation 
10 20 3:1 10 22 
Not uniform, mostly microfibers, 
film formation 
10 25 3:1 10 22 
Not uniform, mostly nanofibers, 
film formation 
7.5 15 1:1 
10 22 
Not uniform, mostly nanofibers, 
some defects 
8 22 
Mostly uniform, mostly 
nanofibers, few defects 
8 15 1:1 
10 22 
Not uniform, mostly nanofibers, 
some defects and beading 
8 18 
Mostly uniform, mostly 
nanofibers, no defects 
8 20 Uniform nanofibers, no defects 
8 20 1:1 
10 22 
Not uniform, nanofibers, some 
defects 
10 18 
Mostly uniform, mostly 
microfibers, few defects 
10 20 
Mostly uniform, nanofibers, few 
defects 
8 20 
Mostly uniform, nanofibers, few 
defects 
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As with the PCU-based solutions, the CD:IC had to be added to the solution after the PCL 
was fully dissolved in the co-solvent system to prevent the displacement of the PFP from 
the CD cavity. However, further difficulties were encountered as the polymer solutions 
were highly viscous and the CD:IC could not be homogeneously dispersed. For this reason, 
vortexing was added as a further step to the electrospinning solution preparation. 
 
  
D C 
A B 
Figure 4-2: Representative SEM images of electrospun mats at 1,000x magnification 
highlighting the film formation on the surface of the fibrous mats when a solvent ratio 
of 3:1 DMF:DCM was used (A) 8 % (v/v) PCL, 15 % (w/w) CD:IC (B) 8 % (v/v) PCL, 
20 % (w/w) CD:IC (C) 10 % (v/v) PCL, 10 % (w/w) CD:IC (D) 10 % (v/v) PCL, 20 
% (w/w) CD:IC 
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Figure 4-3: Representative SEM images of electrospun mats at multiple 
magnifications (A) 7.5 % (v/v) PCL, 15 % CD:IC in 1:1 DMF:DCM (B)  8 % 
(v/v) PCL, 15 % CD:IC in 1:1 DMF:DCM (C) 8 % (v/v) PCL, 20 % (w/w) CD:IC 
in 1:1 DMF:DCM 
80 
 
 
 
 
Following the conditions used by Canbolat et al., the PCL electrospinning solutions were 
initially prepared with a co-solvent system of 3:1 (v/v) DMF:DCM, using a 22 gauge 
needle and a distance of 10 cm between the needle tip and collector.7 Even after 
significantly varying the concentrations of both PCL and CD:IC, a film was observed on 
the surface of the fibrous mat at the macro scale, as can be seen in Figure 4-2. Then, the 
ratio of solvents was altered to 1:1 DMF:DCM, and the result was drastically reduced film 
formation (Figure 4-3). However, as demonstrated in Figure 4-3, the fiber diameter was 
far from uniform, and there were significant defects observed in the fibers. In an attempt 
to decrease the occurrence of defects and unify the fiber diameter, the electrospinning 
parameters were further modified, changing the needle gauge from 22 to 18 or 20, and 
decreasing the distance between the needle tip and collector from 10 to 8 cm. Figure 4-4 
shows representative SEM images at various concentrations of PCL and CD:IC with the 
variation of electrospinning conditions. Although increasing the needle inner diameter has 
the overall effect of increasing the fiber diameter, it was hypothesized that by increasing 
the thickness of the polymer jet, the CD:IC would be better encompassed in the polymer 
matrix, ultimately leading to a decreased occurrence of defects in the fibers. As can be seen 
in Figure 4-4, considerably reduced defects and beads on the fibers were observed and the 
fibers appeared to be more uniform, if thicker overall. 
 
At this time, it was not possible to incorporate higher amounts of CD:IC into the PCL 
polymer matrix while maintaining the desired fiber morphology. At 8PCL-50CD:IC, it 
appears as though the CD:IC actually precipitated out of the polymer (Figure 4-5A). 
Decreasing the polymer concentration to 5PCL-50CD:IC resulted in a vast amount of 
beading (Figure 4-5B). These observations are similar to those made for 5PCU-35CD:IC 
(Figure 4-1A) and 8PCU-60CD:IC (Figure 4-1B). It is possible that with further 
optimization more CD:IC could be incorporated in order to increase the oxygen delivery 
potential of the PCL fibers. At this time, however, the optimized concentration for this 
study was determined to be 8PCL-15CD:IC, prepared in a co-solvent system at a 1:1 ratio 
of DMF:DCM and electrospun with a 20 gauge needle at a distance of 8 cm between the 
needle tip and collector (shown in Figure 4-4B). 
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Figure 4-4: Representative SEM images at 10,000x magnification showing the 
reduction in defects when the electrospinning parameters were altered using 1:1 
DMF:DCM co-solvent system (A) 8 % (v/v) PCL, 15 % (w/w) CD:IC with 18 gauge 
needle at 8 cm (B) 8 % (v/v) PCL, 15 % (w/w) CD:IC with 20 gauge needle at 8 cm 
(C) 8 % (v/v) PCL, 20 % (w/w) CD:IC with 20 gauge needle at 8 cm (D) 8 % (v/v) 
PCL, 20 % (w/w) CD:IC with 20 gauge needle at 10 cm (E) 8 % (v/v) PCL, 20 % 
(w/w) CD:IC with 18 gauge needle at 10 cm (F) 7.5 % (v/v) PCL, 15 % (w/w) CD:IC 
with 22 gauge needle at 8 cm 
A 
C D 
E F 
B 
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The average fiber diameter obtained with the optimized polymer solutions was calculated 
using ImageJ software, measuring a total of 100 fibers from three different fields of view. 
For 8PCU-50CD:IC, the average fiber diameter was calculated to be (232 ± 31) nm which 
is within the range preferred for tissue engineering applications as they are most similar to 
the typical diameter of protein fibers in the native ECM.20 The average fiber diameter for 
8PCL-15CD:IC was calculated to be (342 ± 56) nm. Although significantly larger than the 
fibers fabricated with PCU (p≤0.001), they are still within the acceptable range for tissue 
engineering applications.20 Another important feature is that the fibers obtained were 
uniform in diameter so that the scaffold can better recreate the functions of the native 
ECM.21 Figure 4-6A shows the distribution of fiber diameter in the 8PCU-50CD:IC 
electrospun scaffold, demonstrating the relatively narrow distribution and the close fit to 
the normal distribution (R2=0.97). In contrast, the fiber diameter distribution for the 8PCL-
15CD:IC scaffold (Figure 4-6B) was not as narrow and does not follow the normal 
distribution as closely (R2=0.90). This can be explained by the difficulties experienced 
while electrospinning the PCL-based solutions. Overall, the control over fiber morphology 
is important for scaffold designs that better recreate the functions of the native ECM. 
 
 
  
B A 
Figure 4-5: SEM images at 2,500x magnification showing the defects observed when 
a high concentration of CD:IC is incorporated (A) 8% (v/v) PCL, 50% (w/w) CD:IC 
(B) 5% (v/v) PCL, 50% CD:IC 
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In conclusion, it was possible to incorporate the inclusion complex prepared from α-CD 
and PFP in 3D scaffolds via electrospinning. Incorporating cyclodextrin in the polymer 
solution had a positive effect on the electrospinning process, enabling successful 
electrospinning at low polymer concentrations. It was possible to obtain scaffolds with 
acceptable fiber morphology, as determined by SEM, and there was no sign of CD:IC 
crystal aggregates on the surface of the fibers. This study provides confirmation of the 
Figure 4-6: Fiber diameter distribution (N=100) of electrospun 
fibers and Gaussian distribution for (A) 8PCU-50CD:IC and (B) 
8PCL-15CD:IC 
A 
B 
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feasibility of incorporating the CD/PFC inclusion complexes in 3D constructs for 
application in tissue engineering as oxygen carriers. Arguably the most notable strength of 
this study is the potential of incorporating the inclusion complex in a virtually any polymer 
matrix through electrospinning. Successful incorporation of the CD:IC was observed with 
both the biostable PCU and biodegradable PCL. The optimized concentrations were 
determined to be 8PCU-50CD:IC and 5PCL-15CD:IC leading to fiber diameters of (232 ± 
31) nm and (342 ± 56) nm, respectively. 
 
 Surface Characterization 
The scaffolds were characterized by XPS to reveal the elemental analysis up to a depth of 
5-7 nm from the surface. Characterization was carried out using polymer and CD:IC 
concentrations previously determined to provide fibrous mats with a morphology 
acceptable for tissue engineering applications. XPS of the 8PCU-50CD:IC fibrous mat was 
compared to that of PCU incorporating unmodified α-CD at the same concentration, that 
is 8 % (v/v) PCU and 50 % (w/w) α-CD, and PCU alone, electrospun from a 12 % (v/v) 
solution in DMF. Similarly, the 8PCL-15CD:IC fibrous mat was compared to a PCL 
scaffold incorporating unmodified α-CD at the same concentration, 8 % (v/v) PCL with 15 
% (w/w) α-CD, as well as a PCL control scaffold electrospun from 12 % (w/v) PCL. It was 
necessary to electrospin the PCU and PCL control scaffolds at concentrations higher than 
the 8 % (v/v) concentration used in the CD:IC-modified scaffolds because the polymer 
concentration was too low for successful electrospinning without incorporating CD. 
 
The elemental analysis obtained from XPS is provided in Table 4-3 and the corresponding 
spectra are shown in Appendix 6-1. In both the PCU-CD and PCU-CD:IC fibers, a higher 
oxygen content is observed, confirming the presence of CD within the outer surface of the 
fibrous mat. However, the increase in surface content of oxygen is lower than the amount 
of CD incorporated. This indicates that a portion of the CD molecules are buried in the 
bulk of the fibers, similar to results reported in the literature for PS/CD nanofibers9, 12 The 
increase in oxygen content is much less obvious for the PCL-CD and PCL-CD:IC 
nanofibers because only 15 % (w/w) CD or CD:IC was incorporated in the PCU fibers 
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compared to the 50 % (w/w) concentration of CD or CD:IC in the PCU fibers. No fluorine 
content is observed in the fibers containing the CD:IC because it is buried inside both the 
CD:IC cavity and the polymer matrix and is therefore not detected by the survey scan. 
 
Because some of the CD:IC is buried in the bulk of the fibers, there is a benefit of using a 
biodegradable polymer matrix. For instance, as the PCL degrades, the CD:IC embedded 
within the fibrous matrix would gradually be exposed. By contrast, with a biostable 
polymer matrix, such as PCU, only the inclusion complexes on the surface of the fibers 
would be available for use as oxygen carriers and only if they are not completely covered 
by the polymer. Therefore, utilizing a biodegradable polymer guarantees the availability of 
the CD:IC over the course of an in vitro cell cultivation. It is also possible that the 
experimental parameters could be further optimized in order to obtain highly efficient 
fibers with a high CD content on the surface of the fibers. This may be achieved by varying 
the electrospinning temperature or the solvent system, for example, or by using chemically 
modified CD derivatives which have been reported to phase segregate to the fiber surface 
during solvent evaporation.12 
 
Table 4-3: Elemental analysis from XPS spectra showing atomic % of each element 
observed 
Sample C% O% N% F% 
α-CD 57.6 42.4   
CD:IC 58.4 41.4  0.2 
PCU 71.2 25.1 3.7  
PCU-CD 58.4 41.3 0.3  
PCU-CD:IC 60.9 38.0 1.0  
PCL 74.8 25.2   
PCL-CD 72.9 27.1   
PCL-CD:IC 74.6 25.4   
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4.5 Conclusion 
In this study, a CD:IC prepared from α-CD and PFP was incorporated into 3D scaffolds 
with the ultimate goal of improving oxygen delivery in tissue engineering applications. 
Electrospinning was used as the fabrication technique, and both stable and biodegradable 
polymer matrices were studied: PCU and PCL, respectively. Incorporating cyclodextrin in 
the polymer solutions showed a positive effect on electrospinning, allowing for successful 
electrospinning of bead-free fibers from low polymer concentrations, as expected based on 
previous studies.10, 11 This is because the addition of CD increases the conductivity of the 
polymer solution causing the polymer solution to be subjected to higher stretching under 
the high electric field.12 The CD:IC was successfully incorporated within both polymers 
producing bead-free, uniform fibers with suitable diameters for tissue engineering 
applications, as determined by SEM images. It was possible to incorporate up to 50 % 
(w/w) CD:IC in the PCU fibers but only 15 % (w/w) CD:IC in the PCL fibers. The average 
fiber diameters of the scaffolds were determined to be (232 ± 31) nm and (342±56) nm for 
PCU-CD:IC and PCL-CD:IC, respectively, which is within the acceptable margin for most 
tissue engineering applications.20 
 
The CD:IC-functionalized scaffolds were further characterized using XPS. An increase in 
oxygen content was observed when compared to PCU and PCL control scaffolds which 
confirms the incorporation of α-CD within the fibers. It was determined that a large amount 
of CD:IC was buried within the bulk of the fibers. This suggests that a biodegradable 
polymer matrix, such as PCL, may be better for cell culturing as the CD:IC buried within 
the bulk of the fibers would be exposed as the scaffold material degrades. Overall, these 
results provided the proof of concept necessary to support further studies on the in vitro 
ability of these functionalized fibers to enhance oxygen delivery to seeded cells. 
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5 IN VITRO ANALYSIS OF OXYGEN DELIVERY OF 
CYCLODEXTRIN INCLUSION COMPLEXES WITH 
PERFLUOROPERHYDROPHENANTHRENE 
Overview: This chapter discusses the in vitro analysis of the effect of inclusion complexes 
prepared from alpha-cyclodextrin and perfluoroperhydrophenanthrene on dissolved 
oxygen. Studies were carried out both in solution and on 3D scaffolds incorporating the 
inclusion complex. Preliminary degradation studies were also carried out on the CD:IC-
functionalized 3D scaffolds. 
 
Keywords: dissolved oxygen, oxygen delivery, tissue engineering, 3D scaffold, 
cyclodextrin, inclusion complex, perfluorocarbon 
 
5.1 Introduction 
Scaffold-guided tissue engineering continues to emerge as a strategy for the repair and 
regeneration of diseased or damaged tissues and organs as an alternative to current 
therapies.1 However, one of the major factors hindering the success of scaffold-guided 
tissue engineering is the inability to deliver sufficient oxygen to the growing constructs. 
Although numerous strategies have been developed to overcome this limitation, they have 
been riddled with drawbacks; thus delivering sufficient oxygen remains a fundamental 
consideration for fabricating engineered tissues.2-4 One approach to improve oxygen 
delivery to constructs is the use of perfusion bioreactors whereby oxygen dissolved in the 
culture medium diffuses to the scaffold material. However, the flow rate required to 
maintain an adequate oxygen concentration for cell viability often surpasses the shear stress 
tolerance of cells.5 Alternatively, perfluorocarbons have been extensively explored as 
oxygen carriers due to their high dissolving power for oxygen, though the focus has been 
on fabricating perfluorocarbon emulsions which lack stability and are overall user-
unfriendly.6 Moreover, the high density of the emulsions causes them to settle in the culture 
well or medium reservoir.7 An alternative strategy involves embedding oxygen generating 
compounds, such as calcium peroxide8 or sodium percarbonate9 which decompose in water 
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to produce oxygen, directly into the tissue engineering scaffold. This approach has the 
advantage of providing oxygen throughout the construct, specifically in the center where 
it is difficult to reach by diffusion alone, but it is limited as the oxygen generating 
compound is eventually depleted. Tissue engineering scaffolds incorporating fluorinated 
porous zeolite particles provide an alternative to this approach whereby the embedded 
compound does not generate oxygen but enhances its delivery using the principles of 
oxygen solubility in PFCs.10 
 
In this work, cyclodextrin inclusion complexes with perfluorocarbons have been prepared 
for application as oxygen carriers in tissue engineering. Because inclusion of a guest 
molecule within the cyclodextrin cavity can provide stabilization, it may serve to overcome 
some of the shortcomings of PFC emulsions. Moreover, the complexes have been 
successfully incorporated in 3D scaffolds via electrospinning. This would impart enhanced 
oxygen delivery throughout the construct, and delay or prevent settling of the PCFs in the 
culture well or medium reservoir. It was possible to incorporate the CD/PFC complexes in 
both biostable (PCU) and biodegradable (PCL) polymer matrices while maintaining 
acceptable fiber morphology for tissue engineering. This study explores the ability of the 
cyclodextrin/perfluorocarbon inclusion complexes to act as oxygen carriers in terms of 
their ability to increase dissolved oxygen. 
 
5.2 Materials 
Perfluoroperhydrophenanthrene (PFP, mixture of isomers, 83 % purity) and alpha-
cyclodextrin (α-CD, 100 % purity) were obtained commercially from Alfa Aesar (Ward 
Hill, MA). Solvents were purchased from Caledon Labs (Georgetown, ON). Span80 
(C24H44O6) was used as a surfactant and was purchased from Sigma Aldrich (Milwaukee, 
WI). All other chemicals were purchased from Sigma Aldrich. Unless noted otherwise, all 
chemicals were used as received without any further modification. 
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5.3 Methods 
 Preparation of Inclusion Complex 
Weighed amounts of α-CD and a minimal amount of d.i. water were combined to form a 
paste. Weighed amounts of PFP were added to the α-CD paste at a 2:1 α-CD to PFP molar 
ratio. The paste was thoroughly mixed using a ceramic mortar and pestle for ten minutes. 
The product was collected in a glass vial, dried and stored in a desiccator with potassium 
hydroxide as a desiccant. The products were analyzed with FTIR as discussed previously 
(Section 3.3.3) to ensure successful complexation consistent with previous results (Section 
3.4.2) 
 
 Fabricating 3D Scaffolds 
Fibrous mats were prepared from PCU and PCL via electrospinning, at the optimized 
concentrations and conditions described in Section 4.4.1. PCU-CD:IC was electrospun at 
a concentration of 8 % (v/v) in DMF with 50 % (w/w) CD:IC incorporated, using a 22 
gauge stainless steel needle at a distance of 8 cm from the needle tip to collector. A PCU 
control was electrospun at a concentration of 12 % (v/v) in DMF using a 22 gauge stainless 
steel needle at a distance of 8 cm from the needle tip to collector. PCL-CD:IC was 
electrospun at a concentration of 8 % (v/v) in 1:1 DMF:DCM with 15 % (w/w) CD:IC 
incorporated using a 20 gauge stainless steel needle at a distance of 8 cm from the needle 
tip to collector. A PCL control was electrospun at a concentration of 12 % (w/v) in 1:1 
DMF:DCM using a 22 gauge stainless steel needle at a distance of 10 cm from the needle 
tip to collector.  
 
The viscous polymer solution was transferred to a 0. 5 mL glass syringe which was then 
fixed horizontally on a syringe pump (KD101, KD Scientific, USA). The flow rate was 
maintained at 0.2 mL/h and connected to a high voltage supply (ES30P, Gamma High 
Voltage, USA) which applied a voltage of 15 kV. The polymer solution was refilled every 
2.5 hours to electrospin a total volume of 3 mL. The fibers were collected on a grounded 
rotating mandrel collector which was covered with aluminum foil and a dryer sheet and 
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rotated at roughly 2000 RPM. Following this, the scaffolds were removed from the 
electrospinning assembly and the solvent was allowed to evaporate in the fume hood. 
 
 Dissolved Oxygen Study on Cyclodextrin Inclusion Complexes with 
Perfluoroperhydrophenanthrene 
The dissolved oxygen was measured using a fiber optic oxygen sensor, NeoFox model 
FOXY-AL300 (Ocean Optics, Dunedin, FL), equipped with NeoFox software. The sensor 
uses ruthenium (II) complexes suspended in a support matrix and attached at the tip of a 
fiber optic cable. When excited by a light emitting diode at 475 nm, the ruthenium complex 
fluoresces and emission occurs at 620 nm. When the excited ruthenium complex 
encounters an oxygen molecule, the emission is quenched, allowing the intensity of the 
fluorescence to be related to the oxygen concentration. Accordingly, the more oxygen that 
is present, the lower the emission intensity and vice versa. In the absence of oxygen, the 
maximum fluorescent intensity of emitted light is observed. A multipoint calibration was 
carried out using the factory calibration file provided by Ocean Optics, followed by a single 
point reset at standard temperature and pressure, and 20.9 % oxygen. The oxygen sensor 
was placed in the solution and measured dissolved oxygen every 0.5 seconds. 
 
Various concentrations (1, 2, 4 %) of PFP, α-CD, and CD:IC, with respect to the PFP 
concentration within complex, were suspended in phosphate buffered saline (PBS; pH 7.4) 
with and without 0.1 % Span80 as a surfactant. The samples were rocked for 90 minutes 
(Gel Surfer, DiaMed Supplies Inc., Mississauga, ON). PBS with and without 0.1 % Span80 
was used as a control. The 300 nm diameter probe was placed in the solution while the 
assembly was left open to atmospheric air. Measurements were taken at both RT and 37 
°C, maintained by immersing the assembly in a water bath (VWR International, 
Mississauga, ON). The dissolved oxygen, measured as the oxygen partial pressure (atm), 
was recorded until stable readings were achieved. Henry’s law (Equation 2-6) was used 
to determine the oxygen concentration in the solution, and the Henry’s law constant was 
determined at each temperature according to Blanch and Clark.11 The samples were stored 
in a refrigerator at 4 °C for two weeks, at which point all dissolved oxygen measurements 
were taken again at both RT and 37 °C. All measurements were carried out in triplicates. 
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 Dissolved Oxygen Study on 3D Scaffolds Incorporating 
Cyclodextrin/Perfluoroperhydrophenanthrene Inclusion Complexes 
Squares of the electrospun fibrous mats (roughly 1 cm2) were weighed, placed in a 24-well 
plate and covered with 1 mL of PBS (pH 7.4). The 24-well plates were placed in an 
incubating microplate shaker (VWR International, Mississauga, ON) at 37 °C with 
continuous shaking at 100 shakes/min. After 1, 3, 5, 7, 10, and 14 days, the dissolved 
oxygen was measured using the NeoFox fiber optic oxygen sensor. Following 
measurement of dissolved oxygen, the corresponding squares were removed from their 
well, dried in a desiccator with potassium hydroxide as a desiccant for 72 hours, and 
weighed. The PBS was replenished every 3 days. All measurements were carried out in 
triplicates. 
 
 Statistical Analysis 
The results of the dissolved oxygen studies were analyzed using analysis of variance 
(ANOVA) with the Tukey post-test. The Pearson product-moment correlation coefficient 
was calculated in SigmaPlot (Systat Software Inc., USA). For all analyses, significance 
was assigned for p<0.05. 
 
5.4 Results and Discussion 
 Dissolved Oxygen Study on Cyclodextrin Inclusion Complexes with 
Perfluoroperhydrophenanthrene 
The ability of PFP to enhance oxygen delivery to cells seeded on 3D tissue engineering 
scaffolds was investigated. Because in vitro data using PFP is not reported, it was 
investigated if this molecule could be a candidate to enhance oxygen delivery in tissue 
engineering. Furthermore, the feasibility of utilizing the prepared cyclodextrin inclusion 
complexes from PFP and α-CD was explored. 
 
Measurements of dissolved oxygen (DO) in the presence of different weight percentages 
of PFP, α-CD, and CD:IC were conducted in PBS with a fiber optic probe under a number 
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of conditions: with or without surfactant (0.1 % Span80), at RT or 37 °C, and immediately 
following sample preparation (Day 1) or after two weeks storage in a refrigerator (Day 14). 
It should be noted that the amount of CD:IC incorporated corresponded to the weight 
percent of PFP in the inclusion complex, that is, 2 % CD:IC contains 2 % PFP. Table 5-1 
shows the results of the DO measurements, reported as dissolved oxygen (mg/L) ± standard 
deviation (SD) and the statistical significance of the data, as determined by ANOVA, is 
reported in Appendix 7-2. 
 
The DO measured in the PBS controls (Table 5-1) was comparable to the DO calculated 
using Henry’s law (8.39 mg/L at 23 °C, 6.87 mg/L at 37 °C). When the dissolved oxygen 
was measured immediately following preparation (RT, no surfactant, Day 1), the data 
shows that by incorporating 2 % PFP in PBS, there was a significant increase in dissolved 
oxygen (p=0.01), whereas 1 % PFP was not sufficient to statistically increase the dissolved 
oxygen (p=0.71). This concurs with a previous study in our lab where a minimum threshold 
of 2 % perfluorodecalin was required to statistically increase the dissolved oxygen.10 A 
similar relationship was observed with the incorporation of CD:IC, where a minimum 
threshold of 2 % was required in order to significantly increase the dissolved oxygen at RT 
(p<0.001). When the amount of PFP incorporated was increased from 2 to 4 %, a further 
statistically significant increase was observed (p<0.001). On the other hand, when the 
amount of CD:IC was likewise increased to 4 %, the dissolved oxygen did not increase 
significantly (p=1.00). 
 
This experiment was also carried out at 37 °C, corresponding with body temperature. At 
37 °C, for samples both with and without surfactant, incorporation of even 1 % PFP served 
to significantly increase the dissolved oxygen in PBS (p<0.001 for both). In both cases, 
increasing the concentration from 2 to 4 % resulted in a corresponding increase in dissolved 
oxygen (p<0.001 for both). Because they are the most relevant conditions to represent 
usage of these oxygen carriers in the human body, Figure 5-1 shows the data for the 
dissolved oxygen measurements at 37 °C immediately following sample preparation 
(Day1) without the use of surfactant. 
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Table 5-1: Dissolved oxygen in PBS at various conditions in the presence of α-CD, 
PFP, and CD:IC. Dissolved oxygen was measured with a fiber optic probe. Data are 
means (mg/L) ± SD for experiments performed in triplicate. 
RT, 
No Surfactant, 
Day 1 
RT, 
Surfactant, 
Day 1 
37 °C, 
No Surfactant, 
Day 1 
37 °C, 
Surfactant, 
Day 1 
PBS 
Control 
8.64(±0.07) 
PBS 
Control 
8.50(±0.09) 
PBS 
Control 
6.81(±0.03) 
PBS 
Control 
6.92(±0.04) 
       
1% CD 8.65(±0.03) 1% CD 8.60(±0.03) 1% CD 6.88(±0.02) 1% CD 6.95(±0.05) 
2% CD 8.64(±0.04) 2% CD 8.48(±0.10) 2% CD 6.90 (±0.02) 2% CD 6.94(±0.07) 
4% CD 8.66(±0.01) 4% CD 8.67(±0.021) 4% CD 7.12(±0.04) 4% CD 7.07(±0.027) 
       
1% PFP 8.73(±0.11) 1% PFP 8.73(±0.03) 1% PFP 7.10(±0.07) 1% PFP 7.14(±0.02) 
1% CD:IC 8.70(±0.05) 1% CD:IC 8.73(±0.03) 1% CD:IC 7.29(±0.04) 1% CD:IC 7.28(±0.03) 
2% PFP 8.85(±0.02) 2% PFP 8.89(±0.05) 2% PFP 7.34(±0.08) 2% PFP 7.60(±0.002) 
2% CD:IC 8.96(±0.06) 2% CD:IC 9.32(±0.04) 2% CD:IC 7.41(±0.02) 2% CD:IC 7.69(±0.02) 
4% PFP 9.13(±0.08) 4% PFP 9.41(±0.14) 4% PFP 7.63(±0.01) 4% PFP 7.91(±0.02) 
4% CD:IC 8.98(±0.08) 4% CD:IC 9.63(±0.03) 4% CD:IC 7.87(±0.02) 4% CD:IC 7.95(±0.005) 
        
RT, 
No Surfactant, 
Day 14 
RT, 
Surfactant, 
Day 14 
37 °C, 
No Surfactant, 
Day 14 
37 °C, 
Surfactant, 
Day 14 
PBS 
Control 
7.80(±0.04) 
PBS 
Control 
7.84(±0.08) 
PBS 
Control 
6.66(±0.02) 
PBS 
Control 
6.82(±0.01) 
        
1% CD 7.62(±0.04) 1% CD 7.80(±0.05) 1% CD 6.78(±0.02) 1% CD 6.92(±0.04) 
2% CD 7.74(±0.07) 2% CD 7.98(±0.02) 2% CD 6.78(±0.02) 2% CD 6.88(±0.02) 
4% CD 8.29(±0.03) 4% CD 8.16(±0.01) 4% CD 6.93(±0.09) 4% CD 6.84(±0.02) 
        
1% PFP 8.05(±0.03) 1% PFP 8.26(±0.04) 1% PFP 6.91(±0.02) 1% PFP 7.04(±0.04) 
1% CD:IC 7.94(±0.07) 1% CD:IC 8.36(±0.01) 1% CD:IC 7.13(±0.02) 1% CD:IC 7.27(±0.01) 
2% PFP 8.02(±0.004) 2% PFP 8.47(±0.01) 2% PFP 7.22(±0.01) 2% PFP 7.51(±0.02) 
2% CD:IC 8.14(±0.04) 2% CD:IC 8.91(±0.04) 2% CD:IC 7.32(±0.01) 2% CD:IC 7.61(±0.01) 
4% PFP 8.53(±0.01) 4% PFP 9.29(±0.05) 4% PFP 7.40(±0.01) 4% PFP 7.75(±0.01) 
4% CD:IC 8.66(±0.04) 4% CD:IC 9.54(±0.04) 4% CD:IC 7.71(±0.001) 4% CD:IC 7.92(±0.02) 
        
 
The dissolved oxygen was also measured in samples containing 0.1 % Span80 as a 
surfactant, with the same weight percentages of α-CD, PFP, and CD:IC. Relevant statistical 
data comparing results obtained with and without the use of surfactant are presented in 
Appendix 7-3. Adding a surfactant had a considerable impact on the results at both RT 
and 37 °C, as well as on Day 1 and Day 14. Statistically significant increases in dissolved 
oxygen were observed in all cases at as low as 1 % for both PFP and CD:IC. This is 
specifically notable in comparison to RT, Day 1 conditions where a minimum threshold of 
2 % PFP was required to produce a statistically significant increase without surfactant. 
These changes can likely be attributed to the emulsifying properties of the surfactant, 
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producing a more stable system between the PFP and PBS. Furthermore, increasing the 
concentration from 2 to 4 % served to further enhance the dissolved oxygen, in both the 
case of PFP and CD:IC under all conditions. 
 
Following DO measurements on Day 1, the samples were stored in a refrigerator at 4 °C 
for two weeks in order to test the ability of the perfluorinated compounds, specifically in 
the form of the inclusion complex, to enhance oxygen delivery after storage. Relevant 
statistical data for these long term studies is presented in Appendix 7-4. Most interestingly, 
all of the measurements at 37 °C (without surfactant) were statistically comparable to those 
taken under the same conditions on Day 1. This indicates that including the PFC in the 
cyclodextrin cavity serves to enhance the stability of the PFC. These results are extremely 
relevant as one of the main disadvantages of using PFC emulsions is their lack of stability, 
resultant stringent storage requirements, and overall lack of user-friendliness.1, 6 
Furthermore, with the exception of two conditions, utilizing the CD:IC as opposed to 
unmodified PFP actually served to further enhance the dissolved oxygen. For example, at 
37 °C (without surfactant, Day 1), the dissolved oxygen was (7.63±0.01) mg/L for 4 % 
* 
* 
* 
* 
* 
* * 
Figure 5-1: Dissolved oxygen in PBS (37 °C, no surfactant, Day 1), in the presence of 
different weight percentages of α-CD, PFP, and CD:IC. Dissolved oxygen was 
measured using a fiber optic probe. Data are means ± SD for experiments conducted 
in triplicate, * indicates statistical significance at p<0.05. 
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PFP and (7.87±0.03) mg/L for 4 % CD:IC, demonstrating a significant difference 
(p<0.001). 
 
An interesting trend was observed with the incorporation of 1, 2, and 4 % α-CD when 
compared to PBS. At 37 °C (Day 1), both with and without surfactant, incorporation of 4 
% α-CD resulted in a statistically significant increase in dissolved oxygen (p<0.001 for 
both). After 14 days of storage in a refrigerator at 4 °C, this effect was further enhanced 
with increases in dissolved oxygen occurring at both RT and 37 °C as well as with and 
without surfactant. Furthermore, the dissolved oxygen was statistically increased with as 
low as 1 % α-CD in a number of cases. It has been shown that cyclodextrins can store gases 
in their cavity, particularly α-CD because the small size of its cavity suits the low molecular 
weight of the gases.12 Cramer and Henglein13 showed that by bubbling various gases, such 
as chlorine, xenon, and oxygen in an α-CD/water solution at 7-120 atm, crystalline gas 
complexes could be isolated and remained stable for months at room temperature. The 
amount of gas complexed varied between 0.3 and 1.2 moles of gas per mole of α-CD and 
could be easily evolved by simply dissolving the crystalline complex in water.12, 14 It is 
therefore possible that certain conditions, such as increasing the temperature to 37 °C, 
allowed the α-CD to form an inclusion complex with oxygen, effectively increasing the 
dissolved oxygen in solution. 
 
Further statistical analysis was carried out on the dissolved oxygen measurements by 
computing the Pearson product-moment correlation coefficient in order to determine the 
linear dependence of the dissolved oxygen on the concentration of PFP and CD:IC. The 
results are presented in Table 5-2 and indicate a clear significant linear relationship 
between the concentration of both PFP and CD:IC and dissolved oxygen in all cases. This 
relationship demonstrates that as the concentration of PFP or CD:IC is increased, the 
dissolved oxygen also increases. 
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Table 5-2: Pearson product-moment correlation coefficients and corresponding p 
values demonstrating linear dependence of DO on concentration of PFP and CD:IC 
  PFP CD:IC  PFP CD:IC  PFP CD:IC  PFP CD:IC 
 
 RT, 
No Surfactant, 
Day 1 
 
RT 
Surfactant 
Day 1 
 
37 °C 
No Surfactant 
Day 1 
 
37 °C 
Surfactant 
Day 1 
Correlation 
Coefficient 
 0.94 0.84  0.98 0.96  0.97 0.97  0.97 0.96 
p value 
 4.52
E-06 
6.34E-
04 
 
7.32E-
08 
8.27E-
07 
 
1.26E-
07 
1.21E-
07 
 
9.39E-
08 
4.36E-
07 
 
 RT, 
No Surfactant 
Day 14 
 
RT 
Surfactant 
Day 14 
 
37 °C 
No Surfactant 
Day 14 
 
37 °C 
Surfactant 
Day 14 
Correlation 
Coefficient 
 0.96 0.99  0.99 0.99  0.96 0.97  0.96 0.97 
p value 
 1.16
E-06 
5.50E-
09 
 
2.65E-
10 
2.20E-
09 
 
7.47E-
07 
1.06E-
07 
 
6.17E-
07 
2.98E-
07 
 
In summary, the feasibility of utilizing PFP as an oxygen carrier molecule was shown. At 
37 °C, as low as 1 % PFP resulted in a significant increase in the dissolved oxygen in PBS 
as measured with a NeoFox fiber optic probe. Dissolved gases are transported by 
perfluorinated compounds due to increased solubility in accordance with Henry’s Law. 
The increased solubility in attributed to the existence of loose, non-directional van der 
Waals interactions leading to low cohesive energy densities, which facilitate mutual 
solubilization of oxygen in the fluorine compound. The feasibility of using an inclusion 
complex prepared from α-CD and PFP was also established. In fact, the CD:IC served to 
further increase the dissolved oxygen when compared to the same concentration of PFP at 
a number of conditions. Furthermore, including the PFP within the CD cavity was shown 
to improve the stability over a period of two weeks when stored in a refrigerator at 4 °C. 
Overall, this study indicates that CD:ICs prepared with PFCs can be used as oxygen carriers 
to enhance oxygen delivery in tissue engineering applications. 
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 Dissolved Oxygen Study on 3D Scaffolds Incorporating 
Cyclodextrin/Perfluoroperhydrophenanthrene Inclusion Complexes 
The feasibility of utilizing a cyclodextrin inclusion complex prepared with a PFC as an 
oxygen carrier was explored with promising results. Theoretically, the complexes could be 
added directly to the culture media and the effect on dissolved oxygen would be similar to 
that reported in the previous section (5.4.1). However, this is not an improvement over 
other studies where the PFC was added directly to the culture medium and their high 
density caused them to settle, limiting their potential.7, 15 For this reason, in this study the 
CD:ICs were incorporated into a tissue engineering construct, fabricated using the 
electrospinning technique. This serves to immobilize the PFC within the scaffold and delay 
or prevent settling of the PFC into the culture medium, while providing enhanced oxygen 
delivery throughout the construct, specifically in the center where it is difficult for oxygen 
to permeate by diffusion alone. 
 
Two different materials were explored as polymer matrices for fabricating the tissue 
engineering constructs incorporating the CD:IC. PCU and PCL were selected as stable and 
biodegradable polymers, respectively. The constructs were fabricated via electrospinning 
from concentrations optimized previously (Section 4). The optimized concentration for 
PCU was 8 % (v/v) PCU with respect to solvent and 50 % (w/w) CD:IC with respect to 
PCU, referred to as 8PCU-50CD:IC. The optimized concentration for PCL was 8 % (v/v) 
PCL with respect to solvent, 15 % (w/w) CD:IC with respect to PCL, referred to as 8PCL-
15CD:IC. The CD:IC-functionalized scaffolds were compared to scaffolds fabricated from 
unmodified PCU and PCL. Squares of the fibrous mats (roughly 1 cm2) were placed in 
PBS at 37 °C and the DO was measured after 1, 3, 5, 7, 10, and 14 days with a fiber optic 
probe. Table 5-3 shows the results of these measurements, reported as dissolved oxygen 
(mg/L) ± standard deviation. Figure 5-2 and Figure 5-3 graphically depict these 
measurements for the PCU- and PCL-based scaffolds, respectively. 
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Table 5-3: Dissolved oxygen in PBS in the presence of electrospun 3D fibrous mats 
fabricated from PCU or PCL incorporating an inclusion complex prepared from α-
CD and PFP. Dissolved oxygen was measured with a fiber optic probe. Data are 
means (mg/L) ± SD for experiments performed in triplicate. 
Day PCU Control PCU-CD:IC PCL Control PCL-CD:IC 
1 6.43(±0.22) 8.47(±0.48) 6.57(±0.20) 8.52(±0.80) 
3 7.82(±0.08) 8.07(±0.32) 8.38(±0.18) 9.02(±0.42) 
5 8.13(±0.26) 9.71(±0.32) 8.35(±0.33) 9.94(±0.29) 
7 8.26(±0.35) 10.9(±0.53) 8.24(±0.87) 9.62(±0.45) 
10 7.04(±0.96) 9.38(±0.26) 7.94(±0.42) 9.51(±0.21) 
14 7.93(±0.19) 9.63(±0.62) 8.40(±0.12) 10.0(±0.46) 
  
* 
* 
* 
* 
Figure 5-2: Dissolved oxygen measurements for PCU and PCU-CD:IC scaffolds in 
PBS at 37 °C. Dissolved oxygen was measured using a fiber optic probe. Data are 
means ± SD for experiments conducted in triplicate, * indicates statistical significance 
at p<0.05 
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When compared to the PBS control, neither the PCU nor the PCL scaffolds showed any 
significant increase in dissolved oxygen at any time point, as expected (statistical data is 
presented in Appendix 7-5). As indicated in Figure 5-2, the PCU-CD:IC scaffold showed 
a significant increase in DO on Day 5 (p<0.001). Likewise, the PCL-CD:IC scaffold 
showed a significant increase in DO on Day 3 (p=0.01), as indicated in Figure 5-3. The 
DO was observed to remain significantly increased over the remainder of the 14 day period 
in the presence of both PCU-CD:IC and PCL-CD:IC fibrous mats. 
 
Further statistical analysis was carried out on the dissolved oxygen measurements by 
computing the Pearson product-moment correlation coefficient in order to determine the 
linear dependence of the dissolved oxygen measurement on time. The results are presented 
in Table 5-4 and demonstrate a lack of significant linear relationship between time and the 
dissolved oxygen measured for all materials except the PCL-CD:IC nanofibers. The PCL-
CD:IC nanofibers show a significant but weak relationship between the variables, with the 
* 
* 
* 
* 
* 
Figure 5-3: Dissolved oxygen measurements for PCL and PCL-CD:IC scaffolds in 
PBS at 37 °C. Dissolved oxygen was measured using a fiber optic probe. Data are 
means ± SD for experiments conducted in triplicate, * indicates statistical significance 
at p<0.05 
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DO tending to increase with time. Because PCL is a degradable polymer whereas PCU is 
not, it is likely that this trend would be further enhanced with a stronger relationship evident 
over long-term studies, corresponding to the degradation of PCL. 
 
Table 5-4: Pearson product-moment correlation coefficients for the dissolved oxygen 
concentration and time for CD:IC-functionalized scaffolds 
 PCU Control PCU-CD:IC PCL Control PCL-CD:IC 
Correlation 
Coefficient 
0.29 0.46 0.46 0.61 
p value 0.24 0.06 0.05 0.007 
 
Figure 5-4 shows a graphical comparison of the two polymer materials, PCU and PCL 
with the CD:IC incorporated, and Appendix 7-6 shows the corresponding statistical 
analysis of the DO measurements. There was no statistical difference between the DO 
measured in the presence of either material at any time point. This is interesting because it 
was possible to incorporate considerably more CD:IC in the PCU fibers than in the PCL 
fibers. This may be explained by the fact that PCL is degradable whereas PCU is not, thus 
only the complexes on the surface of the PCU-CD:IC fibers were available whereas when 
the PCL matrix began to degrade, increasingly more complex was released. Further studies 
are necessary to ascertain how the two materials would compare over the long term. It is 
predicted that the oxygen delivery provided by the PCL-CD:IC scaffold would exceed that 
of the PCU-CD:IC material because it is biodegradable. Over the lifespan of the PCL, (> 2 
years)16 CD:IC would become uncovered from the polymer matrix and/or completely 
released. This would serve to prolong the improvement of oxygen delivery to the cells 
seeded on the construct whereas the CD:IC contained within the PCU fibers would remain 
buried throughout the culture time. 
 
  
103 
 
 
 
 
A preliminary study was carried out in order to ascertain if there was a burst of CD:IC 
released from the polymer matrix upon submersion in PBS; the change in mass of the 
fibrous mats were studied alongside the DO measurements. The results of this study are 
presented in Table 5-5. Any increases in mass can be attributed to precipitation of PBS 
salts on the scaffold after they were dried for 72 hours. A desiccator was used instead of 
heat to dry to the scaffolds in order to prevent destruction of the inclusion complex and 
loss of the PFP guest. Consequently, it is possible that only the surface moisture was 
removed such that residual PBS on the fibers would cause a superficial increase in the final 
mass of the fibers. Due to the inconsistency in the change in mass of the fibers, the release 
of CD:IC from the fibers cannot be commented on conclusively. Nevertheless, it was 
observed that overall there was a greater release from the PCU-CD:IC fibers when 
compared to the PCU control fibers. Because PCU is not a degradable polymer, this loss 
can likely be attributed to the leaching of the CD:IC from the surface of the fibers. A similar 
trend was not distinguishable for the PCL-based scaffolds and the results were 
Figure 5-4: Dissolved oxygen measurements for PCU-CD:IC and PCL-CD:IC 
scaffolds in PBS at 37 °C. Dissolved oxygen was measured using a fiber optic probe. 
Data are means ± SD for experiments conducted in triplicate, * indicates statistical 
significance at p<0.05 
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inconclusive. Further studies should be carried out to better ascertain the changes in the 
electrospun fibers after submersion in PBS with respect to the release of CD:IC and its 
effect on dissolved oxygen. For instance, analysis of SEM images would allow for the 
observation of morphological changes occurring in the fibers with mass loss. 
 
Table 5-5: Change in mass (%) recorded for 3D PCU and PCL scaffolds 
incorporating CD:IC and their corresponding controls 
Day PCU Control PCU-CD:IC 
 A B C Average A B C Average 
1 -14.3 -1.85 -19.5 -119 -12.5 -23.8 -32.0 -22.8 
3 5.26 5.56 10.3 7.04 -30.0 -36.0 -43.8 -36.6 
5 -4.35 6.25 -2.63 -0.24 -25.0 -35.6 -47.1 -35.9 
7 3.85 9.52 0.00 4.46 -43.4 -41.9 -51.4 -45.6 
10 -2.04 4.55 0.00 0.83 -37.2 -38.3 -37.0 -37.5 
14 -5.71 0.00 0.00 -1.90 -37.5 175 62.8 66.8 
         
Day PCL Control PCL-CD:IC 
 A B C Average A B C Average 
1 -8.33 -25.0 -11.1 -14.8 -33.3 -21.2 -27.6 -27.4 
3 -14.3 -3.23 -4.55 -7.36 -19.5 -4.17 -5.26 -9.64 
5 -14.3 -9.09 -14.3 -12.6 -14.3 -17.0 -14.0 -15.1 
7 -0.36 -0.31 -0.29 -0.32 -20.5 -20.4 -26.1 -22.3 
10 -20.4 -23.3 -29.0 -24.2 -20.0 -15.4 -16.7 -17.4 
14 -42.1 -16.0 -8.33 -22.1 128.0 16.7 36.7 60.5 
         
 
Overall, incorporating the CD:IC within 3D electrospun scaffolds resulted in an increase 
in the DO measured in the surrounding PBS. The results of this study are promising and 
suggest that incorporating CD/PFC inclusion complexes in scaffolds would be an effective 
strategy for enhancing the oxygen delivery to cells seeded on the constructs. An increase 
in dissolved oxygen was observed with both biostable, PCU, and biodegradable, PCL, 
materials. This promotes the idea that this approach is incredibly versatile, such that the 
CD:IC could theoretically be incorporated in a plethora of different polymer materials via 
electrospinning. Furthermore, these results indicate that at least some of the CD:IC 
embedded within the constructs was on the surface of the fibers and available for oxygen 
delivery. This correlates with the data obtained from XPS (Section 4.4.2) which 
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demonstrated that there was increased oxygen content on the surface of the fibers. 
Although this study served as a proof of concept, further studies are required in order to 
ascertain the ability of these scaffolds to enhance oxygen delivery in the long term. 
 
5.5 Conclusion 
One unsolved problem in tissue engineering is overcoming the diffusional limitations of 
oxygen which lead to hypoxia in the center of tissue engineering constructs. In this study, 
the feasibility of using PFP as an oxygen carrier, specifically in the form of a cyclodextrin 
inclusion complex, was explored. Dissolved oxygen concentration significantly increased 
in the presence of PFP at all conditions tested, with as low as 1% PFP required for a 
statistically significant increase in most cases. At a number of conditions, it was observed 
that incorporating the PFP in the form of a cyclodextrin inclusion complex actually served 
to further enhance the dissolved oxygen in solution. Moreover, including the PFP within 
the α-CD cavity served to enhance the stability of the PFP and the complexes provided a 
statistically significant increase in DO after storage in the refrigerator for 2 weeks. 
 
The CD:IC was then embedded in 3D PCU and PCL scaffolds fabricated via 
electrospinning. Dissolved oxygen concentration increased in PBS in the presence of these 
scaffolds on Day 3 for PCL-CD:IC and Day 5 for PCU-CD:IC, and remained statistically 
higher than the PBS control for both materials over the remainder of the 14 day period. 
This indicates that at least some of the CD:IC remained available for oxygen delivery when 
contained within the polymer matrix. 
 
Taken together, these data suggest the potential for scaffolds functionalized with CD:IC to 
enhance oxygen delivery to seeded cells for application in tissue engineering. Incorporating 
the oxygen carrier directly in the scaffold enables the delivery of oxygen throughout the 
construct, especially in the center where it is difficult to reach by diffusion alone. 
Furthermore, it is an improvement upon using PFCs and their emulsions directly in the 
culture media because the oxygen carriers are embedded within the scaffold and therefore 
will not settle in the media. 
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6 GENERAL DISCUSSION AND CONCLUSIONS 
Overview: This chapter provides a general summery of the overall work of this thesis as 
per the specific objectives mentioned in Section 2.5. The strengths and limitations of this 
work are summarized with directions for future work. Finally, the overall significance of 
this work for tissue engineering is included. 
 
6.1 Conclusions 
The main goal of this study was to enhance the delivery of oxygen to cells seeded on 
scaffolds for application in tissue engineering. The fundamental basis for the strategy 
explored was the ability of PFCs to transport large quantities of oxygen due to increased 
solubility according to Henry’s Law. The initial step involved preparing an inclusion 
complex between cyclodextrin and a perfluorocarbon. Specifically, α-CD and PFP were 
selected as the host and guest, respectively, following preliminary experiments and 
according to the close match between the dimensions of the α-CD cavity and PFP diameter. 
Of the numerous complexation techniques available, co-precipitation, paste mixing, and 
dry mixing were conducted. The products were characterized with FTIR, TGA, and XRD 
in order to establish the most effective complexation technique for the specific host and 
guest molecules utilized. Taken together, the characterization techniques showed that paste 
mixing and dry mixing, at a molar ratio of 2:1 α-CD to PFP, were the most effective 
complexation techniques. Further tests were conducted with the CD:IC prepared by paste 
mixing. 
 
The next step involved incorporating the CD:IC into a 3D tissue engineering construct. 
Electrospinning was selected as the fabrication technique, with PCU and PCL as the stable 
and biodegradable polymer matrices, respectively. SEM micrographs were used to 
characterize the resulting fibrous mats in terms of fiber diameter and uniformity. The 
optimized concentrations were determined to be 8 % (v/v) PCU with respect to solvent, 50 
% (w/w) CD:IC with respect to polymer and 8 % (v/v) PCL with respect to solvent, 15 % 
(w/w) CD:IC with respect to polymer. The fibers in these mats had average diameters of 
(232 ± 31) nm and (342±56) nm for PCU-CD:IC and PCL-CD:IC, respectively, which is 
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within the acceptable margin for most tissue engineering applications. XPS survey scans 
of the fibers indicated that at least some of the CD:IC was present on the surface of both 
the PCU and PCL fibers. 
 
Finally, the ability of the CD:IC and the CD:IC-containing scaffolds to enhance oxygen 
delivery in vitro was studied. Dissolved oxygen, measured with a fiber optic probe in PBS, 
was significantly increased in the presence of as low as 1 % PFP. Furthermore, in some 
cases incorporating the PFC as a CD:IC actually served to further enhance the dissolved 
oxygen. After being embedded within a polymer matrix and electrospun into a 3D fibrous 
mat, the CD:ICs maintained their ability to enhance the oxygen delivery. Statistically 
significant increases in dissolved oxygen measured in the PBS surrounding the fibrous 
mats were observed for both the PCU- and PCL-based materials on Day 5 and 3, 
respectively. This increase was maintained over the remainder of the 14 day period of the 
experiment for both materials. 
 
Taken together, the experiments conducted over the course of this study demonstrate that 
CD:ICs prepared with a PFC are viable oxygen carriers. Embedding the CD/PFC inclusion 
complexes within a 3D scaffold is a feasible approach to enhance oxygen delivery to cells 
seeded on tissue engineering constructs with the ultimate goal of developing clinically 
thick tissues. 
 
6.2 Strengths and Limitations 
In this study, a strategy for enhancing oxygen delivery in scaffold-guided tissue 
engineering was developed. The strategy involved incorporating cyclodextrin inclusion 
complexes with perfluorocarbons as oxygen carriers in tissue engineering scaffolds. One 
of the strengths of this approach is that by incorporating the PFC within the CD cavity, the 
limitations with stability and user-friendliness of PFC emulsions are overcome. Moreover, 
incorporating the oxygen carriers directly within the scaffold prevents, or at least hinders, 
the settling of the PFC droplets in either the culture well or medium reservoir. Having the 
CD:ICs embedded directly in the scaffold also serves to provide enhanced oxygen delivery 
throughout the scaffold, particularly in the center which is difficult to reach by diffusion 
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alone. Furthermore, the advantage of using CD/PFC complexes over oxygen generating 
compounds, such as calcium peroxide1 or sodium percarbonate,2 is that they are not 
depleted and theoretically have an unlimited lifespan. 
 
One of the major strengths with the use of a cyclodextrin/perfluorocarbon inclusion 
complex as an oxygen carrier is that there is potential to incorporate the CD:IC within 
virtually any polymer via electrospinning. In this study alone, it was possible to embed the 
CD:ICs within both stable and degradable polymer matrices. Additionally, the application 
of the CD:ICs as oxygen carriers could be extended to other biomaterials; for example, 
hydrogels containing cyclodextrin have been reported.3-5 Another advantage of utilizing 
cyclodextrin as the oxygen carrier is that cyclodextrins are natural and relatively non-toxic, 
making them suitable for biological applications, they have a low price, and are 
commercially available.6 In the body, CDs are mainly excreted in their intact form by renal 
filtration as they are minimally susceptible to hydrolytic cleavage or degradation by human 
enzymes.7 
 
A limitation of this work is the absence of in vitro cell studies. Preliminary cell culture 
experiments were carried out on the CD:IC-functionalized fibrous mats (Appendix 7-7), 
however, they were not comprehensive enough to conclusively draw conclusions on the 
cytotoxicity of the α-CD/PFP inclusion complex. Although CD is well-known to be 
relatively non-toxic,6 PFC emulsions are generally considered to be cytotoxic to cultured 
human fibroblast cells in a concentration-dependent manner.8, 9 Previous experiments 
carried out in our lab on HCASMCs, on the other hand, demonstrated cell viability in the 
presence of perfluorodecalin.10 In future work, it is therefore necessary to clarify the 
cytotoxicity of the PFC used in this study in the form of a cyclodextrin inclusion complex 
embedded within 3D tissue engineering constructs. 
 
Another limitation of this work is the lack of characterization for the complexes prepared 
from all techniques attempted. As the ultimate objective of this work was to test the ability 
of the inclusion complex to enhance oxygen delivery when embedded within a tissue 
engineering scaffold, once sufficient characterization was carried out to confirm complex 
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formation the focus was shifted to fabricating the scaffolds and carrying out analysis in 
vitro. Theoretically, an entire thesis work could be dedicated to varying the parameters 
associated with each complexation technique and thoroughly characterizing the resulting 
products. 
 
6.3 Future Directions 
In light of the work presented here, future work on this project should include: 
 Short-term in vitro cell studies on the electrospun fibers incorporating CD:IC to 
evaluate cytotoxicity and cell spreading 
 Long-term in vitro cell studies on the 3D PCU-CD:IC and PCL-CD:IC scaffolds to 
further explore their capacity to enhance oxygen delivery, specifically in terms of 
increased proliferation overall and decreased necrosis in the center of the construct 
 Long-term studies to investigate the release of the CD:IC from the degradable PCL 
and stable PCU scaffolds 
 Further characterization of the PCU-CD:IC and PCL-CD:IC scaffolds to clarify the 
positioning of the CD:IC in the fibers 
 Mechanical testing on the 3D PCU-CD:IC and PCL-CD:IC scaffolds to ensure 
appropriateness for tissue engineering applications 
 Electrospinning with different polymers and further research different types of 
biomaterials in order to confirm the versatility of this approach 
 
6.4 Significance 
The focus of this research was the development of a novel inclusion complex, prepared 
between α-cyclodextrin and perfluoroperhydrophenanthrene, and the incorporation of the 
inclusion complex in three-dimensional scaffolds. This study serves as the foundation for 
the use of cyclodextrin/perfluorocarbon inclusion complexes as oxygen carriers in 
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scaffold-guided tissue engineering. Alternative oxygen delivery strategies utilizing 
different cyclodextrins, perfluorocarbons, scaffold polymers, or fabrication techniques 
may yet be developed.  
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Appendix 6-1: XPS spectra of the unmodified α-CD and prepared CD:IC, and the 3D 
PCU and PCL scaffolds incorporating the α-CD and CD:IC 
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Appendix 7-2: Statistical data for dissolved oxygen measurements in PBS at various 
conditions in the presence of α-CD, PFP, and α-CD/PFP CD:ICs. Dissolved oxygen 
was measured with a fiber optic probe. Data are means ± SD for experiments 
performed in triplicate. Statistical significance: x indicates p>0.05, * indicates p≤0.05. 
*** indicates p≤0.001. 
RT, No Surfactant, Day 1 
PBS Control vs. 8.64(±0.07) 1% PFP 8.73(±0.11) 0.71 x 
  1% CD:IC 8.70(±0.05) 0.96 x 
  2% PFP 8.85(±0.02) 0.01 * 
  2% CD:IC 8.96(±0.06) <0.001 *** 
  4% PFP 9.13(±0.08) <0.001 *** 
  4% CD:IC 8.98(±0.08) <0.001 *** 
      
PBS Control vs. 8.64(±0.07) 1% CD 8.65(±0.03) 1 x 
  2% CD 8.64(±0.04) 1 x 
  4% CD 8.66(±0.006) 1 x 
      
1% CD vs. 8.65(±0.03) 1% CD:IC 8.70(±0.05) 0.99 x 
2% CD vs. 8.64(±0.04) 2% CD:IC 8.97(±0.06) <0.001 *** 
4% CD vs. 8.66(±0.01) 4% CD:IC 8.98(±0.08) <0.001 *** 
      
1% CD:IC vs. 8.70(±0.05) 2% CD:IC 8.96(±0.06) 0.001 *** 
2% PFP vs. 8.85(±0.02) 2% CD:IC 8.96(±0.06) 0.42 x 
2% PFP vs. 8.85(±0.02) 4% PFP 9.13(±0.08) <0.001 *** 
2% CDIC vs. 8.96(±0.06) 4% CD:IC 8.98(±0.08) 1 x 
4% PFP vs. 9.13(±0.08) 4% CD:IC 8.98(±0.08) 0.18 x 
      
RT, Surfactant, Day 1 
PBS Control vs. 8.50(±0.09) 1% PFP 8.73(±0.03) 0.01 * 
  1% CD:IC 8.73(±0.03) 0.01 * 
  2% PFP 8.89(±0.05) <0.001 *** 
  2% CD:IC 9.32(±0.04) <0.001 *** 
  4% PFP 9.41(±0.14) <0.001 *** 
  4% CD:IC 9.63(±0.03) <0.001 *** 
      
PBS Control vs. 8.50(±0.09) 1% CD 8.60(±0.03) 0.64 x 
  2% CD 8.48(±0.10) 1 x 
  4% CD 8.67(±0.02) 0.11 x 
      
1% CD vs. 8.60(±0.03) 1% CD:IC 8.73(±0.03) 0.48 x 
2% CD vs. 8.48(±0.10) 2% CD:IC 9.32(±0.04) <0.001 *** 
4% CD vs. 8.67(±0.02) 4% CD:IC 9.63(±0.03) <0.001 *** 
      
1% CD:IC vs. 8.73(±0.03) 2% CD:IC 9.32(±0.04) <0.001 *** 
2% PFP vs. 8.89(±0.05) 2% CD:IC 9.32(±0.04) <0.001 *** 
2% PFP vs. 8.89(±0.05) 4% PFP 9.41(±0.14) <0.001 *** 
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2% CDIC vs. 9.32(±0.03) 4% CD:IC 9.63(±0.03) <0.001 *** 
4% PFP vs. 9.41(±0.137) 4% CD:IC 9.63(±0.0299) 0.02 * 
      
37°C, No Surfactant, Day 1 
PBS Control vs. 6.81(±0.03) 1% PFP 7.10(±0.07) <0.001 *** 
  1% CD:IC 7.29(±0.04) <0.001 *** 
  2% PFP 7.34(±0.08) <0.001 *** 
  2% CD:IC 7.41(±0.02) <0.001 *** 
  4% PFP 7.63(±0.01) <0.001 *** 
  4% CD:IC 7.87(±0.02) <0.001 *** 
      
PBS Control vs. 6.806(±0.0333) 1% CD 6.88(±0.02) 0.06 x 
  2% CD 6.90(±0.02) 0.25 x 
  4% CD 7.12(±0.04) <0.001 *** 
      
1% CD vs. 6.879(±0.0238) 1% CD:IC 7.29(±0.04) <0.001 *** 
2% CD vs. 6.899(±0.0167) 2% CD:IC 7.41(±0.02) <0.001 *** 
4% CD vs. 7.118(±0.038) 4% CD:IC 7.87(±0.02) <0.001 *** 
      
1% CD:IC vs. 7.288(±0.0397) 2% CD:IC 7.41(±0.02) 0.04 * 
2% PFP vs. 7.343(±0.0809) 2% CD:IC 7.41(±0.02) 0.60 x 
2% PFP vs. 7.343(±0.0809) 4% PFP 7.63(±0.01) <0.001 *** 
2% CDIC vs. 7.414(±0.0244) 4% CD:IC 7.87(±0.02) <0.001 *** 
4% PFP vs. 7.632(±0.0119) 4% CD:IC 7.87(±0.02) <0.001 *** 
      
37°C, Surfactant, Day 1 
PBS Control vs. 6.925(±0.0423) 1% PFP 7.14(±0.02) <0.001 *** 
  1% CD:IC 7.28(±0.03) <0.001 *** 
  2% PFP 7.60(±0.002) <0.001 *** 
  2% CD:IC 7.69(±0.02) <0.001 *** 
  4% PFP 7.91(±0.02) <0.001 *** 
  4% CD:IC 7.95(±0.005) <0.001 *** 
      
PBS Control vs. 6.925(±0.0423) 1% CD 6.95(±0.05) 0.99 x 
  2% CD 6.94(±0.07) 1 x 
  4% CD 7.07(±0.03) 0.001 *** 
      
1% CD vs. 6.953(±0.0467) 1% CD:IC 7.28(±0.03) <0.001 *** 
2% CD vs. 6.942(±0.0668) 2% CD:IC 7.69(±0.02) <0.001 *** 
4% CD vs. 7.071(±0.0270) 4% CD:IC 7.95(±0.005) <0.001 *** 
      
1% CD:IC vs. 7.281(±0.03) 2% CD:IC 7.69(±0.02) <0.001 *** 
2% PFP vs. 7.602(±0.00210) 2% CD:IC 7.69(±0.02) 0.12 x 
2% PFP vs. 7.602(±0.00210) 4% PFP 7.91(±0.02) <0.001 *** 
2% CDIC vs. 7.687(±0.0165) 4% CD:IC 7.95(±0.005) <0.001 *** 
4% PFP vs. 7.906(±0.0240) 4% CD:IC 7.95(±0.005) 0.8 x 
      
RT, No Surfactant, Day 14 
PBS Control vs. 7.81(±0.04) 1% PFP 8.05(±0.03) <0.001 *** 
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1% CD:IC 7.94(±0.07) 0.02 * 
  2% PFP 8.02(±0.004) <0.001 *** 
  2% CD:IC 8.14(±0.04) <0.001 *** 
  4% PFP 8.53(±0.006) <0.001 *** 
  4% CD:IC 8.66(±0.04) <0.001 *** 
      
PBS Control vs. 7.80(±0.04) 1% CD 7.62(±0.04) 0.001 *** 
  2% CD 7.74(±0.07) 0.76 x 
  4% CD 8.29(±0.03) <0.001 *** 
      
1% CD vs. 7.62(±0.04) 1% CD:IC 7.94(±0.07) <0.001 *** 
2% CD vs. 7.74(±0.07) 2% CD:IC 8.14(±0.04) <0.001 *** 
4% CD vs. 8.29(±0.03) 4% CD:IC 8.66(±0.04) <0.001 *** 
      
1% CD:IC vs. 7.94(±0.07) 2% CD:IC 8.14(±0.04) <0.001 *** 
2% PFP vs. 8.02(±0.004) 2% CD:IC 8.14(±0.04) 0.05 * 
2% PFP vs. 8.02(±0.004) 4% PFP 8.53(±0.006) <0.001 *** 
2% CDIC vs. 8.14(±0.04) 4% CD:IC 8.66(±0.04) <0.001 *** 
4% PFP vs. 8.53(±0.006) 4% CD:IC 8.66(±0.04) 0.04 * 
      
RT, Surfactant, Day 14 
PBS Control vs. 7.84(±0.08) 1% PFP 8.26(±0.04) <0.001 *** 
  1% CD:IC 8.36(±0.01) <0.001 *** 
  2% PFP 8.47(±0.01) <0.001 *** 
  2% CD:IC 8.91(±0.04) <0.001 *** 
  4% PFP 9.29(±0.05) <0.001 *** 
  4% CD:IC 9.54(±0.04) <0.001 *** 
      
PBS Control vs. 7.84(±0.08) 1% CD 7.80(±0.05) 0.97 x 
  2% CD 7.98(±0.02) 0.01 * 
  4% CD 8.16(±0.01) <0.001 *** 
      
1% CD vs. 7.80(±0.05) 1% CD:IC 8.36(±0.01) <0.001 *** 
2% CD vs. 7.98(±0.02) 2% CD:IC 8.91(±0.04) <0.001 *** 
4% CD vs. 8.16(±0.01) 4% CD:IC 9.54(±0.04) <0.001 *** 
      
1% CD:IC vs. 8.36(±0.01) 2% CD:IC 8.91(±0.04) <0.001 *** 
2% PFP vs. 8.47(±0.01) 2% CD:IC 8.91(±0.04) <0.001 *** 
2% PFP vs. 8.47(±0.01) 4% PFP 9.29(±0.05) <0.001 *** 
2% CDIC vs. 8.91(±0.04) 4% CD:IC 9.54(±0.04) <0.001 *** 
4% PFP vs. 9.29(±0.05) 4% CD:IC 9.54(±0.04) <0.001 *** 
      
37°C, No Surfactant, Day 14 
PBS Control vs. 6.66(±0.02) 1% PFP 6.91(±0.02) <0.001 *** 
  1% CD:IC 7.13(±0.02) <0.001 *** 
  2% PFP 7.22(±0.01) <0.001 *** 
  2% CD:IC 7.32(±0.01) <0.001 *** 
  4% PFP 7.40(±0.01) <0.001 *** 
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4% CD:IC 7.71(±0.01) <0.001 *** 
      
PBS Control vs. 6.66(±0.02) 1% CD 6.78(±0.02) 0.004 * 
  2% CD 6.78(±0.02) 0.01 * 
  4% CD 6.93(±0.09) <0.001 *** 
      
1% CD vs. 6.78(±0.02) 1% CD:IC 7.13(±0.02) <0.001 *** 
2% CD vs. 6.78(±0.02) 2% CD:IC 7.32(±0.01) <0.001 *** 
4% CD vs. 6.93(±0.09) 4% CD:IC  <0.001 *** 
      
1% CD:IC vs. 7.13(±0.02) 2% CD:IC 7.32(±0.01) <0.001 *** 
2% PFP vs. 7.22(±0.01) 2% CD:IC 7.32(±0.01) 0.04 * 
2% PFP vs. 7.22(±0.01) 4% PFP 7.40(±0.01) <0.001 *** 
2% CDIC vs. 7.32(±0.01) 4% CD:IC 7.71(±0.01) <0.001 *** 
4% PFP vs. 7.40(±0.01) 4% CD:IC 7.71(±0.01) <0.001 *** 
      
37°C, Surfactant, Day 14 
PBS Control vs. 6.82(±0.01) 1% PFP 7.04(±0.04 <0.001 *** 
  1% CD:IC 7.27(±0.01) <0.001 *** 
  2% PFP 7.51(±0.02) <0.001 *** 
  2% CD:IC 7.61(±0.01) <0.001 *** 
  4% PFP 7.75(±0.01) <0.001 *** 
  4% CD:IC 7.92(±0.02) <0.001 *** 
      
PBS Control vs. 6.82(±0.01) 1% CD 6.92(±0.04) 0.01 * 
  2% CD 6.88(±0.02) 0.16 x 
  4% CD 6.84(±0.02) 0.50 x 
      
1% CD vs. 6.92(±0.043) 1% CD:IC 7.27(±0.01) <0.001 *** 
2% CD vs. 6.88(±0.02) 2% CD:IC 7.61(±0.01) <0.001 *** 
4% CD vs. 6.84(±0.02) 4% CD:IC 7.92(±0.02) <0.001 *** 
      
1% CD:IC vs. 7.27(±0.01) 2% CD:IC 7.61(±0.01) <0.001 *** 
2% PFP vs. 7.51(±0.02) 2% CD:IC 7.61(±0.01) 0.004 * 
2% PFP vs. 7.51(±0.02) 4% PFP 7.75(±0.01) <0.001 *** 
2% CDIC vs. 7.61(±0.01) 4% CD:IC 7.92(±0.02) <0.001 *** 
4% PFP vs. 7.75(±0.01) 4% CD:IC 7.92(±0.02) <0.001 *** 
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Appendix 7-3: Statistical data showing the effect of surfactant on dissolved oxygen 
measurements in PBS at various conditions in the presence of α-CD, PFP, and α-
CD/PFP CD:ICs. Dissolved oxygen was measured with a fiber optic probe. Data are 
means ± SD for experiments performed in triplicate. Statistical significance: x 
indicates p>0.05, * indicates p≤0.05. *** indicates p≤0.001. 
 No Surfactant Surfactant p value Significance 
RT, Day 1 
PBS Control 8.64(±0.07) 8.50(±0.09) 0.52 x 
     
1% CD 8.65(±0.03) 8.60(±0.03) 1.00 x 
2% CD 8.64(±0.04) 8.48(±0.10) 0.38 * 
4% CD 8.66(±0.01) 8.67(±0.02) 1.00 x 
     
1% PFP 8.73(±0.11) 8.73(±0.03) 1.00 x 
1% CD:IC 8.70(±0.04) 8.73(±0.03) 1.00 x 
2% PFP 8.85(±0.02) 8.89(±0.05) 1.00 x 
2% CD:IC 8.97(±0.06) 9.32(±0.04) <0.001 *** 
4% PFP 9.13(±0.08) 9.41(±0.14) <0.001 *** 
4% CD:IC 8.98(±0.08) 9.63(±0.03) <0.001 *** 
     
37°C, Day 1 
PBS Control 6.81(±0.03) 6.92(±0.04) 0.05 x 
     
1% CD 6.88(±0.02) 6.95(±0.05) 0.67 x 
2% CD 6.90(±0.02) 6.94(±0.07) 1 x 
4% CD 7.12(±0.04) 7.07(±0.03) 0.99 x 
     
1% PFP 7.10(±0.07) 7.14(±0.02) 1.00 x 
1% CD:IC 7.29(±0.04) 7.28(±0.03) 1.00 x 
2% PFP 7.34(±0.08) 7.60(±0.002) <0.001 *** 
2% CD:IC 7.41(±0.02) 7.69(±0.02) <0.001 *** 
4% PFP 7.63(±0.01) 7.91(±0.02) <0.001 *** 
4% CD:IC 7.868(±0.0207) 7.952(±0.00461) 0.461 x 
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RT, Day 14 
PBS Control 7.80(±0.04) 7.84(±0.08) 1 x 
     
1% CD 7.62(±0.04) 7.80(±0.052) <0.001 *** 
2% CD 7.74(±0.07) 7.98(±0.02) <0.001 *** 
4% CD 8.29(±0.03) 8.16(±0.01) 0.02 * 
     
1% PFP 8.05(±0.03) 8.26(±0.04) <0.001 *** 
1% CD:IC 7.94(±0.07) 8.36(±0.01) <0.001 *** 
2% PFP 8.02(±0.004) 8.47(±0.01) <0.001 *** 
2% CD:IC 8.14(±0.04) 8.91(±0.04) <0.001 *** 
4% PFP 8.53(±0.01) 9.29(±0.047) <0.001 *** 
4% CD:IC 8.66(±0.04) 9.54(±0.04) <0.001 *** 
     
37°C, Day 14 
PBS Control 6.66(±0.02) 6.82(±0.01) <0.001 *** 
     
1% CD 6.78(±0.02) 6.92(±0.04) <0.001 *** 
2% CD 6.78(±0.02) 6.88(±0.02) 0.01 * 
4% CD 6.93(±0.09) 6.84(±0.02) 0.02 * 
     
1% PFP 6.91(±0.02) 7.04(±0.04) <0.001 *** 
1% CD:IC 7.13(±0.02) 7.27(±0.01) <0.001 *** 
2% PFP 7.22(±0.01) 7.51(±0.02) <0.001 *** 
2% CD:IC 7.32(±0.01) 7.61(±0.01) <0.001 *** 
4% PFP 7.40(±0.01) 7.75(±0.01) <0.001 *** 
4% CD:IC 7.71(±0.01) 7.92(±0.02) <0.001 *** 
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Appendix 7-4: Statistical data showing the effect of storage for 14 days in a 
refrigerator on dissolved oxygen measured in PBS in the presence of α-CD, PFP, and 
α-CD/PFP CD:ICs. Dissolved oxygen was measured with a fiber optic probe. Data are 
means ± SD for experiments performed in triplicate. Statistical significance: x 
indicates p>0.05, * indicates p≤0.05. *** indicates p≤0.001. 
 
 
Day 1 Day 14 p value Significance 
RT, No Surfactant 
PBS Control 8.64(±0.07) 7.80(±0.044) <0.001 *** 
     
1% CD 8.65(±0.03) 7.62(±0.04) <0.001 *** 
2% CD 8.64(±0.04) 7.74(±0.07) <0.001 *** 
4% CD 8.66(±0.01) 8.29(±0.03) <0.001 *** 
     
1% PFP 8.73(±0.11) 8.05(±0.03) <0.001 *** 
1% CD:IC 8.70(±0.05) 7.94(±0.07) <0.001 *** 
2% PFP 8.85(±0.02) 8.02(±0.004) <0.001 *** 
2% CD:IC 8.96(±0.06) 8.14(±0.04) <0.001 *** 
4% PFP 9.13(±0.08) 8.53(±0.01) <0.001 *** 
4% CD:IC 8.98(±0.08) 8.66(±0.04) <0.001 *** 
     
RT, Surfactant 
PBS Control 8.50(±0.09) 7.84(±0.08) <0.001 *** 
     
1% CD 8.60(±0.03) 7.80(±0.05) <0.001 *** 
2% CD 8.48(±0.10) 7.98(±0.02) <0.001 *** 
4% CD 8.67(±0.02) 8.16(±0.01) <0.001 *** 
     
1% PFP 8.73(±0.03) 8.26(±0.04) <0.001 *** 
1% CD:IC 8.73(±0.03) 8.36(±0.01) <0.001 *** 
2% PFP 8.89(±0.05) 8.47(±0.01) <0.001 *** 
2% CD:IC 9.32(±0.04) 8.91(±0.04) <0.001 *** 
4% PFP 9.41(±0.14) 9.29(±0.05) 0.49 x 
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4% CD:IC 9.63(±0.03) 9.54(±0.04) 0.87 x 
     
37°C, No Surfactant 
PBS Control 6.806(±0.0333) 6.66(±0.01) 0.76 x 
     
1% CD 6.88(±0.02) 6.78(±0.02) 0.83 x 
2% CD 6.90(±0.02) 6.78(±0.02) 1.09 x 
4% CD 7.12(±0.04) 6.93(±0.09) 0.93 x 
     
1% PFP 7.10(±0.07) 6.91(±0.02) 0.83 x 
1% CD:IC 7.29(±0.04) 7.13(±0.02) 0.99 x 
2% PFP 7.34(±0.08) 7.22(±0.01) 0.79 x 
2% CD:IC 7.41(±0.02) 7.32(±0.01) 0.66 x 
4% PFP 7.63(±0.01) 7.40(±0.01) 0.63 x 
4% CD:IC 7.87(±0.02) 7.71(±0.01) 0.30 x 
     
37°C, Surfactant 
PBS Control 6.92(±0.04) 6.82(±0.01) 0.02 * 
     
1% CD 6.95(±0.05) 6.92(±0.04) 0.99 x 
2% CD 6.94(±0.07) 6.88(±0.02) 0.58 x 
4% CD 7.07(±0.0270) 6.84(±0.02) <0.001 *** 
     
1% PFP 7.14(±0.02) 7.04(±0.04) 0.02 * 
1% CD:IC 7.28(±0.03) 7.27(±0.01) 1 x 
2% PFP 7.60(±0.002) 7.51(±0.02) 0.07 x 
2% CD:IC 7.69(±0.02) 7.61(±0.01) 0.17 x 
4% PFP 7.91(±0.02) 7.75(±0.01) <0.001 *** 
4% CD:IC 7.95(±0.005) 7.92(±0.02) 1 x 
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Appendix 7-5: Statistical analysis for dissolved oxygen measured in PBS at 37 °C in 
the presence of 3D electrospun fibrous mats compared to a PBS control. Dissolved 
oxygen was measured with a fiber optic probe. Data are means ± SD for experiments 
performed in triplicate. Statistical significance: x indicates p>0.05, * indicates p≤0.05. 
*** indicates p≤0.001. 
 DO (mg/L) p value Significance DO (mg/L) p value Significance 
Day PCU PCU-CD:IC 
1 6.43(±0.22) 0.34 x 8.47(±0.48) 0.18 x 
3 7.82(±0.08) 0.99 x 8.07(±0.32) 0.78 x 
5 8.14(±0.26) 0.68 x 9.71(±0.32) <0.001 *** 
7 8.26(±0.35) 0.45 x 10.9(±0.53) <0.001 *** 
10 7.04(±0.96) 1.00 x 9.38(±0.26) <0.001 *** 
14 7.93(±0.19) 0.94 x 9.63(±0.62) <0.001 *** 
       
Day PCU PCU-CD:IC 
1 6.57(±0.20) 0.59 x 8.52(±0.80) 0.16 x 
3 8.38(±0.18) 0.32 x 9.02(±0.42) 0.01 * 
5 8.35(±0.33) 0.35 x 9.94(±0.29) <0.001 *** 
7 8.24(±0.87) 0.52 x 9.62(±0.45) <0.001 *** 
10 7.94(±0.42) 0.94 x 9.51(±0.21) <0.001 *** 
14 8.40(±0.12) 0.29 x 10.0(0.46) <0.001 *** 
       
 
Appendix 7-6: Statistical analysis comparing dissolved oxygen measured in the 
presence of 3D electrospun fibrous mats fabricated from PCU and PCL containing α-
CD/PFP CD:ICs in PBS at 37 °C. Dissolved oxygen was measured with a fiber optic 
probe. Data are means ± SD for experiments performed in triplicate. Statistical 
significance: x indicates p>0.05, * indicates p≤0.05. *** indicates p≤0.001. 
Day PCU-CD:IC PCL-CD:IC p value Significance 
1 8.47(±0.48) 8.52(±0.80) 1 x 
3 8.07(±0.32) 9.02(±0.42) 0.37 x 
5 9.71(±0.32) 9.94(±0.29) 1 x 
7 10.9(±0.53) 9.62(±0.45) 0.07 x 
10 9.38(±0.26) 9.51(±0.21) 1 x 
14 9.63(±0.62) 10.0(0.46) 0.99 x 
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Appendix 7-7: Preliminary Cell Studies 
Materials and Methods 
Cell Culture on 3D Scaffolds 
Three-dimensional polymer scaffolds with an area of approximately 3.2 cm2 were cut from 
PCU, PCU-CD:IC, PCL, and PCL-CD:IC electrospun fibrous mats. The scaffolds were 
exposed to UV irradiation for 1 hour per side for disinfection. The mats were transferred 
to culture plates, rinsed once with Hank’s Balanced Salt Solution (HBSS), and soaked in 
fresh HBSS overnight for conditioning (Invitrogen Canada Inc., Burlington, ON) at RT. 
Mouse embryonic fibroblasts (NIH-3T3 cell-line) were seeded directly on the surface of 
the scaffolds, at a density of 100,000 cells/scaffold, affixed to the bottom of the well using 
an O-ring. The cells were maintained in a humidified incubator at 37 °C and 5 % CO2 after 
adding with 0.5 mL/well of advanced DMEM (GIBCO® Invitrogen, Burlington, ON, 
Canada) containing 5 % FBS, 1 % antibiotics, and 0.2 mM L-glutamine. 
 
Cytotoxicity Assay 
Cell toxicity and proliferation were quantified by colorimetric assays of the metabolic 
activity of viable cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Vybrant® MTT Cell Proliferation Assay Kit, Invitrogen Canada Inc.). 
The MTT tetrazolium dye is reduced to insoluble formazan salts in correspondence to the 
activity level of NADPH-dependent oxidoreductase enzymes of metabolically active cells 
producing a purple colour. The concentration of the formazan salts, and therefore metabolic 
activity level of the cells present, is determined using optical density at λ = 570 nm. 
 
At time points of 1, 3, 5, and 7 days, the spent culture media was aspirated and replaced 
with 300 µL of fresh phenol-red free DMEM  (GIBCO® Invitrogen, Burlington, ON, 
Canada) followed by MTT (30 μL, Component A) and allowed to incubate for 4 hours. 
Sodium dodecyl sulphate in dilute acid (300 μL, Component B) was added to the wells to 
solubilize the water insoluble formazan salts upon thorough mixing and incubation 
overnight. The resultant coloured solution was quantified using a BioTek EL307C 
multiplate reader (BioTek Instruments, Inc., Winooski, VT) at the maximum absorbance 
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wavelength of the formazan solution (570 nm). The results of the MTT assays are presented 
as the mean ± standard deviation for experiments conducted with 3 replicates. 
 
Cytotoxicity Assay and Cell Spreading 
The ultimate application of the 3D fibrous scaffolds incorporating CD:ICs prepared with a 
PFP is to enhance oxygen delivery to cells seeded on the construct during in vitro 
maturation. It was therefore necessary to evaluate the interaction of the materials with cells 
to ensure their cytocompatibility. For this, the 3D mats were fixed to the bottom of a tissue 
culture plate well, and cytotoxicity and cell proliferation were analyzed using MTT assays. 
A mouse fibroblast cell line (NIH-3T3) was used to evaluate the effect of the CD:IC-
functionalized fibers on cell viability and metabolic activity over a time period of 7 days. 
The CD:IC-functionalized scaffolds were compared to PCU or PCL scaffolds without any 
modification as a control. As shown in Figure 7-1, there is no significant difference in the 
metabolic activity observed on the CD:IC-functionalized scaffolds as compared to the 
unmodified controls. Both PCU and PCL are well-known biocompatible materials,1 so the 
similarity in metabolic activity suggests that, at the concentrations tested, the CD:IC-
functionalized materials were not cytotoxic.  The differences observed between the PCU- 
and PCL-based materials is potentially due to the different amount of CD:IC incorporated 
within the polymer material. It was possible to incorporate 50 % (w/w) CD:IC in the PCU 
scaffold while maintaining adequate fiber morphology, but only 15 % (w/w) CD:IC was 
incorporated in the PCL scaffold. This data could indicate that there is a threshold above 
which the CD:IC becomes toxic to fibroblasts. Moreover, if there is any uncomplexed CD 
in the electrospinning solution, solvent could be retained in the cavity leading to 
cytotoxicity. Further studies are necessary to elicit the effect of the α-CD/PFP complex on 
cytotoxicity and proliferation, especially over the long-term. 
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Figure 7-1: Fibroblast metabolic activity as determined by MTT assay over a 7 day 
period. Metabolic activity on CD:IC-functionalized materials are compared to that 
on the unmodified base polymer. The data are presented as mean ± standard 
deviation. Experiments were carried out in triplicate. 
* 
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